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In 2009, a total of 91.400 new patients with cancer were diagnosed in the 
Netherlands. In 2012, this had already increased to 101.800 new cases.1 It is 
expected that in 2020, 123.000 new patients will be diagnosed with cancer.2 This 
increase is primarily due to the phenomenon of double-aging: the number of 
aging people is increasing, and they live longer, leading to a larger (elderly) 
population at risk of developing cancer.2 Conversely, the risk of dying of cancer 
is decreasing as an effect of the improving efficacy and growing possibilities of 
both local and systemic cancer treatments, including radiotherapy, surgery, 
hormonal treatment, chemotherapy and immunotherapy. Furthermore, 
treatments for patients with disseminated disease are also improving leading to 
longer survival.3,4 All in all, an increasing number of patients and during a longer 
period of time are at risk of developing metastases which will lead to an absolute 
increase of the number of metastases and subsequent symptoms. 
Bone is the third most common site of metastasis, after lung and liver. Bone 
metastases arise in approximately 50-70% of all patients diagnosed with cancer, 
most commonly in patients suffering from breast, prostate, kidney or lung 
cancer.5 A post-mortem study has shown skeletal involvement in up to 70% of 
patients with metastasised breast or prostate carcinoma, and in 30% of patients 
with thyroid, kidney or bronchus carcinoma.6 This study was performed in 1981 
and it is questionable whether these commonly referred to incidence rates hold 
in the current era of improved and widespread use of systemic treatments on 
one hand, and improved diagnostic imaging on the other, with an increasing use 
of whole body imaging, such as PET-CT. 
The majority of bone metastases are located in the spinal column and the femur, 
followed by the pelvis and the humerus.7-9 Metastases of the long bones are the 
subject of interest in this thesis and future references to bone metastases 
generally refer to those located in the long bones. The femur is the most 
affected of the long bones, followed by the humerus.10 Especially the 
metaphyseal region is a common site for tumour cells due to the high 
vascularization and easy access into the marrow.11  
Metastases are caused by tumour cells that disturb and imbalance the 
physiologic process of bone remodelling, in which the activity of osteoclasts (i.e. 
bone resorption) is coupled to the activity of osteoblasts (i.e. bone formation). 
Depending on the origin of the metastatic cells and mechanism they induce, 
osteolysis (in breast cancer, for example) or sclerosis (in prostate cancer, for 
example) gains the upper hand, although the two processes are often both 
present in metastatic lesions. Osteolysis is primarily the result of osteoclast 
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stimulation. Tumour-derived parathyroid hormone-related peptide (PTHrP) 
stimulates the expression of RANKL (receptor activator of nuclear factor-kB 
ligand) which binds the RANK receptor on osteoclast precursor cells and induces 
the formation of osteoclasts, that in turn resorb bone.12 This osteolysis 
subsequently leads to release of transforming growth factor beta (TGF-B), 
insulin-like growth factor 1 (IGF-1) and ionized calcium, which then bind to 
receptors on the tumour-cell surface and promote both tumour growth and 
PTHrP production. In this manner a ‘vicious circle’ is formed supporting tumour 
growth and bone resorption.13 Sclerosis is caused by factors produced by the 
tumour cell such as endothelin-1, TGF-B2 and several bone morphogenetic 
proteins (BMPs) that stimulate osteoblast proliferation.13 
Bone metastases can cause site-specific symptoms, such as pain or pathologic 
fractures, or systemic symptoms, such as fatigue, anaemia, nausea or anorexia. 
Hypercalcaemia, i.e. increased blood calcium levels, occurs in 10% of the 
patients, predominantly those with lung, breast and kidney cancer. It is caused 
by calcium which is released during osteolysis. The symptoms of 
hypercalcaemia are unspecific, including fatigue, depression, constipation, and 
vomiting. Urgent treatment with rehydration and bisphosphonates is required 
to prevent deterioration in renal function and mental status. If left untreated, 
hypercalcaemia can lead to cardiac arrhythmias and death.14,15 
Clinical features of long bone metastases 
Pain is the most prominent and common symptom for which patients seek 
medical attention.16 Painful bone metastases have a major impact on quality of 
life (QoL)17,18 and effective treatment of pain with radiotherapy has shown to 
lead to an improved QoL.19 Seventy-five to ninety percent of patients experience 
significant cancer-induced pain.20 The pain is usually localized, constant and dull 
in character, gradually progressing with time.21 The presence of pain is not 
correlated with the type of tumour, location, number or size of metastases, 
gender, or age of patients.22 The pathophysiologic mechanisms of bone pain are 
poorly understood but generally exhibit elements of both inflammatory and 
neuropathic pain. Inflammatory infiltration occurs as a result of tissue damage 
caused by tumour growth and release of pain mediators by the cancer cells. The 
neuropathic component can arise from damage to sensory nerves by 
infiltration, compression, stretching, or denervation as the tumour expands and 
the bone degrades.21  
Pathological fractures, called pathologic because they arise in bone with an 
abnormal health and generally occur without traumatic force, have large impact 





with symptomatic bone metastases.14,23 More than half of all pathologic 
fractures occur in the femur.24 In the humerus the incidence of pathological 
fractures ranges between 16-27%.25 It is important to realise that complete 
fracture healing of pathologic fractures cannot be expected. Unlike traumatic 
fractures, only 50% of all fractures will heal in six months, decreasing to merely 
37% in breast cancer and no healing at all in lung cancer.26 The latter results 
date back to 1983, so it is conceivable that current union rates have increased 
slightly with the improvement of systemic and local therapies. However, the fact 
remains that the bone is affected by cancer cells which impair the natural 
tendency to heal. Subsequent non-union or delayed union can lead to implant 
failure and revisions. 
Impending fractures are lesions at high risk of fracturing and therefore require 
prophylactic stabilisation. To identify such lesions and select the correct patients 
for prophylactic treatment, two questions must be answered: (1) how to 
determine the fracture risk? and (2) what is a high risk? To answer the first 
question, the Mirels’ classification (including lesion site, size, and type; and pain) 
is commonly used, but van der Linden et al. have shown that this classification 
leads to significant overestimation of the fracture risk with a specificity of 
13%.27,28 The “3-cm axial cortex destruction” rule was developed by van der 
Linden and Dijkstra et al. for the femur, with a sensitivity of 86% and a negative 
predictive value (i.e. probability that a negative test result leads to no fracture) 
of 97%.29 However, although this axial cortical involvement is accurate in 
identifying high-risk lesions, it still showed a relatively low specificity (58%). This 
is where the second question plays a role: how many patients should we 
unnecessarily operate, to prevent one fracture? The 3-cm rule is associated with 
a positive predictive value (i.e. probability that a positive test result leads to 
fracture) of 23%, so three in four patients are over-treated with a surgical 
procedure. Whether this is acceptable, should be subject of discussion, from 
both a medical and an economical point of view, but above all from a patient 
point of view. However, first consensus should be reached on how to determine 
a patient-specific fracture risk. Such a calculation should not only give a binary 
answer (yes/no) to whether the chance of a fracture to occur at some time is 
increased, but should give hazard ratios for specific time-points. Predictive tools 
using actual CT scan data to calculate a risk of future fracture based on finite 
element analysis (i.e. a computer model that assembles multiple partial 
differential equations, called finite elements, into a larger system of equations 
to model an entire problem) or CT-based structural rigidity analysis are 
promising tools to give quantitative patient-specific predictions.30 Although such 
models provide accurate results in biomechanical lab experiments, and are 
more predictive than an individual physicians estimated risk based on clinical 
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experience, they still face several challenges before they can be applied in 
clinical routine.31 
Treatment 
Symptomatic bone metastases are associated with loss of mobility and social 
functioning, a decreased quality of life 32 and reduced overall survival (OS),33,34 
and therefore require adequate treatment. The aim of treatment is to offer 
maximal palliation. This includes maintaining optimal function of the 
extremities. Only in rare cases (e.g. pure solitary metastases) might aggressive 
surgical management or high dose radiotherapy using stereotactic techniques 
and ablative doses lead to cure or substantial prolongation of life.35,36 
Oligometastatic disease, regarded as 2-5 bone metastases, is increasingly being 
regarded as separate entity between metastatic disease with only a single lesion 
and diffuse metastasised disease. This group might benefit from more 
aggressive treatment to achieve local control and delay progression.37 However, 
whether this more favourable entity is based on a less invasive tumour biology 
or on the more aggressive treatment that is increasingly available, is unclear.  
Bone-specific treatment options include systemic treatments (pain medication, 
bisphosphonates, denosumab, radionuclides) and local treatments 
(radiotherapy, surgical and percutaneous treatments). The latter are the focus 
of this thesis. 
Pain medication is an essential part of the treatment of painful bone metastases, 
even though it is symptom management. The World Health Organization has 
developed a pain ladder for cancer pain relief, starting with non-opioids (first 
paracetamol, followed by the addition of non-steroidal anti-inflammatory drugs 
(NSAIDs)) and adding weak or strong opioids, if necessary.38 In the treatment of 
bone metastases, the step of weak opioids is usually disregarded because the 
side effects weigh too strong as compared to their effectiveness. Severe bone 
pain is one of the most difficult of pains to control as bone metastases are 
generally not located to a single site, breakthrough pains (short, intermittent 
episodes of extreme pain with rapid onset breaking through the administered 
analgesics occurring spontaneously or on weight-bearing) are common, and 
increasing doses of analgesics is frequently limited by significant side effects.  
Bisphosphonates and denosumab are bone-targeting agents and both decrease 
bone resorption and increase mineralisation by inhibiting osteoclast activity.39 
While bisphosphonates directly induce osteoclast apoptosis, denosumab is an 
antibody that binds to RANKL, preventing its interaction with RANK and thus 





subscribed to treat and prevent pain and fractures. Denosumab has been 
described to be effective in patients with a poor response to bisphosphonates,40 
and even superior to Zoledronic acid in several studies.41,42 
Radiotherapy for painful bone metastases is well established and provides an 
effective symptomatic treatment in up to 60-80% of patients, although the level 
of pain relief differs.43 Radiotherapy causes irreversible damage to the DNA of a 
cell, which leads to cell death. This mechanism does not completely explain the 
effect of radiotherapy on bone metastases because the doses used for palliative 
radiotherapy are lower than doses used for tumour eradication.44 A single 
fraction of 8 Gy has been proven as effective as 20 Gy in multiple fractions and 
it is therefore recommended in cases with uncomplicated bone metastases.45,46 
Nonetheless, when the bone metastasis causes bone destruction, multi-fraction 
schemes are still commonly used.47 Radiotherapy is most commonly 
administered through external beams to local fields, but new modalities such as 
stereotactic radiotherapy are being introduced, especially in the setting of 
solitary or oligometastatic disease.48 Studies are ongoing to investigate the 
effect of high dose, high precision radiotherapy on the duration of pain 
response, and on disease-free survival and actual survival of this specific group.  
Surgery is required when fractures are present or pending. Options include plate 
and screw fixation, intramedullary nail fixation, or resection and prosthetic 
reconstruction. Choices are made depending on location, bone stock, and 
fracture type, among others. Precise indications for surgery are unclear and the 
best modalities are a frequently debated subject, as will become apparent in 
this thesis. 
Minimal invasive treatments including ablative techniques (such as 
radiofrequency ablation, microwaves, cryoplasty, high-intensity focused 
ultrasound), cementoplasty, and vascular techniques (e.g. trans-arterial 
embolization), could be options for patients with refractory pain or a short 
survival,49,50 although there is currently not much evidence in the literature. 
The known Unknowns 
Multidisciplinary teams, including medical oncologists, orthopaedic surgeons, 
and radiation oncologists, work together to find the best possible palliative 
treatment for each individual patient. To determine the best treatment, multiple 
factors must be taken into account, including patients’ preferences, type or risk 
of fracture, expected durability and risks of an intervention, location of the 
lesion, and life expectancy. It is important to balance the expected survival of a 
patient with the risks and recovery time of an intervention, as well as the 
Introduction 
 15 
expected life-time of a surgical implant. This means that answers to the 
following questions are required to provide optimal treatment:  
(1) what is the life expectancy of this patient? 
(2) is this long bone going to fracture? 
(3) what are the pros and cons of this intervention? 
Unfortunately, the answers to all three questions are unknown. These three 
gaps of knowledge, ‘the known Unknowns’, lead to overtreatment in patients with 
expected short survival or without genuine impending fractures, and to 
undertreatment in patients with an expected long survival or with genuine 
impending fractures. Both over- and undertreatment have negative effects on 
patients’ quality of life and should be prevented.  
Why is the Unknown unknown?  
Survival estimation is extremely difficult. Overall, 1-year survival percentages 
have been reported between 17% and 70% after surgery for skeletal 
metastases.51 Survival ranges from a few weeks to many years, depending on 
numerous factors. The primary tumour is the most important, but other factors 
such as coexisting visceral, brain and/or skeletal metastases, performance 
status, the presence of a pathologic fracture, a history of previous 
chemotherapy, the disease-free interval, and abnormal laboratory results have 
also been reported as prognostic.52-64 To aid physicians in survival estimation, 
many prognostic models have been developed over the years.58-64 However, 
these all have certain limitations, are often based completely on surgical or 
irradiated patients only, thus introducing confounding, and standard use in 
clinical practise is uncommon. Instead, survival estimations are made based on 
clinical experience, which tend to be incorrect.65  
Adequate fracture prediction is equally intricate. Several criteria have been 
described, as reported, but to date none are sufficiently specific and sensitive to 
prevent both unnecessary prophylactic treatments and avoidable fractures. A 
randomised trial to determine risk factors for fracture is ethically not desirable 
so evidence must be based on prospective patient cohorts or trustworthy 
biomechanical models. Promising progress is being made with CT-based and 
finite element prediction models, but these are not yet reliable for clinical use.31  
Each surgical intervention has its faults and merits. The technical aspects of the 
implantation and fixation of prostheses and osteosyntheses are generally well 
established. However, regarding all events after surgery, the faults and merits 





recovery and rehabilitation after surgery, the duration to full weight-bearing, 
possible post-operative complications, and durability of an implant are not well-
known. Furthermore, the additional value of adjuvant treatments (e.g. cement, 
radiotherapy) to prevent post-operative events has not been defined. Risk 
factors for failure are unknown because insufficient adequate and unbiased 
research has been performed. The lack of evidence is due to the unique patient 
population, making research complicated, and the palliative intent of the 
treatment, as opposed to a curative intent, for which physicians are trained and 
thus seems more appealing to research. The often limited follow-up of this 
patient population further hinders qualitative sound research. 
Given the lack of consensus on the best treatment strategy in different cases, 
treatment is predominantly based on experience and expert opinion. It is 
possible that the experience based treatments are actually unknown Knowns, but 
in an era of evidence-based medicine and value based healthcare it is not 
justifiable that treatment is based on Unknowns. 
Aim of thesis 
As can be concluded from the above, there are multiple Unknowns regarding the 
local treatment for patients with cancer and pathologic fractures of the long 
bones. To turn the Unknowns into Knowns, the OPTIMAL Project was initiated by 
my promotor (prof. dr. P.D.S. Dijkstra) and co-promotor (dr. Y.M. van der Linden) 
in 2014. The OPTIMAL project consists of a retrospective and a prospective part, 
together aiming to “optimise the treatment of patients with long bone metastases”. 
This thesis entails the first, retrospective part and lays a foundation for the 
second prospective part of the OPTIMAL project. The aims of this thesis are to 
develop a prognostic model for estimating survival in patients with cancer and 
symptomatic metastases of the long bones, evaluate current surgical treatment 
modalities and trends, and provide rationale for future prospective randomized 
trials. Determining the definition of an impending fracture and how the fracture 
risk is best calculated is beyond the scope of this thesis. 
Thesis outline 
Following this introduction into the field of long bone metastases, chapter 2 
describes the accomplishment of the first aim of this thesis: a prognostic model 
for survival based on a large multicentre retrospective cohort that shows that 
classification into four prognostic categories is possible with three variables: 
clinical profile of the primary tumour, Karnofsky Performance Score, and the 
presence of visceral and/or brain metastases. Chapter 3 shows why the survival 
prognostic model (as reported in chapter 2) is sustainable in the future. With 
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improving systemic treatment possibilities, primary tumours will increasingly be 
differentiated into subtypes that are treated differently and have different 
expected survival, and therefore require re-classification in the prognostic 
model. This chapter shows that patients who are diagnosed with non-small cell 
lung cancer and bone metastases should not be regarded as a single entity for 
survival estimation; the EGFR mutation status should differentiate non-small cell 
lung cancer patients into a group with a moderate or unfavourable clinical 
profile. Radiotherapy is the most common treatment for painful bone 
metastases. Chapter 4 places a critical note on the use of radiotherapy after 
surgical fixation of a pathologic fracture. As discussed in this chapter, evidence 
behind adjuvant treatment is meagre. Chapter 5 reports on the outcomes of a 
questionnaire among Dutch and international orthopaedic surgeons. The 
results show that better selection of patients who would require more 
specialised care as opposed to standard care would improve overall care of 
patients with pathologic fractures. Chapter 6 evaluates the treatment of actual 
and impending pathologic fractures of the femur with intramedullary nails and 
reports on risk factors for failure. A sequel is presented in chapter 7, which 
focusses on the same questions for intramedullary nails in the humerus. 
Chapter 8 aims to identify factors that indicate the need for an endoprosthesis 
in distal femur pathologic fractures, based on previous literature. Chapter 9 
gives an overall overview of the current surgical treatment of pathologic 
fractures of the long bones. It provides a step-by-step guide to be used when 
patients present with a pathological fracture. The chapter concludes with 
specific treatment recommendations for femur and humerus fractures.   
Chapter 10 summarizes the main results of the studies in this thesis. Chapter 11 
discusses the outcomes of the previous chapters and places them into a clinical 
context. Chapter 5 to 9 have provided rationale for the second, prospective part 
of the OPTIMAL Project, as will be discussed in this chapter. The chapter 
concludes with future directions for research and treatments of long bone 
metastases. In chapter 12 a Dutch summary of this thesis is presented. The 
protocol of the prospective OPTIMAL study and the Dutch translation and 
validation of the Toronto Extremity Salvage Score (TESS) questionnaire are 
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A survival estimation for patients with symptomatic long bone metastases (LBM) 
is crucial to prevent overtreatment and undertreatment. This study analyzed 
prognostic factors for overall survival and developed a simple, easy-to-use 
prognostic model.  
Methods  
A multicenter retrospective study of 1520 patients treated for symptomatic LBM 
between 2000 and 2013 at the radiation therapy and/or orthopedic 
departments was performed. Primary tumors were categorized into three 
clinical profiles (favorable, moderate, unfavorable) according to an existing 
classification system. Associations between prognostic variables and overall 
survival were investigated by using the Kaplan Meier method and multivariate 
Cox regression models. The discriminatory ability of the developed model was 
assessed with Harrell’s C-statistic. Observed and expected survival was 
compared based on an external cohort. 
Results  
Median overall survival was 7.4 months (95% CI 6.7-8.1). Based on the 
independent prognostic factors clinical profile, Karnofsky Performance Score, 
and presence of visceral and/or brain metastases, twelve prognostic categories 
were created. Harrell’s C statistic was 0.70. A flowchart was developed to easily 
stratify patients. Based on cut-off points for clinical decision-making, the twelve 
categories were narrowed down to four categories with clinical consequences. 
Median survival was 21.9 (95% CI 18.7-25.1), 10.5 (95% CI 7.9-13.1), 4.6 (95% CI 
3.9-5.3) and 2.2 (95% CI 1.8-2.6) months, for the four categories. 
Conclusion  
This study presents a model to easily stratify patients with symptomatic LBM 
according to their expected survival. The simplicity and clarity of the model 
facilitate and encourage its use in routine care of patients with LBM, to provide 
the most appropriate treatment for each individual patient. 
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Introduction 
Long bone metastases (LBM) are a common occurrence in patients with 
advanced cancer, arising in up to 70% of the patients with advanced disease.1 
As the prevalence of cancer rises2 and survival rates for even metastatic cancer 
increase, the number of patients with symptomatic LBM is likely to grow. Pain is 
the most common symptom, followed by actual or impending pathologic 
fractures in 10% to 25% of the patients, causing immobility and a decreased 
quality of life.3 Local treatment options primarily consist of radiation therapy 
and multiple types of surgical stabilization. All treatments have the same aims: 
to reduce pain, preserve the function of the extremities, and maintain or 
improve quality of life for patients with mostly limited life expectancy.4,5  
An accurate estimation of the survival at a specific time is essential to avoid 
overtreatment and undertreatment. Treatments that do not fit the expected 
survival time of patients with advanced cancer, with either recovery and 
rehabilitation times that are too long relative to a mostly limited survival, or, 
insufficient stabilizations when a long survival is expected, have a negative effect 
on their mobility and independence and, hence, the quality of life. For patients 
expected to have a short survival, radiation therapy or minimally invasive 
surgical treatments (e.g., intramedullary nail fixation) would be preferable, while 
for patients expected to have a long survival, resection and reconstruction with 
a regular or modular tumor prosthesis could provide a lifelong solution. Correct 
estimates of survival, however, are difficult, and physicians tend to be 
inaccurate.6 For patients with LBM, several tools have been developed to aid 
physicians.7-14 However, they have several shortcomings. First, most models are 
based on small cohorts from either radiation therapy11,14 or orthopaedic7-9,12,13 
departments, instead of both. Survival predictions that are based on a mixed 
cohort would be more consistent when discussing multidisciplinary treatment 
strategies. Second, many models include multiple myeloma as primary 
tumour;7-10,12,13 however, as a primary hematological cancer, it is a different 
entity and has a very different prognosis than osseous metastases from solid 
carcinomas. Third, the development of targeted treatments for several primary 
tumors has subdivided primary tumors into different entities, which makes 
some models outdated.7-9,11-14 Finally, most models include numerous variables, 
including some that are not part of standard work-up (e.g. laboratory 
results).7,8,10,12,13 The complexity of these models, caused by the number of 
variables, inhibits effective clinical use of survival estimation tools in daily 
practice.   
With these limitations in mind, our group previously developed a simple 





carcinoma.15 The model contains only 3 clinical variables: the clinical profile, the 
Karnofsky Performance Score (KPS), and the presence of visceral and/or brain 
metastases (VBM). These led to a categorization in 4 prognostic groups with the 
following median overall survival results: 31.2 months (95% confidence interval 
[CI], 25.2 to 37.3 months), 15.4 months (95% CI, 11.9 to 18.2 months), 4.8 months 
(95% CI, 4.1 to 5.4 months), and 1.6 months (95% CI, 1.4 to 1.9 months). 
The purposes of this study were to (1) identify prognostic factors for survival in 
patients with LBM, (2) develop an accurate and easy-to-use prognostic model 
similar to the previously developed model for spinal bone metastases, and (3) 
test the applicability of the model in an external cohort. 
Materials and methods 
Patients 
A multicenter, retrospective analysis of patients with cancer who were treated 
for symptomatic metastases in the long bones between 2000 and 2013 was 
performed. Consecutive patients from 4 orthopaedic departments and 4 
radiation therapy departments in 6 Dutch hospitals were included. Exclusion 
criteria were: a lesion due to multiple myeloma, solitary plasmacytoma or other 
hematological disease, or a lack of sufficient follow-up data regarding final 
status (alive or dead). After exclusion of 72 patients (no LBM [19], no local 
treatment [43], duplicate patient [5], or lack of sufficient data [5]), 1520 patients 
were eligible for participation in the cohort. 
Medical, radiology, and pathology records were reviewed to record the following 
data at baseline: sex, age, primary tumor, pretreatment performance score, 
presence of visceral and/or brain metastases, location of the metastasis, 
presence of (impending) pathologic fracture, and whether the metastasis was a 
solitary lesion.  If patients were treated multiple times, the first treatment 
(radiation therapy or surgery, or both) in the study period was included.  
The local medical ethical committees approved this study and granted a waiver 
for informed consent. 
Clinical profile 
Primary tumors were categorized into 3 clinical profiles (favorable, moderate or 
unfavorable) on the basis of the classification system established by Bollen et 
al.15 Several tumor types that were not included in the previous classification 
were registered in the current study. Where reasonable, these were added to 
existing primary tumor types: carcinomas of the rectum were added to the 
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group of colon carcinomas and the group “tongue cancer” was expanded to 
include all head and neck cancers. Soft-tissue sarcomas (STS) and “other primary 
tumors” were added as new tumor groups. Classification of STS was based on 
the literature.10 Finally, the classification was adjusted from unfavorable to 
moderate for endometrial carcinoma16 and Ewing sarcoma17 on the basis of new 
insights in the literature. In addition, breast cancer and kidney cancer were 
divided over 2 clinical profiles on the basis of receptor (estrogen, progesterone 
and Her2/neu) status for breast cancer,18 and the number of bone metastases 
for kidney cancer.19,20  
Pretreatment performance was scored by the KPS to reflect the performance 
before a fracture (if present); a higher score means the patient is better able to 
perform daily activities.21 KPS scores were categorized into 2 groups: ≤70% 
(impaired functioning) and 80% to 100% (normal functioning).15 Eastern 
Cooperative Oncology Group/World Health Organization (ECOG/WHO) scores, if 
used, were converted to the corresponding KPS group.22 If the performance was 
recorded without use of a scoring system and only by descriptive notes (e.g. 
good health, vital, or poor status), the descriptions were categorized into the 
two groups by 1 of the authors (J.J.W.).  
The presence of visceral metastases was determined on the basis of radiology 
reports available to the treating physician at the time of decision-making before 
treatment. If radiology reports were not available or the presence of visceral 
metastases was genuinely unclear, this was scored as unknown. The same 
approach was used to assess whether a bone metastasis was a solitary lesion. 
The presence of brain metastases (including metastases of the central nervous 
system) was based mainly on clinical reports because whole brain computed 
tomography (CT) or magnetic resonance imaging (MRI) scans were not routinely 
performed. Only when the presence was unclear for the treating physicians, was 
this scored as unknown. 
Statistical analysis 
Statistical analyses were performed with the use of SPSS software (version 24.0; 
IBM). Survival time was calculated as the difference between the date of first 
treatment for the bone metastasis and the date of death or latest follow-up. 
Survival curves were estimated with the Kaplan-Meier method. Median follow-
up was estimated with the reversed Kaplan-Meier method.23 The following 
variables were used to investigate a possible association with overall survival: 
clinical profile, KPS, presence of VBM, location of the metastasis, sex, and a 
solitary metastasis. A multivariate Cox regression model was estimated with 





metastases were not included in the multivariate analysis because they are 
strongly entwined with specific primary tumors; breast cancer is more common 
in women, and solitary metastasis are more common in kidney cancer. To 
further analyze the effect of KPS and the presence of VBM for each clinical 
profile, the multivariate analysis was stratified for clinical profile. Hazard ratios 
(HRs) and their corresponding 95% confidence interval (CI) were estimated. Not 
all participating departments provided data for the entire study period. Two 
variables, “center” and “year of treatment” were included in all Cox regression 
analyses to account for the presence of heterogeneity between the treatment 
centers and the time period in which the patient was treated. P values of <0.05 
were considered significant. Following the study design by Bollen et al,15 
combinations of the independent prognostic variables led to 12 prognostic 
categories that were visualized in a flowchart. To compress the 12 categories to 
a clinically applicable classification, median overall survival results of all 
categories were compared. As treatment strategies generally differ among an 
expected survival of <3 months, 3 to 6 months, 6 to 12 months and >12 months, 
these cutoff points were applied to narrow the 12 survival categories down to 
these 4 clinically relevant categories. To assess the discriminatory ability of these 
categories, the Harrell C-statistic was used.24  
External cohort  
The developed prognostic model was used on an external cohort. The cohort 
consisted of patients receiving surgical treatment between 2000 and 2013 at an 
Austrian hospital. Observed and expected survival (based on the external 
cohort) for each clinical profile at 1, 3, 6, 12 and 24 months were compared.  
Results 
Baseline characteristics of the patients and metastases are presented in table 
2.1. The most common primary tumor types were breast (33%), lung (24%), 
prostate (15%), and kidney (8%) (table 2.2). Indications for treatment were pain 
(48%), and actual (30%) or impending fractures (23%). The details of the 
treatment strategies are given in table 2.3. 
Survival 
The median follow-up for all patients was 79.1 months (95% CI, 71.0 to 87.2 
months). The median overall survival was 7.4 months (95% CI, 6.7 to 8.1 
months). The 529 patients (35%) with a favorable clinical profile, 419 (28%) with 
a moderate profile, and 472 (38%) with an unfavorable profile had a median 
overall survival of 18.6 months (95% CI, 15.8 to 21.4 months), 7.7 months (95% 
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CI, 6.6 to 8.7 months), and 3.1 months (95% CI, 2.7 to 3.5 months) months, 
respectively (figure 2.1).  
Prognostic factors 
Univariate analyses showed that the clinical profile, the KPS, evidence of VBM, a 
solitary bone metastasis, and sex were significantly associated with OS (p < 
0.001 for all). A multivariate Cox regression analysis was performed based on 
the basis of the 1131 patients for whom full information was available. The 
clinical profile (moderate [HR of 1.8; 95% CI, 1.5 to 2.1] or unfavorable [HR of 3.3; 
95% CI, 2.8 to 3.8]), a KPS of ≤70 (HR of 2.0; 95% CI, 1.8 to 2.3), and evidence of 
VBM (HR of 1.4; 95% CI, 1.2 to 1.5) were significantly associated with a higher 
risk of death. Stratification according to clinical profile in the multivariate 
analysis showed that a low KPS and the presence of VBM were associated with 
a shorter survival for all 3 profiles. A KPS of ≤70 doubled the risk of death in all 
profiles, with a HR of 1.9 (95% CI, 1.5 to 2.4), 2.2 (95% CI, 1.7 to 2.8), and 2.0 (95% 
CI, 1.7 to 2.5) for a favorable, moderate, and unfavorable clinical profile, 
respectively. The effect of VBM was the largest in the favorable profile, with an 
HR of 1.7 (95% CI, 1.3 to 2.1), 1.3 (95% CI, 1.0 to 1.7), and 1.3 (95% CI, 1.0 to 1.5) 
for a favorable, moderate, and unfavorable clinical profile, respectively. 
Prognostic model 
The cohort was divided into 12 categories on the basis of the combination of the 
3 prognostic variables. The median survival and survival at 1, 3, 6, 12, and 24 
months per category are presented in table 2.4. The discriminatory ability of 
these categories was 0.70. Figure 2.2 shows the flowchart to guide the 
stratification of patients with symptomatic LBM, with the corresponding 95% CIs 
for median overall survival for each category. The 4 clinically relevant categories 
(A [29% of the patients], B [19%], C [31%], and D [21%]) represent median 
survival of 21.9 months (95% CI, 18.7 to 25.1 months), 10.5 months (95% CI, 7.9 
to 13.1 months), 4.6 months (95% CI, 3.9 to 5.3 months), and 2.2 months (95% 








Table 2.1 Patient demographics  
Characteristic  
No. of patients 1520 
Age* (yr) 65.0 (12.8) 
Sex (no. [%])  
 Male 690 (46.4) 
 Female 830 (54.6) 
Karnofsky Performance Score† (no. [%])  
 80-100 648 (42.6) 
 ≤70 512 (33.7) 
 Unknown‡ 360 (23.7) 
Visceral metastases§ (no. [%])  
 Present 588 (38.7) 
 Not present 890 (58.6) 
 Unknown‡ 42 (2.8) 
Metastases to brain and/or central nervous system# (no. 
[%]) 
 
 Present 85 (5.6) 
 Not present 1413 (93.0) 
 Unknown‡ 22 (1.4) 
Tumor location (no. [%])  
 Femur 1029 (67.7) 
 Humerus 399 (26.3) 
 Tibia 60 (3.9) 
 Radius 14 (0.9) 
 Ulna 11 (0.7) 
 Fibula 7 (0.5) 
Location in bone (no. [%])  
 Proximal 1066 (70.1) 
 Shaft 303 (19.9) 
 Distal 133 (8.8) 
 Unknown 18 (1.2) 
Solitary bone metastasis (no. [%])  
 Yes 162 (10.7) 
 No 1181 (77.7) 
 Unknown 177 (11.6) 
*The values are given as the mean, with the standard deviation in parentheses. †Determined on the 
basis of the clinical description in 47% of the patients. ‡In total, data were missing for 389 patients; 
for 35 patients, data for >1 of the variables were missing. §As reported in recent radiology reports. 
#Presence of metastases was determined on the basis on recent radiology reports; metastases were 
considered not present if there was no clinical suspicion of brain metastases (therefore, no 
radiology). 
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Table 2.2 Primary tumors and their corresponding clinical profile 




(95% CI) (mo) 
Clinical profile 
Breast - positive* 369 (24.3) 18.7 (15.2–22.1) Favorable 
Breast - unknown† 112 (7.4) 18.7 (14.1–23.2) Favorable 
Kidney - solitary metastasis 25 (1.6) 18.1 (0.0-37.7) Favorable 
Thyroid 23 (1.5) 9.8 (0.0–23.5) Favorable 
Prostate 233 (15.3) 7.8 (6.5–9.1) Moderate 
Kidney - multiple metastases 85 (5.6) 8.1 (4.6–11.7) Moderate 
Other primary tumor‡ 20 (1.3) 3.8 (0.0-12.4) Moderate 
Soft tissue sarcoma 19 (1.3) 6.8 (5.5–8.1) Moderate 
Breast - triple negative§ 16 (1.1) 3.4 (1.4–5.4) Moderate 
Kidney – unknown# 16 (1.4) 10.3 (4.1-16.4) Moderate 
Endometrial carcinoma 9 (0.6) 12.2 (4.3–20.2) Moderate 
Osteosarcoma 8 (0.5) 4.0 (0.2-7.9) Moderate 
Ewing sarcoma 7 (0.5) 17.4 (10.8–54.1) Moderate 
Ovary 6 (0.4) 2.6 (2.0–3.2) Moderate 
Lung 363 (23.9) 2.9 (2.4–3.3) Unfavorable 
Colorectal 48 (3.2) 3.9 (2.6–5.2) Unfavorable 
Unknown primary 44 (2.9) 3.3 (1.5–5.1) Unfavorable 
Esophagus 32 (2.1) 3.4 (1.4–5.4) Unfavorable 
Bladder 25 (1.6) 3.8 (1.9–5.7) Unfavorable 
Melanoma 23 (1.5) 3.9 (2.2–5.6) Unfavorable 
Head and neck cancer 19 (1.3) 3.2 (0.7–5.6) Unfavorable 
Liver and/or pancreas 10 (0.7) 2.3 (0.2–4.4) Unfavorable 
Stomach 8 (0.5) 2.1 (0.7–3.4) Unfavorable 
*Estrogen, proesterone or Her2/neu positive; †Hormone receptor status and Her2/neu status were 
unknown; ‡Consisting of 5 patients each with cervical carcinoma and with multiple primary tumors; 
2 patients each with Merkel cel carcinoma, carcinoma of the adnexa, and uterine sarcoma; and 1 
patient each with a retroperitoneal paraganglioma, a neuroblastoma, a fibrous tumor of the thorax, 
and a carcinoma of the vulva. §Estrogen, progesterone, and Her2/neu negative. #The number of 






Table 2.3 Details of local treatment of bone metastasis 
Treatment No. (%) of patients 
Overall  
 Radiation therapy 1041 (68.5) 
 Surgery only 130 (8.6) 
 Surgery + adjuvant radiation therapy* 349 (23.0) 
Radiation therapy  
 1x8 Gy 656 (63.1) 
 2x8 Gy 83 (8.0) 
 5x4 Gy  124 (11.9) 
 6x4 Gy 133 (12.8) 
 Single fraction other 1 (0.1) 
 Multiple fractions other:   
 Total dose <20 Gy 12 (1.2) 
 Total dose >20 Gy 20 (1.9) 
 Unknown 2 (0.2) 
Surgery  
 Plate 30 (6.3) 
 Intramedullary nail 317 (66.2) 
 Endoprosthesis† 106 (22.1) 
 Dynamic hip screw 8 (1.7) 
 Resection only 7 (1.5) 
 Curettage and cement only 2 (0.4) 
 Unknown 9 (1.9) 
*Radiation therapy was considered adjuvant if administered within 8 weeks of surgery. †Including 
total prosthesis, hemiprosthesis, and modular prosthesis. 
Figure 2.1 Kaplan-Meier curve for overall survival stratified by the  
clinical profile and according to the time (in months) since treatment.  


















































































































































































































































































































































































































































































































































































































































































































Table 2.5 Patient demographics of external cohort 
Characteristic  
No. of patients 250 
Age* (yr) 66.3 (11.4) 
Sex (no. [%])   
 Male 112 (44.8) 
 Female 138 (55.2) 
Karnofsky Performance Score (no. [%])  
 80-100 79 (68.4) 
 ≤70 171 (31.6) 
Visceral metastases† (no. [%])  
 Present 129 (51.6) 
 Not present 121 (48.4) 
Metastases to brain and/or central nervous system‡ (no. 
[%]) 
 
 Present 15 (6.0) 
 Not present 235 (94.0) 
Tumor location (no. [%])  
 Femur 189 (75.6) 
 Humerus 39 (15.6) 
 Tibia 21 (8.4) 
 Ulna 1 (0.4) 
Location in bone (no. [%])  
 Proximal 162 (64.8) 
 Shaft 61 (24.4) 
 Distal 27 (10.8) 
*The values are given as the mean, with the standard deviation in parentheses. †As reported in 
recent radiology reports. ‡Presence of metastases was determined on the basis on recent radiology 
reports; metastases were considered not present if there was no clinical suspicion of brain 
metastases (therefore, no radiology). 
External cohort 
The external cohort included 250 patients (45% were male, with a mean age 66.3 
[and standard deviation] of 66.3 ± 11.4 years) (table 2.5). The median duration 
of follow-up and overall survival of the patients in the external dataset were 84.7 
months (95% CI, 58.4 to 111.1 months) and 7.8 months (95% CI, 6.2 to 9.3 
months), respectively. Overall survival rates at 1, 3, 6, 12, and 24 months (after 
stratification) are given in table 2.6. A large difference in overall survival between 
observed and expected was seen for category 5. This was predominantly due to 
2 patients in the external cohort with kidney cancer and a long survival of 89 
and 110 months. 
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Figure 2.2 Flowchart for stratification of patients with LBM. 
 
Figure 2.3 Kaplan Meier curve for overall survival stratified by 
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Discussion 
To offer patients with cancer and symptomatic LBM the most appropriate and 
tailored treatment, thus balancing morbidity and adverse effects with 
effectiveness, an accurate estimation of the expected survival is crucial. The 
survival estimation should be as precise as possible while obtainable in daily 
clinical practice. This study shows that a simple and clinically relevant estimation 
can be made based on clinical profile, KPS, and the presence of VBM.  
The prognostic significance of these 3 variables has been reported previously.8-
11,13,14 The primary tumor, which is the basis for the clinical profile in this study, 
is the foundation of all prognostic models. Performance status is also included 
in almost all recent models.8-11,13,14 The role of the evidence of VBM is less 
consistent. Although incorporated in several models,8,10-13 others state that the 
effect of VBM is not11 or only partially15 present. The transition from 12 to 4 
categories in the current study shows that, while the presence of VBM is 
associated with survival in all profiles, the impact on clinical decision-making is 
minimal. This is in accordance with the spinal metastasis prognostic model by 
Bollen et al.,15 in which the presence of VBM affects only the favorable clinical 
profile.  
Considering some of the shortcomings of previous prognostic models, the 
present study aimed to develop a quick and easy-to-use yet accurate prognostic 
model. The current model is thus based on a multidisciplinary cohort, excludes 
patients with multiple myeloma, and is up-to-date and easy to use. The clinical 
profile ensures sustainability of the model because of its dynamic description; 
it encompasses not only tumor growth speed, but also contributing factors, such 
as the effectiveness of evolving systemic treatments, which allow adjustment of 
the classification of a primary tumor.  The increase of targeted therapies will 
create subtypes in various primary tumor types in the future, and thus flexibility 
in the categorization is essential. Future adjustments could be changes in the 
classification of lung tumors with EGFR (epidermal growth factor receptor) 
mutations,25 melanomas with BRAF mutations,26 and prostate cancers with low 
initial prostate-specific antigen (PSA) levels and favorable Gleason scores.27  
The presented flowchart is simple to use; only 3 common variables are required, 
without the need for scoring. The chart stratifies between 12 different 
categories that can be narrowed down to 4 clinically relevant categories. The 12 
categories provide a detailed insight into the expected survival, which can be 
helpful knowledge to fine-tune an individuals’ treatment. The 4 grouped 
categories (A through D) are based on the cutoff points relevant for more 





to translate the median survival times to clinical decisions. This more simplistic 
version of the model could be envisioned without the shaded areas (VBM for 
moderate and unfavorable clinical profiles and the 95% CI for the median overall 
survival) in figure 2.2.  
An important limitation of the present study is the retrospective design. With 
this design, uniformity in diagnostics and treatments are not possible. The time 
frame of diagnostic tests has an influence on the interpretation of the presence 
of visceral, brain, and other bone metastases. Differences in local treatments 
between centers and over time are possible. Although a large influence of these 
factors on survival is not expected, they were incorporated in the multivariate 
analyses to correct for any possible effect. Systemic treatments were not taken 
into account in the analysis because they were beyond the scope of this study. 
Missing data are also a drawback of retrospective studies. In this study, the KPS 
was the most common missing variable. This was partly solved by interpreting 
clinical descriptions, but the latter is also a limitation as it is less objective than 
a scoring system.  Finally, the cohort includes only patients who received local 
treatment for a symptomatic bone metastasis. This introduces confounding by 
indication because patients who received solely systemic and/or supportive care 
were not represented in this study. This might have led to selection bias and 
possibly to estimations in this study that are too optimistic. Although this could 
have some influence on the generalizability of the study, the minimal life 
expectancy for referral for palliative radiation therapy is approximately 2 
months, so the effect of selection is expected to be minimal.28  
The discriminatory ability of the model presented in this study (0.70) is 
comparable to the model recently reported by Westhoff et al. They described a 
model that was based only on patients treated with radiation therapy for bone 
metastases throughout the skeleton and contained 2 variables (primary tumor 
and KPS) that yielded a C-statistic of 0.71.  
It is possible that higher discriminatory abilities might be obtainable in models 
with numerous variables; however, studies with such models have not noted C-
statistics and therefore cannot be compared.12,13,29 Additionally, it is important 
to note that the discriminatory ability in the current study is an accepted trade-
off against the simplicity, and thus convenience, of the current model in 
comparison to models with numerous variables. Also, while models with 
numerous complex variables might be able to discriminate in great detail, it is 
relevant to wonder whether such models lead to more relevant or better clinical 
decision-making. 
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The application of the model to the external cohort shows similar results 
between observed and expected survival, suggesting that that the model 
stratifies sufficiently in other data sets. Patients with a moderate clinical profile 
and good KPS (mostly patients with prostate or kidney cancer) showed better 
survival in the external population. This could be attributed to the heterogeneity 
of the populations and differences in systemic treatment and local treatment 
regimens between the 2 countries. 
In conclusion, the current study presents a model for easy and accurate 
stratification of patients with symptomatic LBM according to their expected 
survival. The versatility of the model enables easy adaptation to future 
developments concerning systemic treatments of primary tumors. The 
simplicity of the model should facilitate its use and result in an overall 
movement towards appropriate treatments of patients with metastases of the 
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This study aims to assess first, whether mutations in the epidermal growth 
factor receptor (EGFR) and Kirsten rat sarcoma (kRAS) genes are associated with 
overall survival (OS) in patients who present with symptomatic bone metastases 
from non-small cell lung cancer (NSCLC) and second, whether mutation status 
should be incorporated into prognostic models that are used when deciding on 
the appropriate palliative treatment for symptomatic bone metastases.  
Patients and Methods 
We studied 139 patients with NSCLC treated between 2007 and 2014 for 
symptomatic bone metastases and whose mutation status was known. The 
association between mutation status and overall survival was analysed and the 
results applied to a recently published prognostic model to determine whether 
including the mutation status would improve its discriminatory power. 
Results  
The median OS was 3.9 months (95% confidence interval (CI) 2.1 to 5.7). Patients 
with EGFR (15%) or kRAS mutations (34%) had a median OS of 17.3 months (95% 
CI 12.7 to 22.0) and 1.8 months (95% CI 1.0 to 2.7), respectively. Compared with 
EGFR-positive patients, EGFR-negative patients had a 2.5 higher risk of death 
(95% CI 1.5 to 4.2). Incorporating EGFR mutation status in the prognostic model 
improved its discriminatory power.  
Conclusion  
Survival prediction models for patients with symptomatic bone metastases are 
used to determine the most appropriate (surgical) treatment for painful or 
fractured lesions. This study shows that NSCLC should not be regarded as single 
entity in such models. 
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Introduction 
Lung cancer is the most common type of cancer worldwide and has the highest 
mortality.1 Non-small cell lung cancer (NSCLC) accounts for 85% of all lung 
cancers.2-4 In addition to the histological classification (adenocarcinoma, 
squamous cell carcinoma, and large cell carcinoma) NSCLC is increasingly 
defined at the molecular level by mutations which underlie the disease process. 
The most common are mutations in the epidermal growth factor receptor 
(EGFR) gene, which is present in approximately 10 to 15% of patients, and the 
Kirsten rat sarcoma (kRAS) gene, which is present in approximately 30%.5  
EGFR and kRAS function sequentially in the same signalling pathway and are 
therefore mutually exclusive.6 The discovery of these oncogenes has led to the 
development of targeted systemic therapies in the form of tyrosine-kinase 
inhibitors (TKIs; e.g. erlotinib, gefitinib) for patients with an active mutation in 
the EGFR gene: these gave an increased survival of four to five months.7-9 
Similarly effective treatment is not currently available for kRAS mutations. The 
predictive role of kRAS mutations is still unclear: some trials report a worse 
overall survival,10,11 while others do not identify a difference.12,13 
Bone metastases occur in 30 to 40% of patients with lung cancer.14 However, 
this figure can be expected to increase as the survival of patients with lung 
cancer improves with treatment that is more effective. The local treatment of 
BM consists of radiotherapy and/or surgery, depending on the presentation and 
symptoms. If pain is the most predominant symptom, radiotherapy is the 
mainstay of treatment: it is not invasive and reduces pain in more than 60% of 
patients.15 Surgical treatments, whether for fracture or prophylaxis of 
impending fracture, range from minimal invasive procedures to extensive 
resection and reconstruction. It is usually indicated when mobility and/or 
neurological functioning are affected.   
While the treatment of bone metastases can relieve pain and increase mobility 
and quality of life, it can also cause complications, additional toxicity, and co-
morbidity. The need for local treatment should be weighed against a patients’ 
predicted survival to ensure the best treatment.  
Several methods of estimating survival have been developed to help patients 
and their doctors choose the most appropriate palliative local treatment for a 
painful or fractured metastatic lesion.16-20 Although the models differ, they all 
include the primary tumour type as the most important variable. In all models, 
the primary tumour is subdivided into several categories, based on speed of 
tumour growth and, in some cases, the therapeutic possibilities. Currently, all 





However, with the increased effect of mutations on outcome, consideration 
should be given to whether lung cancer should remain included as single 
tumour type. For example, patients with EGFR mutations might fit better in a 
‘moderate/intermediate’ tumour profile. A different tumour profile in these 
models would give a more optimistic prognosis and result in other strategies of 
local treatment being considered. For example, a prosthesis might be used 
instead of an intramedullary nail to treat a pathologic fracture if a longer survival 
was expected.  
The aim of this study was to determine first, if EGFR and kRAS mutations are 
associated with overall survival in patients with NSCLC who present with 
symptomatic bone metastases, and secondly whether mutation status can be 
used to differentiate between patients when estimating survival. 
Patients and Methods 
We carried out a retrospective analysis of all patients with NSCLC who had been 
treated for bony metastases of the spine, pelvis or long bones in the 
radiotherapy and/or orthopaedics departments of a tertiary referral centre 
between 2007 and 2014. Patients were identified from a search of our surgical 
and radiotherapy databases. Only patients with metastases in the spine, pelvis 
or long bones caused by histologically-proven NSCLC whose tumours had 
undergone analysis for EGFR and kRAS mutations were included. Patient 
characteristics at the time of treatment were collected from medical and 
pathology records and included age; gender; location of bone metastasis; 
presence of visceral or brain metastases; Karnofsky Performance Scale (KPS);21 
local treatment of the bone metastasis; (previous) systemic treatment for the 
primary tumour; mutation status and outcome (alive or dead).  
The presence of visceral metastases was determined on radiology reports. Brain 
metastases were identified clinically; whole brain CTs or MRIs were not routinely 
undertaken. The KPS scores the functional ability of patients with a range from 
0 to 100; with a higher score meaning the patient is better able to perform daily 
activities.21 KPS scores were divided into two groups: 0 to 70 and 80 to 100. 
Systemic treatment was described as ‘standard chemotherapy’ for platinum-
based chemotherapy regimens and ‘targeted therapy’ for tyrosine kinase 
inhibitors. The use of systemic treatment was registered at the time of 
treatment of local bone metastasis. Mutation status was defined as EGFR-
positive, kRAS-positive, or ‘wild type’ if neither EGFR nor kRAS mutations were 
present. EGFR and kRAS mutations were determined by competitive allele-
specific hydrolysis probes (Taqman) PCR technology (CAST).22 If this proved 
inconclusive, additional classic DNA Sanger sequencing of exon 18 to exon 21 of 
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the EGFR-gene was undertaken. All analyses were performed in the same 
laboratory at the Leiden University Medical Center. 
Statistical analysis 
Survival time was calculated as the interval between the treatment for the bone 
metastasis and death or final follow-up. Survival curves were produced using 
the Kaplan-Meier method and compared with log-rank tests. Median follow-up 
was estimated with the reversed-Kaplan-Meier method.23 The association 
between EGFR and kRAS mutations on overall survival (OS) was assessed using 
Cox proportional hazards models. A p-value of <0.05 was considered statistically 
significant.  
 
Figure 3.1 Prognostic model for overall survival as developed by Bollen et al.. Categories (A-D) 
correlate with expected survival in months.  
To illustrate the association of EGFR with overall survival in survival prediction, 
the cohort was stratified according to a previously published model (figure 3.1)16 
both before and after adjusting the primary tumour type for the presence of the 
EGFR mutation. In the model, based on a Cox proportional hazards model, 
primary tumours are divided into three different tumour profiles: favourable 
(median survival 18.6 months; 95% confidence interval (CI) 15.1 to 22.1), 





(median survival 2.2 months; 95% CI 1.9 to 2.6). In combination with two other 
factors (KPS and the presence of visceral and/or brain metastases) the tumour 
profile leads to a final category (A to D). These final categories correlate with 
survival. The median overall survival is 31.2 (95% CI 25.2 to 37.3), 15.4 (95% CI 
11.9 to 18.2), 4.8 (95% CI 4.1 to 5.4) and 1.6 (95% CI 1.4 to 1.9) months for 
category A, B, C, and D respectively. Harrell’s C-statistic was used to assess 
whether adding EGFR to the tumour profile improved the discriminatory ability 
of the prognostic model. 
All analyses were performed using SPSS 23.0 (SPSS Inc., Armonk, New York). 
Results  
In the study period, 432 patients with lung cancer underwent local treatment for 
symptomatic bone metastases. The mutation status was available for 139 
patients (32%) (53% male) with a mean age of 63.6 years (range 36.3 to 80.9). 
The baseline patient and tumour characteristics are presented in table 3.1. An 
EGFR mutation was present in 21 patients (15%) and a kRAS mutation was 
present in 47 patients (34%), 71 patients (51%) were wild type for both 
mutations.  
All patients with EGFR mutations received TKIs at some point during their 
disease process, however only five (24%) were already on TKI treatment when 
they presented with symptomatic bone disease for a mean of 3.5 months (range 
0.8 to 6.4). The other patients received TKIs after a mean of 2.3 months (range 
0.1 to 10.1). The most commonly prescribed TKI was erlotinib (67%; 14 patients). 
Most patients without EGFR mutations (72%; 85 patients) underwent platinum-
based chemotherapy: in 42% (36), chemotherapy was started after local 
treatment of the bone metastasis. The most common chemotherapy regimens 
were carboplatin/vinorelbine (20%) and carboplatin/pemetrexed (20%). 
The median follow-up was 38.1 months (95% CI 26.9 to 49.3). Median OS was 
3.9 months (95% CI 2.1 to 5.7), while mean OS was 8.4 months (95% CI 6.5 to 
10.3). At final analysis, nine patients (6.5%) were still alive, four had EGFR 
mutations, two had kRAS mutations and two patients had ‘wild type’ NSCLC. No 
patients were lost to follow-up. 
Overall survival differed significantly between patients with EGFR mutations, 
kRAS mutations and ‘wild type’ patients. For patients with EGFR mutations, the 
median OS was 17.3 months (95% CI 12.7 to 22.0), while the median OS was 1.8 
months (95% CI 1.0 to 2.7) and 4.0 months (95% CI 1.2 to 6.8) for patients with 
kRAS mutations and ‘wild type’ patients, respectively (p = 0.001, log rank test; 
figure 3.2).  
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The difference in OS between patients with kRAS mutations and ‘wild type’ 
patients was not significant (p = 0.200, Cox regression), so kRAS was added to 
the wild type group, leading to a combined category ‘EGFR-negative’. The 
median OS for the combined category was 2.8 months (95%CI 1.4 to 4.2). The 
corresponding hazard ratio (HR) for EGFR-negative compared with EGFR-
positive for the endpoint overall survival was 2.5 (95% CI 1.5 to 4.2, p=0.001; 
figure 3.3).  
Table 3.1 Patient and tumour characteristics in 139 patients with NSCLC treated with radiotherapy 
and/or surgery for symptomatic bone metastases 





Number of patients (% all patients) 139 21 (15) 47 (34) 71 (51) 
Age; mean in years  63.6  62.5 64.8  63.2  
     
Gender: male 73 (53) 7 (33) 17 (36) 49 (69) 
Karnofsky Performance Score     
 80 – 100 39 (28) 10 (48) 10 (21) 19 (27) 
 0 – 70 86 (62) 9 (43) 34 (72) 43 (61) 
 Unknown 14 (10) 2 (10) 3 (6) 9 (11) 
Visceral or brain metastases     
 Present 66 (48) 8 (38) 25 (53) 33 (47) 
 Not present 73 (52) 13 (62) 22 (47) 38 (54) 
Location bone metastasis     
 Spine 47 (34) 4 (19) 21 (45) 22 (31) 
 Long bone and/or pelvis 44 (32) 9 (43) 8 (17) 27 (38) 
 Spine & long bone and/or pelvis 48 (35) 8 (38) 18 (38) 22 (31) 
Stage IV at diagnosis     
 Yes 118 (85) 18 (86) 43 (91) 57 (80) 
 No 21 (15) 3 (14) 4 (9) 14 (20) 
Treatment of primary tumor     
 None 106 (76) 18 (86) 37 (79) 51 (72) 
 Radiotherapy 24 (17) 1 (5) 9 (19) 14 (20) 
 Surgery 6 (4) 1 (5) 0 5 (7) 
 Radiotherapy & surgery 3 (2) 1 (5) 1 (2) 1 (1) 
Local therapy bone metastasis     
 Radiotherapy  123 (89) 18 (86) 42 (89) 63 (89) 
 Surgery 1 (1) 0 0 1 (1) 
 Radiotherapy & surgery 15 (11) 3 (14) 5 (11) 7 (10) 







Figure 3.2 A Kaplan Meier curve shows the overall survival of 139 non-small cell 
lung cancer patients with bone metastases by mutation status (‘wild type’ for both 
mutations n = 71; epidermal growth factor receptor (EGFR) n = 21; Kirsten rat 
sarcoma (kRAS) n = 47) (p = 0.001). Time (0) = moment of local treatment of 




Figure 3.3 A Kaplan Meier curve shows the overall survival of 139 non-small cell 
lung cancer patients with bone metastases by epidermal growth factor receptor 
(EGFR) mutation status (EGFR-positive n = 21; EGFR-negative n = 118) (p = 0.000). 
Time (0) = moment of local treatment of symptomatic bone metastasis. 
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Table 3.2 Median survival times before and after model adjustment for EGFR mutation 
Predictive 
category* 




95% CI p-value± 
Before adjustment     
A NA NA NA NA NA 
B NA NA NA NA NA 
C 39 10.1 (3.0 – 17.2) 0.5 0.3 – 0.7 <0.001 
D 86 2.0 (1.3 – 2.7) - - - 
After adjustment     
A NA NA NA NA NA 
B 10 17.3 (12.3 – 22.3) 0.3 0.1 – 0.6 0.001 
C 38 6.0 (2.4 – 9.6) 0.5 0.3 - 0.7 0.001 
D 77 1.8 (0.9 – 2.8) - - - 
*Categories A-D based on model in figure 3.1; ±log rank test; OS: overall survival;  
CI: confidence interval; NA: not applicable (no patients in this category). 
 
Based on the overall survival results, the classification of primary tumours in the 
model was re-evaluated. The median survival of patients with EGFR mutations 
differs from that of patients with an unfavourable profile. The classification was 
therefore adjusted and NSCLC with an EGFR mutation was categorized as 
‘moderate’ profile.  As a result, ten patients were reclassified as category B 
instead of category C and nine patients as category C instead of category D. The 
median survival of category C decreased from 10.1 months (95% CI 3.0 to 17.2) 
to 6.0 (95% CI 2.4 to 9.6) (table 3.2). The C-statistic was 0.60 before the 
adjustment and 0.63 after the adjustment, indicating an improvement in the 
discriminatory ability of the model. 
Discussion 
The aim of this study was to determine whether EGFR and kRAS mutations are 
associated with overall survival and can therefore be used as discriminating 
factors for survival in patients presenting with symptomatic bone metastases 
from NSCLC. The results show a significant difference in median survival 
between patients with EGFR mutations (17.3 months, 95% CI 12.7 to 22.0), kRAS 
mutations (1.8 months, 95% CI 1.0 to 2.7), and ‘wild type’ patients (4.0 months, 
95% CI 1.2 to 6.8). The difference in overall survival between patients with kRAS 
mutations and wild type patients was not significant, but the lack of an EGFR 
mutation resulted in a significantly shorter overall survival compared with 
patients with EGFR mutation (HR 2.5; 95% CI 1.5 to 4.2). Applying this result to 
the tumour stratification category of a prognostic model improved the 





An important limitation of this study is its retrospective design and associated 
risk of missing data. In particular, the mutation status was not available for many 
patients who could not therefore be included in the analysis. Due to the 
retrospective design, there is also a risk of indication bias about the systemic 
treatments that patients underwent. The aim of this study, however, was not to 
determine the effect of treatment but whether it is possible to distinguish 
patients who had a better survival. Therefore, although mutation status and 
treatment are inseparably linked, the impact of indication bias on our research 
question is limited. The period of illness will not have influenced the use of TKI 
because the cohort only contained patients from 2007 onwards to avoid bias 
from the availability of the treatment. When predicting survival, factors such as 
visceral metastases and performance score were taken into account as separate 
variables, so they need not be considered when categorising the primary 
tumour.  
The development of TKIs has made EGFR a widely recognized positive predictive 
factor for survival in patients with both early and advanced disease.24-26 With 
only standard platinum-based chemotherapy, patients with an EGFR mutation 
survived longer than patients without the mutation.6 Although the percentage 
of detected EGFR mutations (15%) in the current study was lower than that in 
other studies (25% to 27%)5,27 it was sufficient to detect a significant effect on 
overall survival. This difference in overall survival between patients with and 
without EGFR mutation must be attributed to the effect of TKIs.7,24,28 However, 
considering all patients have stage IV disease, the difference in survival is 
astonishingly large. This makes one wonder whether the effect of TKIs is 
possibly even greater when patients present with symptomatic bone 
metastases than in earlier stage disease. 
The current study does not explore the role of TKIs because all patients received 
TKIs at some point in the disease process. However, many patients did not 
receive TKIs until after treatment of the bone metastasis because the diagnosis 
of the bone metastasis was made at the same time as that of the primary 
tumour. Any effect of treatment after the baseline cannot be taken into account 
when determining the expected survival at baseline.  
When using the results from the current study to predict survival in current 
clinical practice, it does not matter if the difference in survival is made by the 
treatment or the mutation, since most patients will receive or have received 
TKIs. The apparent difference in survival shown by this study applies to any 
NSCLC patient who presents with symptomatic bone metastases, whatever their 
previous course of disease and its treatment. 
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This single-centre study provides a comprehensive analysis of a recent cohort 
of patients with NSCLC and bone metastases. One of the relevant aspects of the 
current study is the timing of assessment (i.e. at presentation with symptomatic 
bone metastases). Although many studies have analysed the risk factors for 
developing symptomatic bone metastases in patients with NSCLC,29-31 only a few 
have studied the prognostic factors once these symptoms become apparent.32-
35 It is exactly at this point that it is important to predict survival so that the 
appropriate local treatment can be chosen. Studies that have focused on this 
time-point are limited either because of the absence of EGFR and kRAS 
mutations in the analyses33-35 or by the relatively small number of patients 
included.32 Sugiura et al.35 reported an increased survival with TKI treatment but 
did not state whether these patients had EGFR mutations. Bae et al.32 have also 
described a protective effect of TKI treatment and, although they note lack of 
significance for an EGFR mutation, this is based on only ten patients with EGFR 
mutations. 
The updated survival prediction model of Katagiri et al.17 is currently the only 
method of distinguishing between different types of lung cancer, albeit in an 
indirect manner. In their model, patients treated with TKIs (gefitinib and/or 
erlotinib) were described as having a ‘moderately growing’ tumour, while all 
other lung cancer patients had ‘rapidly growing’ tumours. Classifications based 
on the medication received or the characteristics of the primary tumour (i.e. 
mutations) probably have the same outcome as it is assumed that most patients 
with an EGFR mutation receive these drugs. However, it is possible that a 
classification based on the medication received is more difficult to apply in daily 
practice because of changes over time in the use of medication. Meanwhile, the 
presence of a mutation is established at baseline and does not fluctuate over 
time, making it a constant variable.  
In conclusion, this study shows that NSCLC patients with bone metastases and 
EGFR mutations who are treated with TKIs have an improved overall survival 
when compared with EGFR-negative patients. This is of importance for all those 
involved in the care of patients with metastatic bone disease from NSCLC 
because prediction of survival is crucial in determining the most appropriate 
treatment strategy, especially the type of surgical treatment, for painful or 
fractured lesions. The sub-types of NSCLC should be incorporated in prognostic 
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Patients with disseminated cancer and bone metastases have a limited life 
expectancy and therefore any treatment should have a clear beneficial effect, 
outweighing all possible downsides. This systematic review aims to identify and 
evaluate available evidence regarding function, pain, quality of life, survival and 
complications of postoperative radiotherapy (RT) after surgical stabilization of 
impending or actual pathologic fractures of the long bones due to bone 
metastases.  
A literature search resulted in two articles reporting on 64 and 110 patients of 
whom 55% and 28% received postoperative RT, respectively. Both studies were 
retrospective cohort studies and postoperative RT had been administered 
depending on the surgeons’ choice. The first study reported better outcomes 
regarding function, re-interventions and survival in patients receiving 
postoperative RT. The second study reported no significant difference regarding 
complications between the two groups. The quality of the evidence was very low 
due to the observational character of both studies, risk of indication bias, small 
study sizes, use of non-standardized outcome measures, and limited statistical 
analyses.  
The current available literature is insufficient to conclude whether postoperative 
RT after surgical stabilization should be standard care. It is important to realize 





Bone metastases arise in up to 70% of all patients suffering from advanced 
cancer.1,2 Half of those patients develop one or more complications, with 
pathologic fractures occurring in 5-10% of patients.3,4 When a fracture affects 
the long bones a surgical stabilization of the bone is required to treat the pain 
and to retain a functional limb.5 Surgery is also indicated as prophylaxis for 
patients with metastatic lesions at a considerable risk of fracturing. Surgical 
treatment options are vast and choices are made depending on localization, size 
and type of lesion, mechanical stability (i.e. fracture or impending fracture), and 
expected morbidity of the procedure in relation to the condition and expected 
survival of the patient. After surgery, patients are often referred for adjuvant 
radiotherapy (RT). Multiple reviews advise a short-course RT using five to ten 
fractions after surgical treatment as it would promote bone healing, prevent 
tumor progression, minimize the risk of implant failure, and decrease the rate 
of secondary procedures.6-12 However, all these studies base their advice on a 
single, retrospective cohort study.13 This was perceived as remarkable by the 
authors, especially because postoperative radiotherapy concerns a prophylactic 
treatment in patients with generally a limited life expectancy. 
The life expectancy plays a large role in determining the most suitable 
treatment, including the necessity of postoperative RT. Several factors play a 
role to determine survival,14,15 however primary tumor type is the most 
important. Postoperative events that could be prevented by radiotherapy, such 
as tumor progression and implant-failure, need time to develop. Therefore, the 
majority of the complications will likely occur only in patients who live long 
enough. For all other patients, the downsides of RT might outweigh the potential 
benefit. Downsides consist of the risk for complications, such as skin and gastro-
intestinal problems, wound-healing problems in the post-operative period,16 
and non-union.17 In addition, despite the generally short schedules that are 
given, multiple (up to ten) extra visits to the hospital are needed for planning 
and performing the treatment.  
On the whole, this palliative, adjuvant and prophylactic treatment requires time 
and energy of a fragile patient and might negatively affect the quality of life, 
while the beneficial effect is unclear. The purpose of this systematic review was 
to identify and evaluate available evidence regarding function, pain, quality of 
life, survival and complications of postoperative RT after surgical stabilization 
compared to surgery only in patients with impending or actual pathologic 






We report our results according to the MOOSE Guidelines for reporting 
systematic reviews.18  
Search strategy 
A literature search with the help of a medical librarian was performed on July 6th 
2015 using the Pubmed, Embase, Web of Science and Cochrane databases 
without publication-date limits. The following keywords were searched: bone 
metastasis, skeletal metastasis, osseous metastasis, skeletal metastatic disease, 
secondary bone neoplasm, spontaneous fracture, pathologic fracture, 
postoperative radiation, postoperative radiotherapy, post-operative irradiation. 
Additionally, reference lists of retrieved papers, review articles, and clinical 
practice guidelines were checked for relevant publications. 
Study selection 
Two authors (JW, PDS) independently selected studies for inclusion. Titles and 
abstracts were screened using predefined eligibility criteria. Studies reporting 
on outcomes regarding function, pain, quality of life, survival and complications 
of patients undergoing surgery and adjuvant radiotherapy compared to patients 
undergoing surgery only for metastases of the long bones in English, Dutch or 
German were included. Meeting abstracts, case reports, guidelines, reviews and 
editorials were excluded (figure 4.1). 
Data extraction 
One author (JW) abstracted the following data items: patient demographics, 
treatment details, follow-up reports, functional outcomes, complications, 
failures, and quality of evidence.  
Quality assessment 
Assessment of the methodological quality of the included articles was 
performed according to the grading of recommendation, assessment, 
development and evaluation (GRADE) approach.19 The evidence for each 
outcome is rated as high, moderate, low or very low. Randomized controlled 
trials (RCTs) provide high-quality evidence unless they are downgraded 
depending on risk of bias, inconsistency, indirectness, imprecision and 
publication bias. Evidence from non-randomized studies is regarded low-quality 




Figure 4.1 Flowchart of the study selection process. N = number of studies. 
Results 
Study selection 
The search strategy resulted in 195 unique titles. Reviewing the reference lists 
did not lead to additional papers. After screening, three studies13,20,21 met the 
inclusion criteria (figure 4.1). However, two publications by Townsend et al. were 
nearly identical; they describe the same cohort with the same research 
questions and multiple identical paragraphs. The most complete paper was 







Exclusion based on (n= 192):
- population (n = 91)
- intervention (n = 28)
- outcome (n = 25)
- study design (n = 16)
- publication type (n = 27)
- language (n = 5)



































Both included studies were retrospective reviews of patient cohorts. Table 4.1 
presents the characteristics of the included studies. The outcome measures 














































































































































































































































































































































































































Townsend et al.20 aimed to compare the outcome of orthopedic stabilizations 
for impending or pathologic fractures with or without postoperative RT in 60 
patients with 64 procedures. Patients who had received previous RT to the 
fracture site were excluded. After surgery patients were referred for RT if the 
treating orthopedic surgeon ought this necessary. This occurred in 55% of the 
cases (table 4.2).  
Table 4.2 Distribution of treatments by fracture type 
  Surgery only Surgery + RT 
Townsend (1994)20 All fractures 29 (45%) 35 (55%) 
 Actual fracture 21 (72%) 18 (51%) 
 Impending fracture 8 (28%) 17 (49%) 
 









**Data not reported. RT: radiotherapy. 
 
Table 4.3 Outcomes and results per treatment group 
 Outcome Total Surgery only Surgery + RT p 
Townsend 
(1994)20 
1. Function status 1 
or 2 
2. Re-intervention 























1. Complications 21 (20%) 17 (21%) 4 (13%) 0.301* 
RT: radiotherapy. *As calculated by the authors of this review (Chi-square test). Van Geffen et al. 
reported the outcome merely as ‘not significant’. 
 
A self-developed scoring system was used to analyze functional outcomes. The 
endpoint for analysis of function (functional status 1 or 2) was defined as 
‘normal, pain-free use of the extremity (status 1)’ or ‘normal use with pain (status 
2)’. The other functional outcomes (status 3 or 4) were defined as ‘significantly 
limited use requiring some type of prosthesis (e.g. walker, cane, crutches)’ or 
‘non-functional (e.g. wheelchair-bound or bedridden)’. In the group of patients 
who had received RT the observed proportion of patients with a functional limb 
at any time was 53% versus 11.5% for surgery only (table 4.3). On multivariate 
analysis, including postoperative RT (univariate p = 0.026), pre-fracture 
functional status (univariate p = 0.045), type of surgical procedure (univariate: 





postoperative RT was significant to achieve a functional status 1 or 2 (p=0.026).  
It is not reported why fracture type was not included in the multivariate model. 
Moreover, according to the methods section of the article, the Cox model 
analysis was run twice with different sets of variables because of the limited 
sample size, however this is not described as such in the results section. The 
study reports less second orthopedic procedures to the same site for patients 
receiving surgery and RT (1 of 35 sites vs. 4 of 29 sites; table 4.3). Finally, the 
study reports a better survival in patients receiving surgery with RT: median 12.4 
months compared to 3.3 months (p=0.025; table 4.3). At univariate level, 
postoperative RT (p=0.025) and type of fracture (p=0.05) were significant 
predictors for survival. On multivariate analysis, postoperative RT (p=0.025; 
table 4.3) and type of surgery (p=0.05) remained significant. No results of other 
variables in uni- or multivariate analysis are reported.  
Van Geffen et al.21 reported on the effect of RT on complication rate as a 
secondary outcome in their retrospective cohort study. The study focused 
primarily on the mobility levels before and after surgery, independent of 
adjuvant therapy. Postoperative RT was administered to 28% of all surgical 
patients (table 4.2). Details concerning indications for certain strategies are not 
provided. The results concerning postoperative RT report 21% complications in 
the non-irradiated group versus 14% of the patients receiving postoperative RT 
(table 4.3). All complications were bone-related, i.e. failure of the osteosynthetic 
device or implant, and progression or recurrence of disease. The authors 
describe this as a remarkable, but not statistically significant difference. 
Unfortunately, no further details are presented.  The authors report no 
difference in pain relief, or use of analgesic drugs between the two groups 
however this is not supported by reported numbers. 
Quality assessment 
Due to the retrospective cohort design and the risk of bias of both included 
studies, the evidence for all study outcomes is regarded as ‘very low’ quality 
according to the GRADE approach.  
Discussion 
This study aimed to evaluate available evidence regarding the effect of 
postoperative RT after surgical stabilization of (impending) pathologic fractures. 
A search of the literature resulted in only two publications that met the inclusion 
criteria. The outcomes of the included studies should be interpreted with 
caution due to the very low quality of the evidence. 
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Firstly, the study designs lead to a large risk of indication bias. In both studies 
the allocation of adjuvant RT was performed by judgment of the surgeon. 
Neither article elaborates on the reasons for referring some patients for 
postoperative RT and not referring others. However, it is very plausible that 
patients who are in relatively good health and with a longer expected survival 
are considered for postoperative RT, while those in poor health and with a short 
expected survival are not referred. As Townsend et al. acknowledge, this is likely 
to explain the large difference in survival they register between the groups with 
or without postoperative RT. The distribution of the number of patients with an 
actual fracture between the treatment groups also supports this bias; a larger 
proportion of surgery-only patients had an actual fracture (72%) than the 
surgery plus radiotherapy patients (51%) (table 4.2). Patients with actual 
fractures are generally in a more advanced disease stadium. Moreover, in the 
study by Townsend et al. these patients were older and had worse pre-fracture 
functional status. It is quite likely that these patients had further progressive 
disease.  
Secondly, the small number of patients (64 and 110 patients) limits the 
generalizability of the studies. Although Townsend et al. had enough patients to 
detect a significant difference, the results of these small retrospective, non-
randomized cohorts cannot be projected as advice for treatment in future 
patients.  
Thirdly, Townsend et al. applied a self-designed, non-validated functional 
scoring system as outcome. The authors do not describe the definition of 
normal use; is normal use implied if walking-aids were not needed, or if a patient 
was not wheelchair-bound or bedridden? Furthermore, a more detailed 
functional outcome by the range of motion or impairment of flexion or 
extension for example, is not described. The difference between status 1 and 2 
is defined by the presence of pain, however the use of pain medication is not 
taken into account. Neither does the article report whether the function is 
reported by the patient, or whether it is interpreted by the clinician.  
Fourthly, due to the lack of complete reporting of uni- and multivariate analyses 
it is unclear how the authors adjusted for confounding variables and the effect 
this had on the outcomes. Hazard ratios are not presented, so the actual effect 
of the prognostic factor is not known. In the article by van Geffen et al. statistical 
results were not described at all. For the functional status in the article by 
Townsend et al. the p-value for post-operative radiotherapy was the same on 
uni- and multivariate analysis without further clarification; this appears as a 
strange coincidence. Neither article describes how they accounted for the effect 





outcome17,22 and survival.15,23 Also, the analysis on the effect of RT on functional 
outcome should not only have considered the type of fracture and surgery, but 
also the extent of tumor excision. Extensive surgery including curettage and 
possibly augmentation will leave less residual tumor, while minimally invasive 
procedures leave all tumor mass in situ. The expected benefit of radiotherapy 
is thus less likely after a more extensive excision, than after a minimally invasive 
procedure. The manner in which the surgery types have been classified in the 
study by Townsend et al. does not sufficiently take the extent of tumor excision 
into consideration. 
Finally, the statistical analyses do not take the competing risk of death into 
account when analyzing the risk factors for local progression and implant 
failure. This would have given a more realistic, and possibly reduced, risk of 
complications.24 
It is remarkable that although the supporting evidence of postoperative RT is 
limited to only two studies with low quality of evidence this adjuvant treatment 
has found such a widespread implementation throughout the Western 
countries. In addition, although a few other studies on the same topic report on 
outcomes after surgery with or without RT, they lack a comparison of the 
outcomes between both treatment strategies.22,25,26 Comparing the outcomes 
of all these studies was not possible due to the heterogeneity of the treatments 
and study populations. Also, the descriptions of the results concerning 
postoperative RT are not detailed enough to enable analysis. This leaves the 
significant clinical question of the efficacy of postoperative RT unanswered.  
Reasons for the apparent lack of research are unclear, but might be due to the 
palliative setting of the surgical treatment, the way surgeons are trained and the 
multidisciplinary aspect of the treatment. Together this might lead to less 
awareness of the need for evidence of this adjuvant treatment.  
The article by Townsend et al. has been cited multiple times, however referring 
papers seldom question the quality of the study.7,8,12,27 Several authors have 
reported a possible irrelevance or disadvantage of adjuvant RT, however not 
based on concise research.28-31 Dijkstra et al. report the risk of impaired healing 
due to the suppression of the chondrogenetic phase of secondary ossification 
caused by radiotherapy.29 Hoskin mentions that postoperative RT might be 
irrelevant in many patients due to the short survival.31 He makes an important 
comment on the lack of knowledge concerning the true incidence of tumor 
progression as well as the clinical significance of progression. However, Hoskin 
also warns for potential problems when a patient survives a sufficient time for 
tumor progression to occur. Epstein et al. also recognize the limited available 
evidence for postoperative RT.32  
Postoperative radiotherapy 
 73 
The effect of postoperative RT should be analyzed with consideration of the 
expected survival of patients with disseminated cancer and in the context of 
quality of life, instead of in quantitative outcomes such as number of 
complications or revision surgeries. Despite improvements in survival over the 
last decades, median survival for patients ranges from 2 months for lung cancer 
to 7 months for prostate and 19 months for breast cancer.14 It is plausible that 
the benefits of RT will outweigh the downsides in patients with a long-term 
survival. However, for patients with a medium-term or short-term survival, the 
negative effects of RT on the quality of life might be larger than the risk of local 
progression or implant-failure. While a beneficial effect of radiotherapy on the 
quality of life has been shown in the setting when radiotherapy is the only 
treatment, this has not been investigated when radiotherapy is administered 
post-operatively. It is possible that all improvements in quality of life for patients 
after surgery and adjuvant radiotherapy are due to the surgical stabilization. In 
that case, adjuvant radiotherapy costs time and brings a risk of side effects, 
which can negatively influence the quality of life.   
Additionally, it is essential to recognize the increase of pharmacological bone-
directed therapies and their role in bone strengthening and prevention of 
complications. Although the specific impact of such treatments on 
postoperative quality of life is unknown, it is not unimaginable that they reduce 
the risk of local tumor expansion and corresponding complications. This would 
even further dilute any effect of postoperative radiotherapy. Furthermore, the 
role of these therapies should be taken into account when interpreting the 
results of the study by Townsend et al., for this study was performed in an era 
before systemic therapies were widely administered.  
Based on the results of this review, a firm conclusion on the standard use of 
postoperative radiotherapy cannot be drawn. However, it can be concluded that 
substantial evidence for postoperative radiotherapy is lacking. In an era where 
evidence-based medicine is the backbone of all decision-making, this can be 
considered as peculiar at the least, especially when it concerns a palliative 
treatment in patients with a limited life expectancy. The number of patients with 
bone metastases in need of surgical fixation will increase in the future. To 
provide the most optimal palliative care to maintain quality of life, conclusive 
research should determine whether postoperative RT has a beneficial effect. 
Establishing a large, multi-center randomized study will provide further insights 
and lead to a firmer substantiated treatment plan for patients with bone 
metastases of the long bones. Foremost, all clinicians should realize that any 
firm evidence for or against postoperative RT is lacking and that it is unknown 
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The aim of this study was to assess the current trends in the estimation of 
survival and the preferred forms of treatment of pathological fractures among 
national and international general and oncological orthopaedic surgeons, and 
to explore whether improvements in the management of these patients could 
be identified in this way.  
Methods 
All members of the Dutch Orthopaedic Society (DOS) and European 
Musculoskeletal Oncology Society (EMSOS) were invited to complete a web-
based questionnaire containing 12 cases.  
Results 
A total of 96 (10.1%; groups 1 and 2) of 948 members of the DOS and 33 (18.1%; 
group 3) of 182 members of the EMSOS replied. The estimation of survival was 
accurate by more than 50% of all three groups, if the expected survival was short 
(<3 months) or long (>12 months). General orthopaedic surgeons preferred 
using an intramedullary nail for fractures of the humerus and femur, 
irrespective of the expected survival or the origin of primary tumour or the 
location of the fracture. Oncological orthopaedic surgeons recommended 
prosthetic reconstruction in patients with a long expected survival.  
Discussion 
Identifying patients who require centralised care, as opposed to those who can 
be adequately treated in a regional centre, can improve the management of 
patients with pathologic fractures. This differentiation should be based on the 
expected survival, the type and extent of the tumour, and the location of the 
fracture. 
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Introduction 
The most common malignant bone tumours in adults are metastases.1 The 
increased number of patients with cancer, due to the ageing population, and 
their increased survival due to continuously improving systemic treatments, 
have increased the number of patients with bone metastases.2 Although 
primary bone tumours are usually treated by specialized oncological 
orthopaedic surgeons, pathological fractures caused by metastases are 
generally treated by all orthopaedic surgeons, and in some countries also by 
trauma surgeons. Some hospitals may have protocols that assign the care of 
these fractures to a certain specialist, but generally treatment is performed by 
whomever the patient is referred to. It is not known whether this has an adverse 
effect on the standard of care, but it can be hypothesized that the frequent 
routine treatment of pathologic fractures leads to an increased understanding 
of these fractures, which may improve their management. In an attempt to 
optimize the care of these patients, there may be room for improvement in the 
current systems, in which pathologic fractures are treated by too many 
surgeons with only some experience in the fixation of pathologic fractures. 
The aim of this study was to assess the current trends in the estimation of 
survival and preferred treatment among national and international general and 
oncological orthopaedic surgeons to explore whether areas of improvement in 
the care of patients with a pathologic fracture might be identified. 
Methods 
All members of the Dutch Orthopaedic Society (DOS) and European 
Musculoskeletal Oncology Society (EMSOS) were invited by email to participate 
in an anonymous web-based questionnaire (enclosed at the end of this chapter), 
followed by a reminder email five weeks later. Dutch oncological orthopaedic 
surgeons were approached through the EMSOS. The first section of the survey 
covered the demographics of the surgeons. The second section dealt with the 
estimation of survival and which factors surgeons considered of influence. The 
third section consisted of 12 clinical cases including actual and impending 
fractures of the humerus and femur. All answers were multiple choice. The 
cases were based on patients who had been treated by the authors to reflect 
daily practise. Six cases were described as the patients had presented; 
subsequently, one aspect of each case, such as the age of the patient or the 
number of bony metastases, was altered to establish the paired cases, leading 
to a total of 12 cases. 





Table 5.1 Demographics of respondents of the questionnaire 
  Group 1  
n (%) 
Group 2  
n (%) 
Group 3  
n (%) 
Total respondents 50 46 33 
Experience    
 Resident 15 (30) 13 (28) 0 
 ≤ 5 years 5 (10) 8 (17) 5 (15) 
 6 – 10 years 11 (22) 13 (28) 10 (30) 
 11 – 20 years 14 (28) 6 (13) 7 (21) 
 > 20 years 5 (10) 6 (13) 11 (33) 
Frequency of pathologic fracture 
treatment 
   
 > 2 times per month 0 2 (4) 17 (52) 
 1 – 2 times per month 0 15 (33) 11 (33) 
 1 – 2 times per 3 months 0 29 (63) 5 (15) 
 1 – 2 times per 6 months 29 (58) 0 0 
 1 – 2 times per year 21 (42) 0 0 
Subspecialty*    
 Hip/knee 21 (42) 18 (39) 13 (39) 
 Arthroplasty 17 (34) 15 (33) 15 (45) 
 General orthopaedics 10 (20) 12 (26) 13 (39) 
 Traumatology 10 (20) 15 (36) 6 (18) 
 Upper extremity 13 (26) 6 (14) 6 (18) 
 Foot/ankle 3 (6) 7 (15) 2 (6) 
 Paediatrics 4 (8) 6 (14) 3 (9) 
 Oncology 0 3 (7) 33 (100) 
 Sports 9 (18) 1 (2) 2 (6) 
 Spine 3 (6) 9 (20) 1 (3) 
 In training 15 (30) 13 (28) 0 
*Respondents (excl. residents) can have more than one subspeciality. 
Respondents 
Of the 948 members of the DOS who were approached, 96 (10.1%) completed 
the survey. Of the 182 members of the EMSOS who were approached, 33 (18.1%) 
replied. Respondents of the DOS were categorized into groups according to the 
frequency with which they treated pathologic fractures: once or twice every six 
months or less was classified as group 1 (52%; 50 of 96) and once or twice every 
three months or more was classified as group 2 (48%; 46 of 96). Respondents 
from the EMSOS were categorised as group 3. The demographics of the 
respondents are shown in table 5.1.  
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OPTIModel 
The OPTIModel for the estimation of survival of patients with metastases of the 
long bones was used as the gold standard for the expected survival. These 
estimations were caterogized as: less than three months, three to six months, 
six to 12 months, and more than 12 months. This model is based on a large 
retrospective cohort and has been externally validated.3  
Table 5.2 Prognostic factors for and methods to estimate survival according to respondents 
 Group 1  
(n=50) (%) 
Group 2  
(n=46) (%) 
Group 3  
(n=33) (%) 
Prognostic factor1    
Primary tumour 48 (96) 45 (98) 28 (85) 
Performance score 40 (80) 36 (78) 21 (64) 
Visceral metastases 30 (60) 27 (58) 27 (82) 
Brain metastases 24 (48) 33 (72) 22 (67) 
Presence of other bone metastases 24 (48) 24 (52) 15 (45) 
Age 15 (30) 19 (41) 13 (39) 
Interval between primary tumour and 
metastasis 
7 (14) 11 (24) 9 (27) 
Number of other bone metastases 13 (26) 6 (13) 7 (21) 
Actual fracture 8 (16) 4 (9) 7 (21)  
Laboratory values 7 (14) 4 (9) 6 (18) 
Pain 4 (8) 4 (9) 3 (9) 
Gender 3 (6) 1 (2) 1 (3) 
    
Survival estimation method2    
Ask oncologist 46 (92) 33 (72) 13 (39) 
Tool/predictive model/nomogram 4 (8) 12 (26) 9 (27) 
Own experience 0 1 (2) 9 (27) 
Do not estimate survival 0 0 2 (6) 
1Respondents were allowed to give a maximum of five answers. 2Respondents could give one 
answer. 
Results 
What factors influence survival?  
Respondents reported a mean of 4.6 factors (2 to 5) as being prognostic. The 
primary tumour was selected as a prognostic factor by 121 respondents (94%). 





How is survival estimated? 
The methods of estimating survival are shown in table 5.2. A total of 79 
respondents (82%) in groups 1 and 2 asked an oncologist for an estimation. 
This portion was smaller for group 3 (13/33; 39%). Almost one third of the 
latter group (9/33; 27%) based their estimate on their experience, while only 
one respondent in group 2 provided this answer. Prognostic models, tools, or 
nomograms were used by 25 (19%) respondents.  
The estimation of survival for the cases 
Respondents were asked to estimate survival in 11 cases (table 5.3). If a short 
survival of less than three months was expected according to the OPTIModel, 
the answers mainly corresponded in all groups (81%, 68%, and 79% for groups 
1, 2, and 3, respectively). An effect of age was observed; the answers were more 
unequivocal if the patient was older. Group 3 respondents answered most 
consistently for patients with a long expected survival (>12 months); the mean 
rate of correct answers was 80% (64 to 97). The non-expert, not-frequent group 
1 was less consistent if a long survival was expected; the mean rates of correct 
answers was 52% (45 to 58), while the non-expert, frequent group 2 recognized 
a long survival quite reliably with a mean rate of 68.5% (59 to 76). The difference 
in the estimation of long survival was especially evident in two cases with a 
solitary metastasis of a renal cell carcinoma (case 3a and 4a). In these two cases, 
the non-expert groups less frequently recognised the long expected survival. In 
the other four cases with a long survival, the difference between the expert and 
non-expert groups was less evident. In these more common cases from daily 
practice, the difference in the estimation of survival was more apparent 
between those that treat these patients regularly or not (groups 1 and 2). It was 
also easier for respondents to estimate a long survival in younger patients, as in 
cases 1a and 6a. In the older patients, as in case 1b and 6b, respondents were 
more inclined to give a shorter prognosis. Likewise, more respondents 
estimated a short survival for an older patient as when comparing case 2a with 
2b. The cases with an intermediate expected survival (three to six months or six 
to 12 months) had low rates of correspondence between the respondents of 
each group (37%, 52%, and 52% for group 1, 2, and 3, respectively). The variation 
of answers was especially evident in group 1; in the other groups, however, the 
percentages of ‘correct’ answers were also not high (up to 64%).  
Treatment 
In 12 cases, respondents were asked to choose the most appropriate treatment 
bearing in mind the location and the type of lesion (i.e. actual or impending 
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fracture), as shown on a radiograph, and the expected survival. Six cases had 
comparable fractures of the proximal humerus. Table 5.4 shows the preferred 
form of treatment chosen by the respondents. If survival was expected to be 
short (less than three months or between three and six months) the choices did 
not differ much between the three groups. The most popular choice within each 
group was an intramedullary nail (62%, 48%, and 68%, for group 1, 2, and 3, 
respectively), although fixation with a plate, radiotherapy, and conservative 
therapy were also well-considered options. If survival was expected to be 
between six and 12 months, differences between the groups became clear: 
groups 1 and 2 were indecisive about the most appropriate option, with answers 
ranging between all options, while group 2 predominantly remained to have a 
preference for intramedullary nails. Group 3 also continued to consider nails or 
plates, but increasingly tended towards prosthetic reconstruction. If a survival 
of >12 months was expected, the difference between the groups was most 
evident: group 3 would treat almost every patient (90%) with a prosthesis, while 
groups 1 and 2 considered all surgical options, treating only approximately 50% 
to 60% with a prosthesis. Of the latter respondents, one third (33%) would use 
a conventional shoulder prosthesis as opposed to a tumour reconstruction, 
while most of group 3 (84/90; 93%) would use a tumour prosthesis. 
Six other cases described patients with a fracture of the proximal femur. 
Responses of the appropriate treatment in relation to the estimated survival are 
shown in table 5.5. Approximately 20% of the respondents in all groups would 
choose conservative treatment if survival was less than three months. Most 
(60%-77%), however, preferred fixation with an intramedullary nail, despite the 
short survival. If survival was expected to be between three and six months, an 
intramedullary nail was the most preferred treatment for groups 1 and 2 (80%), 
while group 3 considered prosthetic reconstruction (61%). The latter 
respondents wavered between a hemiarthroplasty, a total hip arthroplasty or a 
modular tumour prosthesis. When the expected survival became longer, and 
especially >12 months, most (73%) of group 3 would choose a tumour 
prosthesis, while most (55%) of groups 1 and 2 preferred an intramedullary nail. 
Discussion 
In the future, surgeons should have more specific knowledge about the 
indications for treatment and the varying forms of treatment that are available 
for the increasing number of patients who will present with a pathological 
fracture, in order to ensure the best outcome. Many aspects of this treatment 
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Table 5.4 Treatments of actual pathologic fractures of the humerus by survival estimation per 
respondent group; results of six cases (1a, 1b, 3a, 3b, 5a, 5b). The results are given as percentages 
within each survival estimation subgroup of each respondent group (e.g., <3 months, group 1). 
Totals of each subgroup (denominator) are reported in the last row. 
  Group 1 Group 2 Group 3 
Estimated Survival1 <3  3-6  6-12  >12  <3 3-6 6-12 >12 <3 3-6 6-12 >12 
Conservative  13 3 2 0 21 4 0 0 15 0 2 1 
Radiotherapy  12 13 15 12 3 5 6 4 19 16 7 1 
Nail  68 67 41 24 48 68 55 26 62 51 38 2 
Plate  7 7 11 12 24 15 21 9 4 30 24 5 
Shoulder prosthesis 0 4 15 12 0 4 13 25 0 0 0 6 
Tumour prosthesis 0 7 15 39 3 5 5 36 0 2 29 84 
Total responses 60 72 85 83 29 82 62 100 26 43 45 82 
 
Table 5.5 Treatments of actual pathologic fractures of the proximal femur by survival estimation 
per respondent group; results of six cases (2a, 3b, 4a, 4b, 6a, 6b). The results are given as 
percentages within each survival estimation subgroup of each respondent group (e.g., <3 months, 
group 1). Totals of each subgroup (denominator) are reported in the last row.  
  Group 1 Group 2 Group 3 
Estimated Survival1 <3  3-6  6-12  >12  <3 3-6 6-12 >12 <3 3-6 6-12 >12 
Conservative  18 0 0 0 19 3 0 0 22 0 0 0 
Radiotherapy  0 0 0 0 1 0 0 0 0 0 0 0 
Nail  70 81 63 55 77 80 76 54 60 39 11 14 
Hemi  9 10 23 1 1 3 10 3 5 11 21 5 
THP 2 6 1 11 1 3 14 14 2 11 8 8 
Tumour prosthesis 1 2 12 33 0 13 0 30 13 39 61 73 
Total responses 94 48 73 83 70 40 58 108 55 18 38 86 
THP: total hip prosthesis 
We should, however, wonder whether it is feasible for all surgeons currently 
managing these fractures, to remain up to date in this area. Should the 
treatment of pathologic fractures become a sub-speciality and should patients 
with these fractures be referred to such specialists? In order to assess whether 
these ideas are worth exploring, we designed a study based on a questionnaire 
to evaluate current similarities and differences in treatment between 
orthopaedic surgeons who treat pathologic fractures infrequently (group 1) or 
frequently (group 2), and those who specialize in oncology (group 3). 
This study has limitations. First, the response rate of the questionnaire was low. 
The method of distribution of the questionnaire, by email, carries the risk of not 
reaching all the intended recipients. Although email lists of both societies were 





The low response rate might also be due to a low interest in pathologic fractures, 
compared with general orthopaedic problems, such as arthroplasty or 
traumatic fractures. Second, there might have been response bias among the 
respondents. Third, the groups of respondents were not completely 
comparable, as, for instance, group 3 did not contain residents. The distribution 
of experience is thus less broad in group 3 than in the other groups. This could 
affect the interpretation of the results as the differences could be attributed to 
the extent of experience. However, in the Netherlands, all residents receive 
training in orthopaedic oncology. It thus may have been that the residents who 
responded to the questionnaire were those with an interest in oncology after 
their oncology internship. Despite not having completed their training, these 
residents might have more knowledge about pathologic fractures and treat 
them more often than orthopaedic surgeons with extensive experience. This 
issue remains debatable, but it was clearly appropriate to include residents in 
the general orthopaedic categories in this exploratory study. Fourth, with regard 
to the survival estimation, the fact that the questionnaire was only sent to 
surgeons can be regarded a limitiation. In the light of the results of the question 
on how survival is estimated, to which many respondents replied that they ask 
the opinion of the medical oncologist, it could be that medical oncologists 
should have been included in the study. Although it would be interesting to 
compare the estimations of medical oncologists, orthopaedic surgeons, and 
prognostic models, this was not the aim of the study. Fifth, despite aiming to 
present varying cases, few fitted into the “intermediate” survival groups (three 
to six months, six to 12 months) compared with those with a long survival (>12 
months). A more equal distribution among survival groups would have provided 
more insight into this difficult group, regarding both the estimate of survival and 
preferred treatment. Finally, in order to encourage completion of the 
questionnaire, the descriptions of the cases were based on real clinical cases 
and the replacement of clinical variables in the paired cases was limited to one 
variable, either age of the patients or number of metastases. Although there 
were three comparable cases with fractures of the proximal humerus and femur 
each, this is not a great number of comparable cases. As a result of these 
limitations, the outcomes of this study should be interpreted with care. The 
conclusions should be regarded as foundation for further research that should 
take these limitations into account.  
The palliative intent of the treatment of pathologic fractures aims for a “once-in-
a-lifetime fixation” and the correct estimation of survival is important in order 
to prevent over treatment in patients with a short survival, and undertreatment 
in those with a long survival. The results show that in most cases the estimation 
of survival of most respondents in each group was in accordance with the 
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estimation of the OPTIModel, but number of correct estimations differed 
greatly. Overall, the mean proportions of respondents estimating the correct 
survival were 53%, 64%, and 72% for groups 1, 2, and 3, respectively. The highest 
correct rates in group 1 were for the cases with a short estimated survival, while 
group 3 scored best on the cases with a solitary kidney metastasis. The long 
survival of the latter cases was not recognised by as many respondents in the 
other two groups, possibly indicating that recent studies showing a favourable 
outcome for patients with solitary kidney metastases4 are less known among 
general orthopaedic surgeons. It is interesting to note that all three groups had 
difficulty with the cases with an intermediate survival. This, together with the 
good short-term estimations by group 1, might be due to the so-called “horizon 
effect”, which suggests that clinicians are more accurate when recognising a 
shorter survival than a longer survival, similar to that recognized in weather 
forecasting.5 The relatively good estimations for patients with a long estimated 
survival, especially respondents in groups 2 or 3, however, shows a trend 
opposite to the “horizon-effect”. These differences cannot be explained. 
However, based on the answers respondents gave to the question “how do you 
estimate survival?” we can conclude that the non-experts consult an oncologist 
more frequently and are probably less used to estimating survival in general, 
compared with the oncological orthopaedic surgeons, who are more frequently 
confronted with this question when treating primary bone tumours.  
The results show an influence of the age of the patient in all three groups. More 
respondents identified a long survival if the patient was younger, and a short 
survival if the patient was older. Thus, while few respondents identified age as 
prognostic factor for survival in the first question, it might play a role 
subconsciously. It may simply reflect human nature in that death is easier to 
accept when it occurs at an older age. However, no prognostic studies for 
survival after a pathologic fracture have shown an effect of age.3,6-8 Surgeons 
should be aware of the subliminal effect of age and not let their estimations of 
survival be biased by it.  
The results dealing with the estimation of survival cannot be compared with 
other studies, because to our knowledge no other questionnaires dealing with 
pathologic fractures asked respondents to give an estimation of survival.9-11 One 
could discuss whether these results agree or disagree with those of studies that 
report that estimation of survival by physicians is frequently inaccurate.5,12 
Depending on the interpretation of the rate of correct estimation in this study, 
is a correct estimation of 60% accurate or is it too inaccurate? This is a difficult 
question to answer. The answer partly depends on the amount of influence of 





is a validated tool, its estimation of survival cannot be 100% correct. ‘Correct’ 
estimation in the context of this study should therefore be interpreted with 
caution, for we will never have a 100% correct estimation. Finally, it is not known 
whether some respondents already used a prognostic model to estimate 
survival for the cases in the questionnaire. If that is the case, the true 
estimations based on ones’ experience might be even less correct, for the 
results might be biased by ‘correct’ estimations by models. Nonetheless, we 
believe that an overall rate of ‘correct’ estimations of 63% would suggest that 
prognostic tools should be used. The most benefit can be gained for the mid-
term estimations. The use of a prognostic model would lead to more accurate 
estimation in the approximately 25% who estimated survival incorrectly in cases 
with an evidently short or long survival. 
Respondents were asked to choose the most appropriate treatment for 12 
cases, taking the estimated survival into account. For fractures of both the 
humerus and femur, most general orthopaedic surgeons would treat the 
fracture with an intramedullary nail, irrespective of the expected survival. 
Oncological orthopaedic surgeons, however, preferred to use a prosthesis if 
expected survival was >12 months. The percentage of oncological surgeons who 
recommended a prosthetic reconstruction for cases with a long expected 
survival was approximately twice that of general orthopaedic surgeons. This is 
in accordance with a previously performed survey by Janssen et al. regarding 
fractures of the humerus.11 The fact that oncological surgeons are more 
comfortable with prosthetic reconstruction is not surprising, as their expertise 
lies in this field. However, the answers regarding resection and prosthetic 
reconstruction included the option to refer a patient for such treatment. The 
answers of general surgeons thus do not reflex the fact that they uncommonly 
perform this procedure, but that they less frequently recognise the need for 
such an implant. Many recent studies, however, have shown that prosthetic 
reconstruction is preferable to an intramedullary nail, especially if a long survival 
is expected.13-16 The difference in this study is important for these patients, as 
currently their chance of receiving what is regarded as most appropriate 
treatment depends on the surgeon to whom they are referred. This trend 
should be further evaluated on a broader scale and by country, in order to 
further improve care. Should all orthopaedic surgeons be better educated, or 
should the care of certain patients be assigned to those with oncological 
training? Both are probably not feasible. The first because accumulating detailed 
knowledge is only regarded as worthwhile if the knowledge can be applied 
regularly. The second because of the incidence of pathologic fractures and the 
limited number of oncological orthopaedic surgeons in a region. Additionally, 
many of the pathologic fractures are excellently treated by general orthopaedic 
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surgeons and do not require specialized care. The most important issue is the 
selection of those patients who need centralized, specialized care. In order to 
aid that selection, a digital application can be used. The OPTIModel provides 
insight into both the expected survival, based on a recently published prognostic 
model,3 and possible forms of treatment as suggested by experts in the field 
using the OPTIModel app, available in app stores and on www.optimal-
study.nl/tool. The use of such a supportive tool can help differentiate patients 
with a short survival who are adequately treated with an intramedullary nail in 
a regional hospital from patients with a long expected survival who need referral 
to a specialized centre for prosthetic reconstruction. 
This study focused on a different aspect than most studies that aim to improve 
the treatment of patients with a pathologic fracture. While asking detailed 
questions about treatment in the questionnaire, the conclusions were used to 
evaluate how the care can be improved on a more general scale. Based on the 
results, patients might benefit if there were better differentiation between those 
who are adequately treated in a regional centre and those who require referral 
for specialist care. This differentiation should be based on expected survival, the 
location of the fracture and the type of fracture (impending or actual). Digital 
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How many years have you been working as a (consultant) orthopaedic surgeon? 
o Resident 
o Less than 5 years 
o 6 – 10 years 
o 11 – 20 years 
o More than 20 years 
 
How often do you treat patients with a pathologic fracture? 
o More than 2 times per month 
o 1 – 2 times per month 
o 1 – 2 times per 3 months 
o 1 – 2 times per half year 
o 1 – 2 times per year 
o (almost) never 
 
Other subspeciality interests: check all that apply 
o General orthopaedics 
o Joint reconstruction 
o Hip/knee 
o Foot/ankle 
o Upper extremity 
o Spine 
o Sport orthopaedics 
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Survival estimation 
Which factors do you regard as influencers of the remaining survival when patients 
present with an actual or impending pathologic fracture? select at most 5 answers 
◊ Age 
◊ Gender 
◊ Primary tumour 
◊ Presence of other bone metastases 
◊ Number of other bone metastases 
◊ Presence of brain metastases 
◊ Presence of visceral metastases 
◊ General health / performance status 
◊ Pain 
◊ Interval between diagnosis of primary tumour and diagnosis of pathologic 
fracture 
◊ Actual fracture or impending fracture 
◊ Blood values (e.g. Hb, leukocyte count, thrombocyte count, albumin, calcium, 
biliribine, LDH, CRP) 
 
How do you estimate the remaining survival? 
o Based on my own experience 
o Using a tool/nomogram/model 
o I ask the oncologist/radiotherapist 
o I do not estimate the remaining survival 
 
If using a tool/nomogram/model, please state which one is used: 







1A. A 35­year­old woman presents 
with a pathologic fracture of the 
proximal humerus caused by a 
breast cancer (ER/PR+, HER2­) 
metastasis. There are no brain or 
lung metastases, but eight other 
bone metastases (located in spine, 
pelvis and femurs) are present. The 
other bone metastases give no 
complaints and the patient is able 
to continue her daily living. Her left 
arm is now however causing 
continuous pain.  
1B. A 70­year­old woman presents 
with a pathologic fracture of the 
proximal humerus caused by a 
breast cancer (ER/PR+, HER2­) 
metastasis. There are no brain or 
lung metastases, but eight other 
bone metastases (located in spine, 
pelvis and femurs) are present. The 
other bone metastases give no 
complaints and the patient is able 
to continue her daily living. Her left 
arm is now however causing 
continuous pain.  
 
See the X­ray and MRI image below for more information. Distally in the 
humerus no other lesions are present.  
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Case 2 
2A. A 32­year­old man presents 
with a subtrochanteric pathologic 
fracture caused by lung carcinoma 
(EGFR negative). The disease has 
spread diffusely throughout the 
lungs and skeleton. Brain 
metastases are suspected because 
of significant changes in the 
behaviour of the patient. He has 
been bedridden since several weeks 
due to the pain in the hip.  
2B. A 70­year­old man presents 
with a subtrochanteric pathologic 
fracture caused by lung carcinoma 
(EGFR negative). The disease has 
spread diffusely throughout the 
lungs and skeleton. Brain 
metastases are suspected because 
of significant changes in the 
behaviour of the patient. He has 
been bedridden since several weeks 
due to the pain in the hip.  








3A. A 68­year­old woman has a 
fracture of the humerus shaft 
caused by a solitary metastasis of a 
renal cell carcinoma. There are no 
visceral metastases and the primary 
tumour has been resected. The arm 
is very painful (despite pain 
medication: paracetamol 4g/day 
and fentanyl transdermal patch 
50μg/3 days) and the patient is 
unable to use her arm.  
3B. A 68­year­old woman has a 
fracture of the humerus shaft 
caused by a metastasis of a renal 
cell carcinoma. Multiple other bone 
metastases are present in the spine 
and pelvis. There are no visceral 
metastases and the primary 
tumour has been resected. The arm 
is very painful (despite pain 
medication: paracetamol 4g/day 
and fentanyl transdermal patch 
50μg/3 days) and the patient is 
unable to use her arm.  
See the X­ray below and a transverse slice of the CT. 
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Case 4 
4A. A 40­year­old man presents 
with an intertrochanteric fracture 
caused by a solitary metastasis of a 
renal cell carcinoma. There are no 
visceral metastases and the primary 
tumour has been resected. The hip 
is painful and limits the walking 
ability of the patient. Otherwise the 
patient is able to lead his life 
relatively normal.  
 
4B. A 40­year­old man presents 
with an intertrochanteric fracture 
caused by a metastasis of a renal 
cell carcinoma. Multiple bone 
metastases (>10) are present 
throughout the entire skeleton. 
There are no visceral metastases 
and the primary tumour has been 
resected. The hip is painful and 
limits the walking ability of the 
patient. Otherwise the patient is 
able to lead his life relatively 
normal.  







5A. A 38­year­old man presents 
with a fracture of the proximal 
humerus shaft caused by a lung 
carcinoma (EGFR negative) 
metastasis. Throughout the 
mediastinum multiple enlarged 
lymph nodes have been detected as 
well as multiple bone metastases 
(>20) in the entire skeleton. The liver 
shows several lesions suspect for 
metastases. Until the current 
fracture the patient was able to 
perform his daily activities, however 
his condition is deteriorating slowly. 
With a walker he is able to walk 100 
meters. The patient has had 
radiotherapy for several painful 
spine metastases, with good effect.  
5B. A 75­year­old man presents 
with a fracture of the proximal 
humerus shaft caused by a lung 
carcinoma (EGFR negative) 
metastasis. Throughout the 
mediastinum multiple enlarged 
lymph nodes have been detected as 
well as multiple bone metastases 
(>20) in the entire skeleton. The liver 
shows several lesions suspect for 
metastases. Until the current 
fracture the patient was able to 
perform his daily activities, however 
his condition is deteriorating slowly. 
With a walker he is able to walk 100 
meters. The patient has had 
radiotherapy for several painful 
spine metastases, with good effect.  
See the X­ray below.  
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Case 6 
6A. A 42­year­old woman presents 
with a subtrochanteric fracture 
based on breast cancer (ER+/PR+, 
Her2­). There are no lung, liver, or 
brain metastases, but there are 
other bone metastases present in 
her pelvis and left femur. The 
patient is still very active and did not 
feel limited by her disease until this 
fracture occurred. 
6B. A 72­year­old woman presents 
with a subtrochanteric fracture 
based on breast cancer (ER+/PR+, 
Her2­). There are no lung, liver, or 
brain metastases, but there are 
other bone metastases present in 
her pelvis and left femur. The 
patient is still very active and did not 
feel limited by her disease until this 
fracture occurred. 






Questions for case 1A and 1B | case 3A and 3B | case 5A and 5B  
What is your estimation of the remaining survival? 
o Less than 3 months  
o 3 to 6 months  
o 6 to 12 months 
o more than 12 months 
 
What would your treatment of this patient be (based on the estimated survival)? 
o Plate fixation with cement 
o Plate fixation without cement 
o Intramedullary nail fixation with cement 
o Intramedullary nail fixation without cement 
o Shoulder prosthesis 
o (refer patient for a) (modular) tumour prosthesis after en bloc resection with 
free margins 
o (refer patient for a) (modular) tumour prosthesis after intralesional resection 
o Radiotherapy 
o Conservative; pain medication 
 
Questions for case 2A and 2B | case 4A and 4B | case 6A and 6B  
What is your estimation of the remaining survival? 
o Less than 3 months 
o 3 to 6 months 
o 6 to 12 months 
o more than 12 months 
 
What would your treatment of this patient be (based on the estimated survival)? 
o Intramedullary nail fixation with cement in the collum 
o Intramedullary nail fixation with cement in the shaft 
o Intramedullary nail fixation with cement to fill the lesion 
o Intramedullary nail fixation with cement in the collum and to fill the lesion 
o Intramedullary nail fixation without cement 
o Hemiarthroplasty 
o Total hip arthroplasty 
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o (refer patient for a) (modular) proximal femur tumour prosthesis after en bloc 
resection with free margins 
o (refer patient for a) (modular) proximal femur tumour prosthesis after 
intralesional resection 
o Radiotherapy 








Actual and impending pathologic fractures of the femur are commonly treated 
with intramedullary nails because they provide immediate stabilization with a 
minimally invasive procedure and enable direct weight bearing. However, 
complications and revision surgery are prevalent, and despite common use, 
there is limited evidence identifying those factors that are associated with 
complications. 
Questions/purposes 
Among patients treated with intramedullary nailing for femoral metastases, we 
asked the following questions:  
(1) What is the cumulative incidence of revision surgery and what factors 
are associated with revision surgery? 
(2) What is the cumulative incidence of implant breakage and what factors 
are associated with implant breakage? 
(3) What is the cumulative incidence of revision surgery and what factors 
are associated with revision surgery? 
Methods  
Between January 2000 and December 2015, 245 patients in five centers were 
treated with intramedullary nails for actual and impending pathologic fractures 
of the femur caused by bone metastases. During that period, the general 
indications for intramedullary nailing of femoral metastases were impending 
fractures of the trochanter region and shaft and actual fractures of the 
trochanter region if sufficient bone stock remained; nails were used for lesions 
of the femoral shaft if they were large or if multiple lesions were present. Of 
those treated with intramedullary nails, 51% (117) were actual fractures and 
49% (111) were impending fractures. A total of 60% (128) of this group were 
women; the mean age was 65 years (range, 29-93 years). After radiologic 
followup (at 4-8 weeks) with the orthopaedic surgeon, because of the palliative 
nature of these treatments, subsequent in-person followup was performed by 
the primary care provider on an as-needed basis (that is, as desired by the 
patient, without any scheduled visits with the orthopaedic surgeon) throughout 
each patient’s remaining lifetime. However, there was close collaboration 
between the primary care providers and the orthopaedic team such that 
orthopaedic complications would be reported. A total of 67% (142 of 212) of the 
patients died before 1 year, and followup ranged from 0.1 to 175 months (mean, 
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14.4 months). Competing risk models were used to estimate the cumulative 
incidence of local complications (including persisting pain, tumor progression, 
and implant breakage), implant breakage separately, and revision surgery 
(defined as any reoperation involving the implant other than débridement with 
implant retention for infection). A cause-specific multivariate Cox regression 
model was used to estimate the association of factors (fracture type / 
preoperative radiotherapy and fracture type / use of cement) with implant 
breakage and revision, respectively. 
Results  
Local complications occurred in 12% (28 of 228) of the patients and 6-month 
cumulative incidence was 8% (95% confidence interval [CI], 4.7-11.9). Implant 
breakage occurred in 8% (18 of 228) of the patients and 6-month cumulative 
incidence was 4% (95% CI, 1.4-6.5). Independent factors associated with 
increased risk of implant breakage were an actual (as opposed to impending) 
fracture (cause-specific hazard ratio [HR_cs], 3.61; 95% CI, 1.23-10.53, p = 0.019) 
and previous radiotherapy (HR_cs, 2.97; 95% CI, 1.13-7.82, p = 0.027). Revisions 
occurred in 5% (12 of 228) of the patients and 6-month cumulative incidence 
was 2.2% (95% CI, 0.3-4.1). The presence of an actual fracture was independently 
associated with a higher risk of revision (HR_cs, 4.17; 95% CI, 0.08-0.82, p = 
0.022), and use of cement was independently associated with a lower risk of 
revision (HR_cs, 0.25; 95% CI, 1.20-14.53, p = 0.025).  
Conclusion  
The cumulative incidence of local complications, implant breakage, and 
revisions is low, mostly as a result of the short survival of patients. Based on 
these results, surgeons should consider use of cement in patients with 
intramedullary nails with actual fractures and closer followup of patients after 
actual fractures and preoperative radiotherapy. Future, prospective studies 
should further analyze the effects of adjuvant therapies and surgery-related 







The femur is the most common long bone affected by bone metastases.1 
Treatment modalities of actual and impending pathologic fractures should 
provide direct and robust (prophylactic) stabilization to enable immediate 
weight bearing without pain and to regain quality of life. Intramedullary (IM) 
nails are commonly used to treat actual and impending pathologic fractures of 
the femur because of the smaller surgical exposure, which may result in less 
blood loss and surgical time, perhaps enabling more rapid postoperative 
rehabilitation. In general, no extensive muscle releases are used and immediate 
weight bearing is possible.2 Furthermore, the construct provides prophylactic 
protection of the long bone against future fractures in other regions as a result 
of its mechanical support over the entire length. The downside of IM nails is that 
they are designed as load-sharing devices, but they function as load-bearing 
devices in actual pathologic fractures that generally show only minimal healing 
tendencies, unlike traumatic fractures.3 Should a non-union ensue, hardware 
breakage (either of the distal interlocking screws or of the nail itself) will occur 
over time because of the loads involved.4-6 Although an IM nail suffices as 
palliative treatment for many patients because their survival will not exceed the 
fatigue life of the implant,7 the occurrence of complications and need for 
revision surgery are not compatible with the palliative intent of the treatment, 
which aims to meet the patient’s need for the balance of his or her lifetime and 
to require minimal surveillance.8 
Long survival is recognized as one of the most important risk factors for failure 
and stresses the importance of adequate survival estimation.9-12 Previous 
studies on the use of IM nails have limitations because they are heterogenic and 
describe small cohorts with short-term followup.2,5,7,9,11,13,14 Few have looked at 
treatment-related risk factors for failure or revision. If such factors, however, are 
prognostic, surgeons can further improve treatment.  
Therefore, this multicenter study aims to answer the following questions among 
patients treated with IM nailing for femoral metastases: (1) What is the 
cumulative incidence of local complications? (2) What is the cumulative 
incidence of implant breakage and what factors are associated with implant 
breakage? (3) What is the cumulative incidence of revision surgery and what 
factors are associated with revision surgery? 
Patients and methods 
Between January 2000 and December 2015, 245 patients in five centers were 
treated with IM nails for actual and impending pathologic fractures of the femur 
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caused by bone metastases. Two hundred twelve patients with 245 actual or 
impending femoral pathologic fractures were evaluated in this retrospective 
study after local institutional review board approval. Patients with flexible nails 
(such as Nancy nails), angle blade plates, dynamic hip screws, retrograde nails 
(13 patients, 15 nails), IM nails with a bicortical proximal fixation, or in whom the 
nail was a revision (n = 2) were excluded (total n = 18). During the study period, 
the general indications for IM nails were impending fractures of the trochanter 
region and shaft and actual fractures of the trochanter region if sufficient bone 
stock remained; nails were used for lesions of the femoral shaft if they were 
large or if multiple lesions were present. Throughout the study period, these 
indications were generally adhered to. Nails were placed percutaneously except 
when a large cortical defect called for extensive curettage and cementation. 
Reaming was performed according to the manufacturers’ guidelines. Indications 
for the type of nail and the use of cement were set by the treating surgeon as 
was the indication for postoperative radiotherapy. In general, cement was used 
for additional fixation of the collum screw (the lag screw in the femoral head) or 
filling of the metastatic lesion. As a result of the multicenter aspect of the study 
and developments over time, several different IM nails were used (table 6.1). 
Prophylactic antibiotics were administered to all patients according to each 
centers’ own protocol (most commonly cefazolin). Adjuvant cement was 
administered to 50 femurs (22%; table 6.1). In general, cement was used if bone 
stock was regarded insufficient for adequate screw fixation or if the lesion was 
very large. Thirty-nine patients (17%) had received radiotherapy on the lesion 
before surgery (table 6.1), of whom the majority (n = 25 [64%]) had received one 
fraction of 8 Gy. The median time between radiotherapy and surgery was 8 
weeks (range, 0.4–134 weeks). Preoperative radiotherapy was most commonly 
administered for pain. Twenty-seven patients (69%) sustained a pathologic 
fracture after radiation after a median of 3.5 weeks (range, 0.4-134 weeks), 
whereas 12 patients (31%) were treated for an impending fracture after a 
median of 13 weeks (range, 0.9-59 weeks). Postoperative radiotherapy was 
administered after 124 stabilizations (54%; table 6.1) after a mean of 4 weeks 
(SD 2.0). No protocol existed for administration of postoperative radiotherapy; 
whether it was used depended on local practice. The most common regimens 
were one or two fractions of 8 Gy (n = 29 [23%] and n = 33 [27%], respectively) 
and five or six fractions of 4 Gy (n = 26 [21%] and n = 27 [22%], respectively). 
Irradiation schemes were determined by the local protocols of each centers’ 
radiotherapy department. Radiotherapy was given more often to patients after 
prophylactic stabilization than to those treated for actual fractures (65% versus 





Demographic data, fracture and treatment details, and followup data including 
complications, revisions, and survival were collected from medical files. Fracture 
details included location, date of diagnosis, type (actual or impending), primary 
tumor, and previous radiotherapy. Treatment details included type of IM nail, 
locking mechanism, use and location of adjuvant cement, curettage, and 
postoperative radiotherapy. Radiotherapy was regarded as postoperative if 
given within 12 weeks of surgery. Dates of death were obtained from medical 
records or the municipal personal records database. If patients were alive, the 
last known dates were collected from the medical records. 
After radiologic followup (at 4-8 weeks) with the orthopaedic surgeon, because 
of the palliative nature of these treatments, subsequent in-person followup was 
performed by the primary care provider on an as-needed basis (that is, as 
desired by the patient, without any scheduled visits with the orthopaedic 
surgeon) throughout each patient’s remaining lifetime. However, there was 
close collaboration between the primary care providers and the orthopaedic 
team such that orthopaedic complications would be reported. A total of 67% 
(142 of 212) of the patients died before 1 year and 17% (36 of 212) were alive 
after 2 years. Followup ranged from 0.1 to 175 months (mean, 14.4 months).  
Local complications included persisting pain (that is, lasting pain despite surgery 
and adequate analgesics), tumor progression, and implant breakage. Persisting 
pain and tumor progression were scored as such if these were stated as the 
reason for adjuvant treatment (such as radiotherapy or surgery). The subgroup 
of implant breakage was further analyzed separately. Implant breakage 
included all nail and screw fractures, migrations, deformations or 
malplacements, and peri-implant fractures. Infections and systemic 
complications (deep venous thrombosis, pulmonary embolism, fat or cement 
embolism, pneumonia, urinary tract infection, cardiac events, sepsis, 
intraoperative death, and postoperative death [within 3 weeks of surgery]) were 
recorded. Revision was defined as any reoperation that was performed as a 
result of local complications, but reoperations for infection in which the implant 
was retained were not counted. 
Two hundred twelve patients with 228 actual and impending fractures were 
included in this study with a median age of 65 years (range, 29-93 years) and 
prominently women (60% [n = 128]). Metastases originated most commonly 
from breast cancer (36% [n = 76]) followed by lung (24% [n = 51]), kidney (11% 
[n = 24]), and prostate (11% [n = 23]) cancer. The remaining 18% (n = 38) included 
primary tumors of the thyroid, colorectum, head and neck, and bladder, among 
others. Actual fractures (117 [51%]) were most commonly located in the 
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subtrochanteric region (50 [43%]; table 6.2), whereas impending fractures (111 
[49%]) were primarily in the shaft (53 [48%]; table 6.2). 
Median overall survival (OS) was 6 months (95% confidence interval [CI], 4.4-7.3). 
Overall 6-month, 1-year, and 2-year survival for the entire cohort was 49%, 33%, 
and 19%, respectively. Median OS was longer for impending fractures (median, 
8 months; 95% CI, 3.1-12.7) than for impending fractures (median, 5 months; 
95% CI, 3.5-5.8) (figure 6.1). There were differences in median OS between 
primary tumor types: 11 months (95% CI, 4.9-17.1) for breast cancer, 7 months 
(95% CI, 2.4-11.6) for prostate cancer, 6 months (95% CI, 1.5-11.2) for kidney 
cancer, 3 months (95% CI, 1.0-4.2) for lung cancer, and 6 months (95% CI, 3.8-
7.4) for other primary tumors (figure 6.2).  
Figure 6.1 The Kaplan-Meier curve for OS is stratified for fracture type. 
Statistical Analysis 
Time to local complication, implant breakage, revision, and survival time were 
calculated from the date of surgery. For survival analysis, only the first treatment 
was included for patients with bilateral treatments. A competing risk model was 
used to estimate the cumulative incidence of local complication, implant 
breakage, and revision with death as a competing event.15 The cumulative 
incidence was defined as the probability of failing from a specific cause before 
time (t). Factors (fracture type; fixation type; pre- and postoperative 
radiotherapy; cement) were explored for the association with implant breakage 
or revision with a univariate cause-specific Cox regression. Subsequently 
multivariate cause-specific Cox regression analyses were performed, evaluating 





respectively:  type of fracture and postoperative radiotherapy and type of 
fracture and use of cement. As a result of the limited number of events for both 
endpoints, we were not able to include a third factor in the multivariate 
analyses. A p value < 0.05 was considered significant. Competing risk analysis 
was performed by using the mstate library in R.16,17 
Figure 6.2 The Kaplan-Meier curve for OS is stratified for primary tumor type. 
 
Table 6.1 Treatment characteristics of 228 intramedullary nails  
Characteristic All 
 
Actual fracture  Impending 
fracture 
Total 228 117 111 
Nail type    
 Gamma nail† 164 (72) 79 (68) 85 (77) 
 PFN/PFNa‡ 21 (9) 16 (14) 5 (5) 
 IMHS§ 24 (11) 8 (7) 16 (14) 
 TFN|| 9 (4) 5 (4) 4 (4) 
 T2–Recon¶ 6 (3) 6 (5) 0 (0) 
 UFN**/CFN†† 4 (2) 3 (3) 1 (1) 
Adjuvant cement    
 Yes, mechanical support* 22 (10) 12 (10) 10 (9) 
 Yes, at location of tumor  16 (7) 9 (8) 7 (6) 
 Yes, mechanical support* and 
tumor location 
12 (5) 2 (2) 10 (9) 
 No 178 (78) 94 (80) 84 (76) 
Radiotherapy    
 Previous only 32 (14) 23 (20) 9 (8) 
Intramedullary nails for femoral metastases 
 113 
(Table 6.1 continued) 
 Previous and postoperative 7 (3) 4 (3)  3 (3) 
 Postoperative only 117 (51) 48 (41) 69 (62) 
 None 72 (32) 42 (36) 30 (27) 
Reaming     
 Yes 213 (93) 109 (93)  105 (95) 
 No 7 (3) 5 (4) 2 (2) 
 Unknown 7 (3) 3 (3) 4 (4) 
Fixation     
 Static 166 (73) 85 (73) 81 (73) 
 Dynamic 52 (23) 22 (19) 30 (27) 
 Unknown 10 (4) 10 (9) 0 (0) 
Proximal locking    
 Femoral head fixation (single) 211 (93) 103 (88)  108 (97) 
 Femoral head fixation with 
second screw 
17 (8) 14 (12) 3 (3) 
Distal locking    
 None 3 (1) 0 (0) 3 (3) 
 1 locking screw 48 (21) 23 (20) 25 (23) 
 2 locking screws 176 (77) 93 (80) 83 (75) 
 3 locking screws 1 (0) 1 (1) 0 (0) 
Values are numbers with percentages in parentheses; *mechanical support of collum screw in the 
femur neck; †gamma nail (Stryker Trauma GmbH, Schonkirchen, Germany); ‡proximal femoral nail 
(antirotation) (Synthes GmbH, Oberdorf, Germany); §intramedullary hip screw (Smith & Nephew, Inc, 
Cordova, TN, USA); ||titanium trochanteric fixation nail (Synthes GmbH); ¶T2–Recon (Stryker Trauma 
GmbH); **unreamed femoral nail, ††distal femoral nail (Synthes GmbH). 
 
Table 6.2 Locations of actual and impending pathologic fractures of the femur 
Femurs (n = 228) Actual fracture,  
number (%) 
Impending fracture,  
number (%) 
Total 117 111 
Head and neck 10 (9) 14 (13) 
Pertrochanteric 23 (20) 31 (28) 
Subtrochanteric 50 (43) 13 (12) 







Three-month, 6-month, and 9-month cumulative incidences of local 
complications were 4% (95% CI, 1.7-7.1), 8% (95% CI, 4.7-11.9), and 9% (95% CI, 
5.1-12.5), respectively (figure 6.3).  Overall, 28 IM nails (12%) were involved with 
35 local complications (table 6.3), including tumor progression in nine patients 
(4%) and persisting pain in five patients (2%). Four of the nine patients with 
tumor progression and three of the five patients with persisting pain had not 
received postoperative radiotherapy. Tumor progression was treated with 
(re)irradiation (n = 6) or revision surgery (n = 3). Persisting pain was treated with 
adjuvant radiotherapy (n = 5) after a mean of 4 months (range, 3-6 months).  
Figure 6.3 Cumulative incidence functions are shown for local complication. 
 
Overall, the 3-month, 6-month, and 9-month cumulative incidences of implant 
breakage were 3% (95% CI, 0.8-5.3), 4% (95% CI, 1.4-6.5), and 4% (95% CI, 1.7-
7.1), respectively (figure 6.4). Overall, 21 implant breakages occurred in 18 IM 
nails (8%; table 6.3). In three patients one of the distal screws broke before the 
nail fractured; both complications were registered. Seven nails fractured at the 
site of the collum screw junction, leading to a nail fracture percentage of 3%. 
The majority of the structural failures occurred after fixation of actual pathologic 
fractures (n = 13 of 18 [72%]). 
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Figure 6.4 Cumulative incidence functions are shown for structural failure. 
 
Table 6.3 Local complications per fracture location 














Implant breakage 16/5 1/0 2/2 7/0 6/3 21 
 Fracture of nail 6/1 1/0 1/0 3/0 1/1 7 
 Fracture or 
migration of 
distal screw 
10/2 - 1/0 4/0 5/2 12 
 Deformation of 
nail 
0/1 - 0/1 - - 1 
 Malplacement 0/1 - 0/1 - - 1 
Persisting pain 5/0 - 1/0 2/0 2/0 5 
Tumor progression 4/5 0/1 1/1 1/0 2/3 9 
Total 25/10 1/1 4/3 10/0 10/6 35 







After controlling for confounding between fracture type and radiotherapy, both 
factors were independently associated with an increased risk of implant 
breakage: actual (as opposed to impending pathologic) fractures had a cause-
specific hazard risk of 3.61 (95% CI, 1.23-10.53, p = 0.019) and radiotherapy 
before surgery of 2.97 (95% CI, 1.13-7.82, p = 0.027) (table 6.4). Revision surgery 
resulting from structural failure was performed for the seven fractured nails, 
the displaced nail, and the initially malplaced collum screw (nine of 18 [50%]).  
The 3-month, 6-month, and 11-month cumulative incidences of revision were 
0.4% (95% CI, 0.0-1.3), 2% (95% CI, 0.3-4.1), and 3% (95% CI, 0.5-4.7), respectively 
(figure 6.5). Twelve patients (5%) underwent revision (table 6.5). The majority of 
the lesions were located per-/subtrochanteric or in the shaft (nine of 12). The 
presence of an actual fracture was independently associated with a higher risk 
of revision (cause-specific hazard ratio, 4.17; 95% CI, 0.08-0.82, p = 0.022), and 
use of cement was independently associated with a lower risk of revision (cause-
specific hazard ratio, 0.25; 95% CI, 1.20-14.53, p = 0.025) (table 6.4).  Five of the 
12 revisions caused further complications that resulted in further interventions. 
Infection (n = 2), protrusion of the collum screw (n = 1), and loosening or fracture 
of the collum screw (n = 2) were reasons for rereoperation. In addition to 
surgery, both patients with infections were treated with lifelong antibiotics. The 
three patients with implant breakage developed further complications, which all 
resulted in further surgery. 
Figure 6.5 Cumulative incidence functions are shown for revision. 
  




































































































































































































































































































































































































































































































































































































































































































































































































































































Table 6.5 Characteristics of fractures undergoing revision surgery 
Characteristics Revisions, 
number (%) 
Total (nails) 12 
Primary tumor  
 Breast 5 (42) 
 Kidney 2 (17) 
 Prostate 1 (8) 
 Other 4 (33) 
Fracture type  
 Actual 8 (67) 
 Impending 4 (33) 
Location  
 Collum 1 (8) 
 Pertrochanteric 3 (25) 
 Subtrochanteric 3 (25) 
 Proximal shaft 3 (25) 
 Midshaft 1 (8) 
 Distal shaft 1 (8) 
Radiotherapy  
 Previous only: 1*8 Gy 2 (17) 
 Previous only: 2*8 Gy 3 (25) 
 Postoperative only: 2*8 Gy 1 (8) 
 Postoperative only: 6*4 Gy 2 (17) 
 Previous and postoperative 0 (0) 
 None 4 (33) 
Cement  
 Yes 5 (42) 
 No 7 (58) 
Locking  
 Static 10 (83) 
 Dynamic 2 (17) 
Local complication  
 Structural failure: nail fracture 7 (58) 
 Structural failure: displaced nail 1 (8) 
 Structural failure: malplacement 1 (6) 
 Tumor progression 3 (25) 
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Discussion 
The aim of the IM fixation of actual and impending pathologic fractures is to 
minimize pain and stabilize the limb for the patient’s remaining lifetime. Long 
survival has been associated with complications of IM nails,9,18 but only one 
study has looked into factors associated with these complications.11 Our study 
presents a larger cohort and aims to identify treatment-specific factors as 
opposed to patient-specific factors. In this study, after controlling for 
confounding variables, we found that actual fractures (as opposed to impending 
fractures) and previous radiotherapy were independently associated with an 
increased risk of implant breakage, actual fractures (again, as opposed to 
impending fractures) were associated with an increased risk of revision, 
whereas use of cement was associated with a lower likelihood of a patient 
undergoing revision during his or her remaining lifetime. Although the 
cumulative incidences of implant breakage and revision were low in this series, 
we note that this likely was because of the very short survival of most of these 
patients (median survival was 6 months after surgery). Finally, we identified an 
alarmingly high frequency of re-revision once a revision was performed. 
This study has several limitations. First, underestimation of all endpoints might 
be possible because followup was not standardized. However, patients were 
seen throughout their remaining lifetimes by primary care providers on an as-
needed basis and had clinically meaningful problems arisen; it seems likely that 
these would have been reported, which may mitigate the problem of 
underestimation. In addition, the methods here probably are fairly reflective of 
real-world palliative practice. Also, based on the medical system in The 
Netherlands and Austria and the small sizes of both countries, we can assume 
that loss of patients to other hospitals is limited. Second, the retrospective 
design may have introduced selection bias. This bias may involve details of the 
surgical strategies such as nail type, adjuvant cement, and postoperative 
radiotherapy, but it probably does not influence the choice of the IM nail itself, 
because general indications are recognized for the main implant choice and we 
are not comparing IM nails with other treatment modalities in this study. The 
decisions for the details of treatment were made by the surgeons as opposed 
to according to a pre-set, shared algorithm.  
The study also is limited by the small number of events of interest. This is 
predominantly caused by the short survival of patients with metastatic cancer, 
which is inevitable with the study population, but nonetheless limits the analytic 
possibilities, especially with regard to the multivariate analysis. As a result of the 
few implant breakages (n = 21) and revisions (n = 12), only two factors could be 





analyses, confounding by adjuvant radiotherapy could therefore not be 
excluded; however, this was regarded as less relevant for our specific (implant-
related) research questions. The results imply that further research should 
focus on the role and effect of adjuvant treatments (cement and radiotherapy). 
Finally, patients might have received systemic treatments, which we did not 
include in the analysis. This could be regarded as a limitation, because it might 
have affected the course of disease of patients. However, the focus of our study 
was on a detailed analysis of local treatment and the complexity of systemic 
treatments would intervene too much with obtaining these local results. Given 
the personalization of systemic therapies, there is such a variety of systemic 
treatments given at different time points that the factor cannot be regarded as 
one. Including this variable would complicate the analysis to such level that the 
results would stray from our initial research questions.  
The frequency of complications we observed (12% [28 of 228]) is comparable to 
some studies,6 whereas others report fewer complications.9,13 The differing 
results can be attributed to the definitions for complication. The current study 
regarded all causes of secondary treatment for mechanical stabilization (surgery 
and/or radiotherapy) and all structural problems of the implant as 
complications because the surgical treatment of an actual or impending fracture 
is meant to meet the patient’s needs for his or her remaining lifetime. The 
cumulative incidence of complications (figure 6.3) shows that although the 
assumption might be that all complications occur in the short term, this is not 
the case. 
Implant breakage caused most of the observed local complications (60% [21 of 
35]). As a result of the nature of pathologic fractures and their general lack of 
bone healing, IM nails and locking screws carry more pressure and during a 
longer period than in general trauma care. The common persisting non-union 
often leads to implant fractures (that is, breakage of screws and nails) over 
time.19 In the current cohort, 3% (seven of 228) of the nails fractured, all at the 
junction with the collum screw. The design of modern IM nails, with the collum 
screw locked into the proximal nail, prevents protrusion of the collum screw 
through the femur head, but inevitably causes a weak point of the nail by 
reducing the diameter (1.5-3 mm) of the nail adjacent to the hole.20 Although 
the power of this study was insufficient to perform any further analyses into 
specific causes of the nail breakage (e.g., nail diameter, collum screw length, 
type of screws for distal locking), the frequent fractures at the junction with the 
collum screw suggest that a larger proximal diameter of the nail is mandatory, 
especially in patients with an expected survival of > 6 months. Two independent 
factors associated with implant breakage were identified: both actual fracture 
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and previous radiotherapy increase the risk of implant breakage threefold. This 
emphasizes the importance of accurate fracture prediction. If a lesion 
erroneously gets classified as low risk for fracture, it is possible that the patient 
will get referred for radiotherapy, subsequently develops a pathologic fracture, 
and then has to undergo surgery burdened with both risk factors for 
complications. Unfortunately, up to date there is still no accurate and quick 
method for determining the risk of fracture. The well-known Mirels classification 
is still commonly used21 despite studies showing its poor predictive value 
resulting in an overestimation of the fracture risk.22 We would therefore advise 
to refrain from using the Mirels classification any longer. Van der Linden et al. 
advise to use 3-cm cortical involvement as a cut-off point.23,24 The most 
promising are CT-based algorithms that are currently being developed.25 Once 
such models will be able to provide quick predictions in the clinical setting, 
hopefully the everlasting question of how to determine the fracture risk will 
belong to the past.  Actual fracture as a risk factor has been recognized 
previously26 and the clinical and economic benefits of prophylactic stabilization 
are well known.27 The association of radiotherapy before surgery with an 
increased risk of implant revision has been reported;11 we were able to analyze 
the topic further with respect to additional risk factors in the present study. 
When a patient presents after radiotherapy and with an actual fracture, the 
prognosis of the implant is already influenced, even before any incision has 
been made. If these patients are expected to survive for a reasonably long 
period of time, a prosthesis could be considered. However, in patients with only 
short- or medium-term expected survival, an IM nail remains an adequate 
choice because the risk of complications and revision seems low. Use of 
adjuvant cement and stricter followup with regular radiographs to recognize 
failure in an early stage could be considered for patients with risk factors.  
Others have reported the risk of revision to range between 0% and 14%, which 
is comparable to the revision percentage in this cohort (5% [12 of 228]). 
5,6,9,11,13,14,28-30 It was striking to observe that the early revisions (within 6 months) 
were predominantly the result of tumor progression (of kidney, thyroid, and 
breast cancer), whereas implant breakage generally did not occur until later. 
This observation has not, to our knowledge, been described previously and 
could be an expression of the aggressiveness of certain tumors. The primary 
reason for the low frequency of complications and revisions is the short overall 
survival of this patient population (median, 6 months). Most patients die of 
metastatic disease before complications have had time to develop. The 
association between failure and revision and survival is well known,5,9,11,13,31-33 
but to our knowledge, this is the first study that shows this result in such a large 





implant selection of this cohort was well chosen to the needs of the patient and 
his or her disease, including survival estimation. The latter is an important step 
to identify the adequate surgical modality. Only a precise survival estimation will 
enable a “once and for all” treatment, which should be aimed for in the palliative 
setting, and prevent over- and undertreatment. Several models have been 
developed to aid surgeons in estimating survival.34-36 One of these models has 
been transformed into a dynamic application (OPTIModel; www.optimal-
study.nl/tool), which is available in app stores free of charge. Survival is 
estimated with a prognostic model including three variables (tumor profile, 
presence of visceral and/or brain metastases, Karnofsky performance score). 
The prognostic model was based on a large retrospective study and validated 
by an external data set. 37 
We found that the cumulative incidences of local complications, implant 
breakage, and revisions after IM nails for femoral pathologic fractures are low, 
but that the success rate of revision surgery is poor. Actual (as opposed to 
impending) fractures and preoperative radiotherapy were independently 
associated with a higher risk of implant breakage, and actual fractures and lack 
of the use of cement were independently associated with a higher risk of 
revision. Surgeons might consider treating patients with these risk factors and 
a long expected survival with prosthetic reconstructions. If expected survival is 
short or medium term, IM nailing remains a suitable option; however, adjuvant 
cement and closer followup should be considered. Future studies should focus 
on the role of adjuvants (cement and radiotherapy) and their effect on implant 
survival. To prevent the limitations faced by the current study, these studies 
should be large, prospective, and, ideally, randomized. In light of the palliative 
intent of the treatment, not only complications and functional outcomes should 
be registered, but also the effect of treatment (and possible complications) on 
the quality of life. 
  
Intramedullary nails for femoral metastases 
 123 
References 
1. Toma CD, Dominkus M, Nedelcu T, Abdolvahab F, Assadian O, Krepler P, Kotz R. 
Metastatic bone disease: a 36-year single centre trend-analysis of patients admitted to a 
tertiary orthopaedic surgical department. J Surg Oncol 2007;96-5:404-10. 
2. Tanaka T, Imanishi J, Charoenlap C, Choong PF. Intramedullary nailing has sufficient 
durability for metastatic femoral fractures. World J Surg Oncol 2016;14-1:80. 
3. Gainor BJ, Buchert P. Fracture healing in metastatic bone disease. Clin Orthop Relat Res 
1983-178:297-302. 
4. Maes M, Deboer Y, Brabants K. Failure of the titanium trochanteric gamma nail in 
ununited metastatic fractures. Acta Orthop Belg 2012;78-4:552-7. 
5. Wedin R, Bauer HC. Surgical treatment of skeletal metastatic lesions of the proximal 
femur: endoprosthesis or reconstruction nail? J Bone Joint Surg Br 2005;87-12:1653-7. 
6. Weiss RJ, Ekstrom W, Hansen BH, Keller J, Laitinen M, Trovik C, Zaikova O, Wedin R. 
Pathological subtrochanteric fractures in 194 patients: a comparison of outcome after 
surgical treatment of pathological and non-pathological fractures. J Surg Oncol 2013;107-
5:498-504. 
7. Shemesh S, Kosashvili Y, Sidon E, Yaari L, Cohen N, Velkes S. Intramedullary nailing 
without curettage and cement augmentation for the treatment of impending and 
complete pathological fractures of the proximal or midshaft femur. Acta orthopaedica 
Belgica 2014;80-1:144-50. 
8. Willeumier JJ, van der Linden YM, van de Sande MAJ, Dijkstra PDS. Treatment of 
pathological fractures of the long bones. EFORT Open Reviews 2016;1-5:136-45. 
9. Piccioli A, Rossi B, Scaramuzzo L, Spinelli MS, Yang Z, Maccauro G. Intramedullary 
nailing for treatment of pathologic femoral fractures due to metastases. Injury 2014;45-
2:412-7. 
10. Wedin R. Surgical treatment for pathologic fracture. Acta Orthop Scand Suppl 2001;72-
302:2p., 1-29. 
11. Miller BJ, Soni EE, Gibbs CP, Scarborough MT. Intramedullary nails for long bone 
metastases: why do they fail? Orthopedics 2011;34-4. 
12. Zacherl M, Gruber G, Glehr M, Ofner-Kopeinig P, Radl R, Greitbauer M, Vecsei V, 
Windhager R. Surgery for pathological proximal femoral fractures, excluding femoral 
head and neck fractures: resection vs. stabilisation. Int Orthop 2011;35-10:1537-43. 
13. Steensma M, Boland PJ, Morris CD, Athanasian E, Healey JH. Endoprosthetic treatment 
is more durable for pathologic proximal femur fractures. Clin Orthop Relat Res 2012;470-
3:920-6. 
14. Sarahrudi K, Greitbauer M, Platzer P, Hausmann JT, Heinz T, Vecsei V. Surgical 






15. Putter H, Fiocco M. Tutorial in biostatistics: Competing risks and multi-state models. 
Statist. Med 2007;26:2389-430. 
16. de Wreede L, Fiocco M, Putter H. mstate: An R Package for the Analysis of Competing 
Risks and Multi-State Models. Journal of Statistical Software 2011;38-7:1-30. 
17. de Wreede L, Fiocco M, Putter H. The mstate package for estimation and prediction 
in non- and semi-parametric multi-state and competing risks models. Comput Methods 
Programs Biomed 2010;99. 
18. Wedin R, Bauer HC, Rutqvist LE. Surgical treatment for skeletal breast cancer 
metastases: a population-based study of 641 patients. Cancer 2001;92-2:257-62. 
19. Fine NF, Sexton SA, Williams DH. The learning curve with a new cephalomedullary 
femoral nail. Injury 2017;48-7:1575-8. 
20. Alvarez DB, Aparicio JP, Fernandez EL, Mugica IG, Batalla DN, Jimenez JP. Implant 
breakage, a rare complication with the Gamma nail. A review of 843 fractures of the 
proximal femur treated with a Gamma nail. Acta Orthop Belg 2004;70-5:435-43. 
21. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing 
impending pathologic fractures. Clin Orthop Relat Res 1989-249:256-64. 
22. Van der Linden Y, Dijkstra P, Kroon H, Lok J, Noordijk E, Leer J, Marijnen C. 
Comparative analysis of risk factors for pathological fracture with femoral metastases. J 
Bone Joint Surg Br. 2004;86-4:566-73. 
23. van der Linden YM, Kroon HM, Dijkstra SPDS, Lok JJ, Noordijk EM, Leer JWH, Marijnen 
CAM. Simple radiographic parameter predicts fracturing in metastatic femoral bone 
lesions: results from a randomised trial. Radiotherapy and Oncology 2003;69-1:21-31. 
24. Derikx LC, Verdonschot N, Tanck E. Towards clinical application of biomechanical 
tools for the prediction of fracture risk in metastatic bone disease. J Biomech 2014. 
25. Ulaner GA, Zindman AM, Zheng J, Kim TW, Healey JH. FDG PET/CT Assesses the Risk 
of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer. Clin Nucl 
Med 2017;42-4:264-70. 
26. Harvey N, Ahlmann ER, Allison DC, Wang L, Menendez LR. Endoprostheses last longer 
than intramedullary devices in proximal femur metastases. Clin Orthop Relat Res 
2012;470-3:684-91. 
27. Blank AT, Lerman DM, Patel NM, Rapp TB. Is Prophylactic Intervention More Cost-
effective Than the Treatment of Pathologic Fractures in Metastatic Bone Disease? Clin 
Orthop Relat Res 2016. 
28. Janssen SJ, Kortlever JT, Ready JE, Raskin KA, Ferrone ML, Hornicek FJ, Lozano-Calderon 
SA, Schwab JH. Complications After Surgical Management of Proximal Femoral 
Metastasis: A Retrospective Study of 417 Patients. J Am Acad Orthop Surg 2016;24-7:483-
94. 
29. Takaaki T, Jungo I, Charoenlap C, Choong PFM. Intramedullary nailing has sufficient 
durability for metastatic femoral fractures. World Journal of Surgical Oncology 2016;14:1-
6. 
Intramedullary nails for femoral metastases 
 125 
30. van Doorn R, Stapert JW. Treatment of impending and actual pathological femoral 
fractures with the long Gamma nail in The Netherlands. Eur J Surg 2000;166-3:247-54. 
31. Mavrogenis AF, Pala E, Romagnoli C, Romantini M, Calabro T, Ruggieri P. Survival 
analysis of patients with femoral metastases. J Surg Oncol 2012;105-2:135-41. 
32. Wedin R, Bauer HC, Wersall P. Failures after operation for skeletal metastatic lesions 
of long bones. Clin Orthop Relat Res 1999-358:128-39. 
33. Yazawa Y, Frassica FJ, Chao EY, Pritchard DJ, Sim FH, Shives TC. Metastatic bone 
disease. A study of the surgical treatment of 166 pathologic humeral and femoral 
fractures. Clin Orthop Relat Res 1990-251:213-9. 
34. Forsberg JA, Eberhardt J, Boland PJ, Wedin R, Healey JH. Estimating survival in patients 
with operable skeletal metastases: an application of a bayesian belief network. PLoS One 
2011;6-5:e19956. 
35. Katagiri H, Okada R, Takagi T, Takahashi M, Murata H, Harada H, Nishimura T, Asakura 
H, Ogawa H. New prognostic factors and scoring system for patients with skeletal 
metastasis. Cancer Med 2014. 
36. Janssen SJ, van der Heijden AS, van Dijke M, Ready JE, Raskin KA, Ferrone ML, Hornicek 
FJ, Schwab JH. 2015 Marshall Urist Young Investigator Award: Prognostication in Patients 
With Long Bone Metastases: Does a Boosting Algorithm Improve Survival Estimates? Clin 
Orthop Relat Res 2015. 
37. Willeumier JJ, van der Linden YM, van der Wal C, Jutte PC, van der Velden JM, Smolle 
MA, van der Zwaal P, Koper P, Bakri L, de Pree I, Leithner A, Fiocco M, Dijkstra PDS. An 
Easy-to-Use Prognostic Model for Survival Estimation for Patients with Symptomatic Long 








Actual and impending pathologic fractures of the humerus can be challenging 
to treat. The (prophylactic) fixation of a pathologic fracture due to bone 
metastases is a palliative treatment and should aim at direct rotation-
stabilization, enabling immediate use while corresponding with the expected 
survival. Up to date, no risk factors for failure of intramedullary nails in humeral 
pathologic fractures have been identified. 
Purposes 
Among patients treated with intramedullary nails for actual or impending 
pathologic fractures caused by bone metastases of the humerus: 
(1) What is the cumulative incidence of failure? 
(2) What are risk factors for failure? 
(3) What per-operative and postoperative (neurological) complications 
occur? 
Methods  
Between 2000 and 2015, 178 patients in eight centers were treated with IM nails 
for 182 actual (n=143, [79%]) or impending (n=39, [21%]) pathologic fractures of 
the humerus caused by bone metastases, of which 62% were located in the 
diaphysis. Throughout the study period general indications for an 
intramedullary nail were an impending fracture, a fracture of the diaphysis, or a 
proximal fracture with sufficient bone stock in the humeral head. The cohort 
consisted predominantly of women (61% [n=108]) and the median age was 62.7 
years (range 33.5–88.9).  
Results  
Twenty-three failures were registered, leading to an overall failure rate of 12.6% 
(23/182). Cumulative incidence of failure was 1.1% at 1 month (95%CI 0–2.6), 
3.3% at three months (95%CI 0.7–5.9), 3.8% at six months (95%CI 1.0–6.6), 8.2% 
at 1 year (95%CI 4.2–12.3), and 10.0% at two years (95%CI 5.6–14.5). Univariate 
Cox regression analysis did not show any significant association between risk 
factors and failures. Intraoperative complications were reported in six patients 
(3.3%), all concerning fractures caused by introducing the nail. Seven patients 
(3.8%) had neurological complications of the radial nerve. 
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Conclusion  
Although overall results are good, surgeons should be aware of the fact that 
intramedullary treatment of pathologic humeral fractures may not prove as 
simple as one may expect. Most important is to pursue a non-rotating and 
durable fixation that corresponds with the estimated survival to prevent 







After the femur, the humerus is the second most common location for long 
bone metastases, causing actual and impending pathologic fractures in 16-27% 
of patients with metastatic bone disease.1,2 The (prophylactic) fixation of an 
actual or impending pathologic fracture caused by bone metastasis is a 
palliative treatment and fixation should be “once and for all” to limit the burden 
for the patient and to regain quality of life as soon as possible. The treatment of 
such fractures of the humerus however can be challenging. Like all pathologic 
fractures caused by bone metastases, fracture healing cannot be expected.3 
Most pathologic fractures in the humerus and femur are due to rotational 
movements, but reconstruction of the humerus may prove more difficult than 
of the femur, as the predominant force on the femur is an axial compression, 
while the humerus is subject to a combination of axial compression (especially 
if a patient uses crutches or a walking aid), distraction (inherent in lifting and 
pulling), and rotational forces.4,5 The rotator cuff, deltoid, pectoralis major and 
latissimus dorsi muscles can inflict great torsional movement on destructed 
bone or the fracture parts. Also the movement of the lower arm greatly affects 
the stability of a fractured humerus. The most important aspect of the fixation 
is therefore a non-rotating fixation that can withstand the rotational forces as 
well as control impaction and distraction and therefore enables maximal 
functioning. 
An adequate fixation can be realized with an intramedullary (IM) nail, plate 
fixation, or prosthetic reconstruction.4 Cement can be used to provide adjuvant 
stability.6 An IM nail is ideally suited for impending fractures and for actual 
fractures in the area between 2-3 cm distal to the greater tuberosity and 5-6 cm 
proximal to the olecranon fossa provided that the bone stock on both ends of 
the humerus is sufficient.7,8 For such actual fractures a plate fixation can also be 
regarded a suitable option.9 Nailing may have several advantages over plate 
fixation, including; a minimal invasive approach and minimal soft tissue 
dissection, short operative time, protection of a long segment of bone, rigid 
fixation possibilities, and early rehabilitation.8  
Important factors to take into account when deciding on the type of stabilization 
are the type and location of the fracture, the expected survival, and the amount 
of bone stock. The choice for a certain modality is currently based primarily on 
experience and preference of the surgeon.10 As with the surgical treatment of 
many other pathologic fractures, insufficient research has been published to 
adequately determine which modality would fit a patient best. No randomized 
studies have been performed, and most retrospective studies report only small 
cohorts. Only two large cohorts of more than 100 patients have been published 
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that have tried to identify risk factors for poor outcomes related to specific 
patient characteristics or stabilization modalities.2,11 Such retrospective studies, 
trying to make comparisons between treatment modalities, are however 
strongly affected by indication bias and comparisons should not be made. To 
derive the most relevant conclusions from retrospective data, we believe focus 
should be on a single treatment modality in a large dataset. That does not fully 
eliminate indication bias, but can inform surgeons more specifically about the 
pearls and pitfalls of the modality once it is selected.  
This multicenter study aims to determine the cumulative incidence of and risk 
factors for failure of intramedullary nailing for actual or impending pathologic 
fractures caused by bone metastases of the humerus.  
Methods 
Between 2000 and 2015, 185 patients in eight centers were treated with IM nails 
for actual or impending pathologic fractures of the humerus caused by bone 
metastases. One hundred and seventy-eight patients, with 182 actual or 
impending humeral fractures were evaluated in this retrospective study, after 
local institutional review board approval. Patients with primary bone tumors 
(including multiple myeloma, solitary plasmacytoma, or malignant lymphoma of 
bone), pathologic fractures from other causes than metastases, unavailable 
medical records (2 patients), or receiving revision surgery after failed 
stabilization elsewhere (5 patients) were excluded. The study includes 72 
patients that were reported in a previous cohort of humerus pathologic 
fractures.11 
Surgical treatment  
Stabilization was prophylactic for an impending fracture in 21% of the cases 
(n=39). The most common location for both actual and impending fractures was 
the diaphysis (62% each; n=89 and n=24, respectively) (table 7.1). The type of 
operative procedure, including the type of nail, the method of fixation, and the 
use of adjuvant cement, was determined by the surgeon, taking the location, 
type of fracture, primary tumor, expected survival and patients’ expectations 
into account. Throughout the study period, indications for an intramedullary 
nail were generally an impending fracture, a fracture of the diaphysis, or a 
proximal fracture providing sufficient bone stock in the humeral head. As 
multiple hospitals participated in this study, a range of intramedullary nails was 
used. Reaming was performed according to the manufacturers’ guidelines. Most 
commonly, a nail of 250 mm long and 7.5 mm wide was used for stabilization 





(20%; n=36), a spiral blade in combination with a bicortical screw (10%; n=19), or 
one (24%; n=44), two (34%; n=61) or three (10%; n=18) locking screws (table 7.1). 
Almost all nails (98%) were fixated distally with one (48%; n=88), two (45%; n=82) 
or three (3%; n=5) bicortical screws. All patients received pre-operative 
prophylactic antibiotics according to each centers’ protocol (most commonly 
cefazolin). Adjuvant cement was applied in 10% of the nails (n=19) for 
reinforcement of the humeral head (11%; n=2) or shaft (11%; n=2), filling of the 
metastatic lesion (47%; n=9), or a combination (32%; n=6). In general, cement 
was used if bone stock was regarded insufficient for adequate screw fixation or 
if the lesion was very large. Mode of cement application was open in 15 cases 
(79%) and percutaneous in 4 cases (21%). In 21% of the fractures (n=38; 30 actual 
and 8 impending fractures), radiotherapy had previously been applied, most 
commonly for pain. Post-operative radiotherapy was given in 58% following 
surgical stabilizations (n=105) after a mean of 5.1 weeks (SD 6.1). The choice of 
administering postoperative radiotherapy was not protocol-bound, but subject 
to local practice.  
Primary outcome 
The aim of palliative stabilization of actual and impending pathologic fractures 
of the humerus is to maintain or regain function and control pain with a single 
intervention. The primary outcome of this study therefore was any failure of 
achieving this goal. This included all implant failures, and persisting pain or 
tumor progression requiring local treatment. Medical and radiological records 
were screened to collect demographic data and details on the fracture (location, 
type, primary tumor), the treatment (type of nail, number of screws, curettage, 
use and location of adjuvant cement, post-operative radiotherapy), and follow-
up (complications, revisions, and last known date). Intraoperative complications, 
neurological complications, and infections were recorded separately.  
Due to the palliative nature of the treatment and the poor health of many 
patients in this population, follow-up is not standardized. After radiological 
follow-up (at 4–8 weeks) at the orthopedic surgeon, subsequent in-person 
follow-up was generally performed by the primary care giver (for example, 
general practitioner, referring medical doctor). Follow-up visits to the 
orthopedic surgeon were made on an as-needed basis, thus when required by 
the patient. However, close collaboration between the primary care giver and 
the orthopedic surgeon ensured reporting of orthopedic complications. Among 
patients who were alive at final analysis, a follow-up moment (either in-person, 
by telephone or by the primary care giver) at one year was available. A total of 
69% (123 of 178) of the patients died within one year, and 17% (30 of 178) were 
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alive at 2 years. Follow-up ranged from 0.03 to 167 months. Median follow-up 
as calculated by reversed Kaplan Meier was 60.4 months (95%CI 15.0–105.7). 
Patients 
One-hundred and seventy-eight patients with 182 actual and impending 
fractures were included in this study with a median age of 62.7 years (range 
33.5–88.9) and prominently women (61% [n=108]). Breast (29%), lung (25%), and 
kidney (16%) cancer were the most common primary tumors (table 7.2). Visceral 
and/or brain metastases were present in 107 patients (60%). 
Survival 
Median overall survival (OS) was 5.7 months (95%CI 4.8–6.7). The median OS of 
patients treated for an impending fracture (8.6 months [95%CI 5.5–11.7]) did not 
significantly differ from patients treated for actual fractures (5.3 months [95%CI 
4.2–6.4]). Between primary tumors there was a large difference in median OS: 
2.7 months (95%CI 0.2–5.2) for lung cancer, 6.9 months (95%CI 5.4–8.4) for 
breast cancer, and 21.6 months (95%CI 0.0–48.2) for kidney cancer. 
Statistical analysis 
Time to failure and survival time were calculated from the date of surgery. For 
survival analysis, only the first treatment was included for patients with bilateral 
nails. A competing risk model was used to estimate the cumulative incidence of 
failure with death as competing event.12 The cumulative incidence was defined 
as the probability of failing from a specific cause before time (t). Univariate 
cause-specific Cox regression analyses were performed to determine whether 
factors such as location, fracture type, proximal and distal fixation, cement, and 
pre- and postoperative radiotherapy were associated with failure. Survival 
curves were estimated by using the Kaplan-Meier method and compared with 
log-rank analysis. Median follow-up was estimated with the reversed Kaplan-
Meier.13 A p-value <0.05 was considered significant. SPSS (version 23.0, SPSS Inc., 
Armonk, NY) was used to perform statistical analysis. The cumulative incidence 
was estimated with the mstate library in R environment.14,15 
Results 
Twenty-three failures were registered, leading to an overall failure rate of 12.6% 
(23/182). Cumulative incidence of failure was 1.1% at 1 month (95%CI 0–2.6), 
3.3% at three months (95%CI 0.7–5.9), 3.8% at six months (95%CI 1.0–6.6), 8.2% 
at 1 year (95%CI 4.2–12.3), and 10.0% at two years (95%CI 5.6–14.5) (figure 7.1). 





implant fracture, non-union, migration of nail or screw) whereas nine failures 
had a predominantly oncological cause (ranging from painful moderate tumor 
progression to massive recurrence) (table 7.3). 
One patient developed acute compartment syndrome directly postoperatively, 
requiring immediate fasciotomy followed by revision surgery several weeks 
later. All other complications occurred after 0.4 to 57.2 months. The majority of 
complications with an oncological cause occurred after 12 months, while 
mechanical complications occurred predominantly between 6 to 12 months 
after surgery (table 7.4). Seventeen of the 23 failures (74%) underwent revision 
surgery. Two failed implants were not revised because of the patients’ condition. 
Four patients with progressive disease received radiotherapy or a brace as 
opposed to revision surgery. 







Humeri total 182 143 39 
Side: right 102 (56) 83 (58) 19 (49) 
Location    
 Proximal 61 (34) 50 (35) 11 (28) 
 Diaphyseal 113 (62) 89 (62) 24 (62) 
 Distal 8 (4) 4 (3) 4 (10) 
Median length of nail (SD)* 250 (22) 250 (22) 260 (22) 
Median diameter of nail (SD)* 7.5 (1.1) 7.5 (1.0) 7.5 (1.4) 
Proximal fixation    
 Spiral blade only 36 (20) 30 (21) 6 (15) 
 Spiral blade + 1 screw 19 (10) 14 (10) 5 (13) 
 1 screw 44 (24) 31 (22) 13 (33) 
 2 screws 61 (34) 49 (34) 12 (31) 
 3 screws 18 (10) 16 (11) 2 (5) 
 Not reported 4 (2) 3 (2) 1 (3) 
Distal fixation    
 None 4 (2) 4 (3) 0 
 1 screw 88 (48) 66 (46) 22 (56) 
 2 screws 82 (45) 66 (46) 16 (41) 
 3 screws 5 (3) 5 (3) 0 
 Not reported 3 (2) 2 (1) 1 (3) 
Reamed    
 Yes 138 (76) 109 (76) 29 (74) 
 No 44 (24) 34 (24) 10 (26) 
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(Table 7.1 continued) 
Adjuvant cement    
 Yes 19 (10) 15 (10) 4 (10) 
 No 163 (90) 128 (90) 35 (90) 
Location of cement±    
 Humeral head 2 (11) 2 (13) 0 
 Fracture / lesion 9 (47) 7 (47) 2 (50) 
 Humeral head & lesion 6 (32) 4 (27) 2 (50) 
 Entire shaft 2 (11) 2 (13) 0 
Preoperative radiotherapy    
 Yes 38 (21) 30 (21) 8 (21) 
 No 144 (79) 133 (79) 31 (79) 
Postoperative radiotherapy    
 Yes 105 (58) 79 (55) 26 (67) 
 No 77 (42) 64 (45) 13 (33) 
*in mm; data of 65 nails missing. ±percentage of nails with cement. SD: standard deviation. 
 
Table 7.2 Primary tumour types 
Primary tumour N (%) 
Breast 51 (29) 
Lung 45 (25) 
Kidney 28 (16) 
Thyroid 9 (5) 
Prostate 8 (5) 
Oesophagus 7 (4) 
Unknown primary 7 (4) 
Melanoma 5 (3) 
Colorectal 4 (2) 
Liver/pancreas 3 (2) 
Bladder 2 (1) 
Other 9 (5) 
Univariate Cox regression analyses did not show any significant association 
between factors such as fracture type, fracture location, fixation technique, 
adjuvant cement, or pre- or postoperative radiotherapy and the risk of failure 
(table 7.5).  
Intraoperative complications were reported in six patients (3.3%), all concerning 
fractures caused by introducing the nail. Seven patients (3.8%) had neurological 
complications: one patient had post-operative paresis of the radial nerve for 





the radial nerve, which recovered spontaneously between one week and six 
months. No local infections were reported.  
Table 7.3 Characteristics of patients and treatments with failed intramedullary nails  
Characteristic Failures no. (%) 
Total (nails) 23 
Primary tumour  
 Breast 6 (26) 
 Kidney 6 (26) 
 Lung 4 (17)  
 Thyroid 2 (9) 
 Prostate 2 (9) 
 Unknown primary 2 (9) 
 Colorectal 1 (4) 
Fracture type  
 Actual 20 (87) 
 Impending 3 (13) 
Location  
 Proximal 8 (34) 
 Diaphyseal 14 (61) 
 Distal 1 (4) 
Proximal fixation  
 Spiral blade  8 (34) 
 1 screw 4 (17) 
 2 screws 6 (26) 
 3 screws 4 (17) 
 Not reported 1 (4) 
Distal fixation  
 None 0 
 1 screw 9 (39) 
 2 screws 13 (57) 
 Not reported 1 (4) 
Cement  
 No 21 (91) 
 Yes 2 (9) 
Radiotherapy  
 Previous only 3 (13) 
 Postoperative only 14 (61) 
 Previous and postoperative 2 (9) 
 None 4 (17) 
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Figure 7.1 Cumulative incidence of failure for actual (AF) and 
impending fractures (IF). 
 
Table 7.4 Distribution of timing of complications according to origin (mechanical or oncological)  
Months after surgery Mechanical Oncological 
0 to less than 3 2 3 
3 to less than 6 1 0 
6 to less than 12 6 1 
12 to less than 18 2 0 
18 to less than 24 1 1 
More than 24 1 4 
Total 13 9 
 
Table 7.5 Cause specific hazard ratio (HR) along with 95% confidence interval (CI) from a univariate 
Cox-regression model for failure 
Variables HR 95% CI P value 
Location    
Proximal -  0.932 
Shaft 1.13 0.47 - 2.72 0.787 
Distal 0.82 0.10 - 6.70 0.855 
Fracture: actual vs. impending  2.91 0.82 - 10.35 0.098 
Proximal spiral bladea 0.88 0.37 – 2.10 0.769 
Number of distal screwsb 0.74 0.31 – 1.74 0.486 
Use of cementc 0.80 0.19 – 3.42 0.761 
Previous RTc 0.92 0.34 – 2.50 0.868 
Post-op RTa 1.70 0.71 – 4.60 0.235 






Pathologic fractures of the humerus account for 15-31% of all pathologic 
fractures16-20 and their optimal treatment is unclear. Choices for the optimal 
surgical modality depend partly on risk factors for failure, but these are 
unknown for intramedullary (IM) nails of the humerus. This retrospective cohort 
of 182 IM nails, the largest cohort regarding humeral IM nails for actual and 
impending pathologic fractures to date, shows an overall good result, but a 
failure percentage of 12.6% with the cumulative incidence increasing with a 
longer survival. None of the included variables were identified as risk factors for 
failure. 
This study is limited by several factors. First, it is plausible that the actual 
incidence of complications is higher and the cumulative incidence is an 
underestimation because follow-up was not standardized. Nearly all studies on 
the treatment of bone metastases are limited by this aspect, because these 
patients, whose treatment is palliative and who are commonly in the last phase 
of life, are seen on indication as opposed to a pre-determined follow-up scheme. 
Second, the retrospective design of the study inherently introduces selection 
bias. Although this study does not compare treatment modalities, indication 
bias might have affected the Cox regression analyses for factors associated with 
failure. Furthermore, the retrospective design also limits the extent of available 
data for analysis. Detailed information on function and pain relief would have 
provided valuable information for this study, however documentation of these 
outcome measures has been insufficient in past medical records.  
The number of failures (23; 12.6%) reported in this cohort is higher than 
reported in two other large studies; both Wedin et al. and Janssen et al. report 
7% failures. 2,11 All reported failure percentages, including this study, are most 
likely an underestimation, predominantly due to lack of standardized follow-up. 
Furthermore, the short survival of this patient population limits the number of 
registered events and possibly gives a distorted perception of the performance 
of IM nails. The increasing cumulative incidence over time as shown in this study 
supports this assumption. To provide the most genuine number of failures, we 
scored all events that did not meet the primary goal of treatment (i.e. regain 
function and provide pain control with a single stabilization) as failure. If only 
revisions are scored, as in the studies by Janssen et al. and Wedin et al., this 
gives an even greater underestimation, because in the palliative setting it is not 
uncommon that patients with an indication for revision surgery are treated 
conservatively because their medical condition is too poor to undergo surgery.  
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The failures can be roughly categorized by their origin, mechanical or 
oncological, although a combination of both elements might be present in some 
cases. The timing of the occurrence of these complications (table 7.4) provides 
further information of what can be expected during follow-up. Also, based on 
these results, other surgical modalities could be considered in cases with a long 
expected survival. Oncological complications predominantly arise very shortly 
postoperatively or after one year. For patients with large and quick growing 
tumor masses, an open approach could thus be considered as opposed to a 
minimally invasive IM nail. In patients with an expected long survival, surgeons 
should be aware of the risk of failure and perhaps consider more extensive 
resection and reconstruction. The latter stresses the importance of survival 
estimation when determining the most appropriate surgical modality for each 
individual patient.21 Mechanical complications arise largely between 6 and 12 
months postoperatively. All healthcare providers should be aware of this, to 
provide timely referral and thus keep quality of life as optimal as possible. 
In this large cohort, no factors (such as location, fracture type and fixation, use 
of cement, and preoperative and postoperative radiotherapy) were identified as 
significantly associated with an increased risk of failure. No previous studies 
have tried to identify factors related with failures of specifically intramedullary 
nails in the humerus for pathologic fractures. Studies by Janssen et al. and 
Wedin et al. only analyzed factors associated with failure of all modalities (i.e. 
prostheses, nails, and plates).2,11 Unfortunately, regarding prognostic factors, 
the current study has brought us no further yet, for it remains questionable 
whether it is now correct to conclude that these factors play no role in the risk 
of failure. Based on experience with femoral stabilizations, an association would 
be expected at least with fracture type (actual or impending).22 The lack of this 
association can be due to (a combination of) two factors: first, the number of 
impending fractures included in the cohort is small. Second, the short survival 
could eliminate an actual association. The lack of a significant difference in 
median overall survival between patients with actual or impending fractures 
corresponds with the results of Wedin et al.,2 but is in contrast to IM nails in the 
femur.22 This is most likely due to the difference in biomechanical loading which 
causes humeral impending fractures to be diagnosed later than femoral 
fractures thereby masquerading the difference in remaining survival between 
impending and actual fractures. Regarding the use of cement and preoperative 
radiotherapy, the lack of an association is possibly due to small number of 






The use of cement is supported by several authors, especially in more dated 
studies.6,23 Laitinen et al. showed that the number of complications did not differ 
between patients treated with and without cement, but that those treated with 
cement experienced faster pain relief.24 Choi et al. used cement in all 
intramedullary fixations, including proximal femoral lesions. They advocate the 
use of cement, especially in lesions affecting the humeral head; in those cases, 
a stable fixation could be achieved despite extensive osteolysis and thin cortex 
due to the use of cement.25 In other recent studies however, the effect of cement 
is not evaluated because the outcomes are subject to selection bias, for cement 
is generally used in larger and more extensive lesions, which are a priori at a 
higher risk of failure. No biomechanical studies have evaluated the effect of 
cement in pathologic fractures of the humerus, as opposed to proven effects in 
the femur.26 One of the difficulties to take into account when using cement in 
(extensive) humeral fractures is the risk of cement leakage and, depending on 
the location, associated damage of the radial nerve or joint space. Based on 
experience, we would advise to use cement only in situations where an IM nail 
is indicated but the bone-stock is insufficient to ensure firm stabilization 
proximal and distal to the fracture.  
This study intentionally did not evaluate the indication for an IM nail. The results 
can however help when choosing between different surgical modalities. When 
choosing between a prosthesis and an IM nail, the 0% infection in this cohort of 
IM nails is a factor to take into account. Also, the relatively high percentages of 
peri-operative complications (3.3%) and postoperative complications affecting 
the radial nerve (3.8%) show that we should not only associate these 
complications with plate fixations. Particular focus should be on the radial nerve 
during reduction of a dislocated fracture and distal fixation.  
In conclusion, this large retrospective cohort shows that intramedullary nails 
should be regarded as a safe and effective treatment for actual and impending 
pathological humeral fractures. If mechanical failure develops, this occurs 
mainly 6 to 12 months postoperatively. Although overall results are good, 
surgeons should be aware of the fact that intramedullary treatment of 
pathologic humeral fractures may not prove as simple as one may expect. Most 
important is to pursue a rotation-stable and durable fixation that corresponds 
with the estimated survival to prevent complications that occur mainly with 
prolonged survival. 
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Pathologic fractures of the distal femur caused by bone metastases are not as 
common as those in the proximal femur but provide great difficulty to 
adequately treat. This systematic review shows that insufficient literature exists 
to draw clinically relevant conclusions for essential questions, such as ‘what 
factors indicate an endoprosthetic reconstruction for distal femur pathologic 
fractures?’ Due to paucity of literature in the systematic review, a current 
concepts review (including treatment flowchart), based on instructional reviews 
and experience, was also performed.  




Patients with actual or impending pathologic fractures caused by bone 
metastases require surgical stabilisation to regain function and quality of life. 
Pathologic fractures show none or only minimal healing tendencies so they 
cannot be treated with the same principles as traumatic fractures. The palliative 
intent of the treatment adds further difficulty, because the scope of the 
treatment should correlate with the expected survival. Stabilisation must enable 
immediate full weight-bearing, be sufficient for the remaining lifetime while 
avoiding the need for extensive rehabilitation.  
The femur is the most common long bone affected by bone metastases and 
subsequent pathologic fractures.1 One third of the femur metastases is located 
in the inter- and subtrochanteric regions, followed by the neck and diaphysis.2,3 
The distal femur is the least affected region of the femur; in our large 
retrospective database approximately 10% of all femoral metastases were 
located distally.4 However, the distal femur is one of the most difficult areas to 
treat.  
Treatment options include endoprosthetic reconstruction (EPR; total knee or 
modular tumour prostheses), single or double plate fixation, intramedullary (IM) 
nail fixation, and cement arthroplasty.5 Due to the magnitude of prosthetic knee 
reconstructions, internal fixation is generally preferred, but due to the location 
sufficient screw fixation on both sides of the lesion is often not possible. 
Additionally, adequate fixation of screws in the condyls is often difficult due to 
poor bone stock. Adjuvant cement can provide more grip for the screws, but is 
challenging to apply to the desired location. Cement alone can also be used to 
fill the lesions, but is only a short-term solution when a short survival is 
expected. 
A brief glimpse on current literature shows little mentioning of how to treat 
pathologic fractures of the distal femur, while all orthopaedic and trauma 
surgeons come across these fractures and need to decide on the most optimal 
treatment. With the lack of evidence, treatment is based on clinical experience, 
but only few surgeons have sufficient experience to depend on. The treatment 
of these difficult fractures is therefore a common subject of discussion and 
consultation among colleagues. As survival of patients with metastatic disease 
prolongs 6,7 and the incidence of pathologic fractures grows,8 including those of 
the distal femur, the need to identify the optimal treatment of pathologic 
fractures of the distal femur increases. The optimal treatment however differs 
for each individual patient. Factors that identify the most suitable treatment 





peer-reviewed publications. To that end, this study aims to perform a systematic 
review to identify factors that indicate the need of an endoprosthetic 
reconstruction for a distal femur pathologic fracture. Additionally, a current 
concepts review was performed. 
Methods 
This systematic review is reported according to the MOOSE guidelines for 
reporting observational studies.9 
Literature search 
The search strategy was developed by an experienced medical librarian (JWS), 
and applied in the following databases: PubMed, Embase (OVID-version), Web 
of Science, COCHRANE Library, CENTRAL, CINAHL/Emcare (OVID-version), and 
ScienceDirect. The following keywords were used and combined with the 
Boolean operators ‘OR’ and ‘AND’: distal femur, metastasis, pathologic fracture, 
fracture, neoplasm AND surgery, treatment, endoprosthesis, intramedullary 
nail, plate, implant. For the different concepts, all relevant keyword variations 
were used (i.e. keyword variations in the controlled vocabularies as well as free 
text word variations). The search strategy was optimized for all consulted 
databases. The final search was performed on 15-12-2017. Reference lists of 
retrieved papers, review articles, and clinical practice guidelines were checked 
for relevant publications. Inclusion was limited to results in English or Dutch and 
publications between 1990 and 2017. Meeting abstracts, case reports, and 
review articles were excluded. Articles reporting on functional outcomes, 
complications, revisions or survival after treatment with prostheses, plate-screw 
fixations, IM nails, or cementplasty for an actual or impending pathologic 
fracture of the distal femur due to bone metastases were defined as eligible.  
Articles were selected in two steps, both performed by two authors (JJW, 
CWPGvdW) independently. First, all titles and abstracts were screened according 
to the predefined criteria. Subsequently, all potentially eligible studies and all 
studies that could not be scored based on title and abstract were retrieved in 
full-text and screened based on the same criteria. Disagreements were 
dissolved by consensus after both steps. 
Data extraction and analysis 
The same two authors independently extracted data using an electronic data 
collection form. Available data concerning study characteristics, patient 
demographics, and outcome measures was collected. Outcome measures 
included functional outcomes as measured by an internationally accepted 
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standardized instrument and local complications (infections, structural failures 
(including implant loosening or breakage, dislocation, peri-prosthetic fracture), 
and tumour progression).  
Statistical analysis 
All data were summarized descriptively. Complications were reported as 
frequencies with percentages for each surgical modality. No pooled effects were 
estimated because the studies included did not report complication rates 
(including 95% confidence intervals), but only frequencies.  
Quality assessment 
The methodological quality of all included studies was assessed using the 
Methodological Index for non-Randomized Studies (MINORS) scale.10 MINORS is 
a validated score for non-randomised studies based on eight items with a 
maximum score of 16 for non-comparative studies. A score of 12 or higher was 
considered as ‘high’ methodological quality, 9-11 was considered ‘moderate’, 
and 8 points or less was considered ‘low’ quality.11 All included studies were 
assessed independently by two authors (JJW, CWPGvdW). Any discrepancies 
were resolved by consensus. 
Results 
Literature search 
The literature search identified 469 unique titles. Figure 8.1 shows the flowchart 
of in- and exclusion resulting in two articles to be included in this review.12,13 In 
total, 441 articles were excluded because the study population did not include 
distal femoral metastases, and 21 articles were excluded because although the 
study included distal femoral metastases, the results were not reported 
specifically for this group. Another 20 articles were excluded because they were 
reviews or case reports, 11 articles were excluded because they were not in 
English or Dutch, and one article was excluded because the full-text was not 
available. The two included studies reported on outcomes after surgery of 
metastases in the long bones or femur in general, but provided (some of) their 
results specified per location and were thus eligible for inclusion. 
Study characteristics 
Mavrogenis et al. report on 29 distal femur fractures in 29 patients, 16 of which 
treated with femoral reconstruction nails (Grosse & Kempf Locking Nail System 





knee distal femoral prostheses (HMRS, Howmedica Modular Reconstruction 
System, Stryker, UK). Wedin et al. describe the results of 16 distal femoral 
fractures in 16 patients, one of which treated with a prosthesis, ten treated with 
plate fixation (eight with gliding screws, two with regular screws), and five with 
other treatment modalities (e.g. curettage). Unfortunately, no further treatment 
details are presented. In total, the two studies reported on 45 distal femora: 14 
treated with EPR, 16 with IM nails, 10 with plates, and five with other modalities. 
Baseline patient characteristics were not reported specifically for the distal 
femur and can therefore not be presented in the current review. 







Excluded (n = 439)
- population (n = 409)
- publication type (n = 20)
- language (n = 10)
Papers included for 
qualitative synthesis
(n = 2 )
Excluded (n = 28)
- population (n = 5)
- results not specified for distal 
femur metastases (n = 21)
- language (n = 1)
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Table 8.1 MINORS scale for methodological quality. Items are scored 0 (not reported), 1 (reported 
but inadequate) or 2 (reported and adequate). Total score of 16 points is possible. 














1 2 0 1 0 2 2 0 8 
Wedin et al. 2 2 0 2 0 0 0 0 6 
1: A clearly stated aim: the question addressed should be precise and relevant in the light of 
available literature. 
2: Inclusion of consecutive patients: all patients potentially fit for inclusion (satisfying the criteria for 
inclusion) have been included in the study during the study period (no exclusion or details about the 
reasons for exclusion).  
3: Prospective collection of data: data were collected according to a protocol established before the 
beginning of the study. 
4: Endpoints appropriate to the aim of the study: unambiguous explanation of the criteria used to 
evaluate the main outcome which should be in accordance with the question addressed by the 
study. Also, the endpoints should be assessed on an intention-to-treat basis. 
5: Unbiased assessment of the study endpoint: blind evaluation of objective endpoints and double-
blind evaluation of subjective endpoints. Otherwise the reasons for not blinding should be stated. 
6: Follow-up period appropriate to the aim of the study: the follow-up should be sufficiently long to 
allow the assessment of the main endpoint and possible adverse events. 
7: Loss to follow up less than 5%: all patients should be included in the follow up. Otherwise, the 
proportion lost to follow up should not exceed the proportion experiencing the major endpoint. 
8: Prospective calculation of the study size: information of the size of detectable difference of 
interest with a calculation of 95% confidence interval, according to the expected incidence of the 
outcome event, and information about the level for statistical significance and estimates of power 
when comparing the outcomes. 
Quality assessment 
The mean MINOR quality assessment score was 7 (table 8.1), which was 
considered low methodological quality. There were no items of major 
discrepancy between the reviewers.  
Functional outcomes 
Neither study reported on functional outcomes. 
Complications  
In the study by Mavrogenis et al. four complications were reported among 13 
EPR (31%). The complications included three infections and one aseptic 





the distal femur made up 83% of all complications reported (5 of 6); only one of 
81 (1.2%) treated proximal and diaphyseal fractures failed, while five of the 29 
(17.2%) treated distal femurs failed.  
Wedin et al. reported two complications in the patients treated with plates 
(20%), and two in those who received curettage and augmentation (40%). 
Causes of the latter four failures were stress fractures in two patients and 
tumour progression in two cases after 7 and 13 months. The distal femur 
complications were 21% of all femoral complications reported in the study (15 
complications in 143 proximal and diaphyseal fractures). 
Overall, four of 14 EPR (29%; 9% of all distal femora), one of 16 IM nails (6%; 2% 
of all distal femora), two of ten plate fixations (20%; 4% of all distal femora), and 
two of five variety of treatments (40%; 4% of all distal femora) led to 
complications. 
 
Table 8.2 Complications 







et al. 2012 








Wedin et al. 
1999 
EPR 1 0 (0)   
Mavrogenis 
et al. 2012 




Wedin et al. 
1999 
Plate 10 2 (20) Tumour 
progression 
Stress fracture 
Revision of plate 
with cement 
Revision of plate 
with cement 
Wedin et al. 
1999 
Other± 5 2 (40) Tumour 
progression 
Stress fracture 
Plate with cement 
Screw with cement 
*Time between surgery and complications. ± Patients with complications had received curettage and 
cement; EPR: endoprothetic reconstruction; IMN: intramedullary nail; DAIR: debridement, 
antibiotics, irrigation, retention. 
 




This study aimed to systematically review the literature on treatment of distal 
femoral pathologic fractures and identify factors that indicate the need for 
endoprosthetic reconstruction. The predominant conclusion is that there are 
hardly any studies reporting on pathologic fractures of the distal femur. Despite 
broad inclusion criteria, this systematic review identified only two studies that 
reported outcomes regarding this subgroup of fractures; 21 studies were 
excluded because, despite describing the relevant study population, they did 
not report the outcomes specifically for the distal femur (figure 8.1). Moreover, 
there are no studies focussing solely on the treatment of distal femoral 
pathologic fractures. The paucity of studies on the distal femur as opposed to 
the elaborate number of studies on the proximal femur is not in proportion with 
the difference in incidence. A reason for the lack of publications is not apparent 
and cannot be clearly explained. Rarity cannot be the only reason, for studies 
have been published on the most uncommon diseases. Perhaps these fractures 
have up to now simply been overshadowed by those of the proximal femur.  
The second conclusion is that based on the included studies no factors can be 
identified that indicate the need for an EPR. Overall, the revision rates of plates 
and variety of treatments (e.g. curettage and cement) are higher than of EPRs 
and IM nails.13 However, taking the limitations of the studies into account, firm 
conclusions are not possible. The interpretation of the results of the two 
included studies is difficult because no baseline data is presented of the patients 
treated for distal femur fractures. Thus although information on the primary 
tumour and fracture type is reported in those cases that failed, these factors 
cannot be placed into perspective of the entire cohort and no risk factors can 
be deduced. Additionally, only one of the studies reported exactly what implants 
were placed and neither studies gave details on the extent of the metastatic 
lesion. 
Several limitations are present in this study. An important limitation is the lack 
of baseline characteristics because it impairs detailed comparison of the 
cohorts. Follow-up was neither adequately reported in the included studies. 
Short follow-up or loss to follow-up can lead to underreporting of complications. 
Although an elaborate literature search was performed in six databases and 
bibliographies were checked for missed publications, it is possible that relevant 
publications were not found. Also, restricting the language to English and Dutch 
possibly excluded relevant studies. Further, despite the aim to focus on only 
distant femoral metastases, heterogeneity regarding prostheses and implants, 
surgical techniques and surgeons, and adjuvant treatments could not be 





Although this is a limitation for this study, it is also a representation of clinical 
practise and therefore acceptable. 
In the light of the conclusions and limitations of this study, advice regarding the 
use of EPR for distal femoral fractures can solely be expert based. Several 
instructional reviews make recommendations. Quinn et al. advise to treat 
smaller lesions in the distal femoral area with plate osteosynthesis and 
polymethylmethacrylate (PMMA), while larger destructive lesions should be 
treated with plate fixation when the articular surface can be maintained and the 
joint is otherwise normal. If the latter is not the case, a total knee replacement 
is indicated. Quinn et al. do not further elaborate whether plate fixation should 
be with locking plates or classical plates.14 Scolaro et al. note that lateral locking 
plate osteosynthesis (LPO) with lesion curettage and PMMA provide reliable 
fixation for extra-articular and well-contained lesions, but IM nailing with PMMA 
or EPR are also options. For intra-articular or uncontained lesions an EPR should 
be used.5 A similar conclusion is presented by Bryson et al., noting that if bone 
stock is adequate conventional fixation with locking plates of retrograde nailing 
with PMMA is usually sufficient.15 Anract et al. report that LPO (with cement to 
strengthen the construct) should be used in patients whose life expectancy is 
short or when union of the fracture can be expected after adjuvant therapy. In 
other situations, resection and reconstruction with a tumor prosthesis is 
advised.16 Concerning the use of LPO as described by Anract et al. we do not 
completely agree, for union should rarely be expected. Therefore, in our own 
instructional review, we recommend locking plate fixation with adjuvant PMMA 
if the bone stock is sufficient for adequate grip of the screws, irrespective of any 
expected union. If the condyles are largely affected or a long survival is expected 
a prosthesis should be considered. If the lesion is more metaphyseal and 
impending with sufficient bone stock in the condyls, an IM nail should be 
considered.17 Whether IM nails should be placed ante- or retrograde is 
debatable and is not discussed in the cited instructional reviews. In trauma 
surgery, (reamed) antegrade and retrograde placed nails for distal femur 
fractures have shown comparable results regarding union and 
complications.18,19 These results are however difficult to translate to the 
(impending) pathologic fracture population. For the fixation of pathologic 
fractures, all nails should be locked and sufficiently bridge the lesion, which for 
antegrade nails often means they should extend to the subchondral level. The 
risk of intra-articular metastatic spread is a proclaimed downside of retrograde 
nailing. Opening of the joint can lead to other complaints such as knee pain or 
osteoarthritis. Nail protrusion caused by insufficient distal fixation in poor bone 
stock can require revision surgery, although adequate use of PMMA can 
decrease this risk. Also, the alignment of the knee in the frontal plane can be a 
 Treatment of distal femoral metastases 
 
 155 
problem with retrograde placing of nails. Finally, it should be noted that the use 
of retrograde nails has its limitations as it leaves the femoral neck unprotected 
and thus at risk for fracture after stabilisation. The incidence of these 
complications in pathologic fracture treatment is however not known. One small 
study reports of one nail protrusion into the knee after retrograde fixation in 12 
distal femur fractures.20  
As mentioned in previous instructional reviews, plate osteosynthesis plays a 
large role for distal femoral fixations; much larger than for other femoral 
locations. Osteosynthesis with locking compression (LC) plates is the current 
standard, as opposed to reduction with dynamic compression (DC) plates. LC 
plates function as internal fixators with multiple fixation points, creating a stable 
construct 21 and therefore double plating (two DC plates in 90-degree angle) is 
redundant. In fractures where both LPO and IM nail fixation would be suitable 
options, it is not evident which of the two should be preferred. However, PMMA 
commonly plays a role in the stabilisation – requiring clear access of the fracture 
– and this is easily combined with open reduction and plate fixation. Adequate 
cementation with IM nailing is difficult and often insufficient. Some authors 
prefer IM nails over LPO because less soft tissue dissection is required which is 
preferable as to prevent local soft tissue complications from post-operative 
radiotherapy.20 The necessity of post-operative radiotherapy however, not only 
after ORIF but also after EPR, should be reconsidered. The use of post-operative 
radiotherapy has become common practise, but the evidence upon which it is 
based is limited to one 20-year-old retrospective study with few patients.22  
Based on the instructional reviews, EPRs are indicated when the articular 
surface is affected, the condyles are largely affected or a long survival is 
expected. The latter is the case when it concerns a solitary metastasis, especially 
from renal cell cancer 23 or a favourable presentation of breast or thyroid cancer. 
This is illustrated by the case presented in figures 8.2a - d. The depicted case is 
an example in which a primary en-bloc resection and prosthetic reconstruction 
should have been considered. The location of the fracture and the expected 
long-term survival of the patient were signs that a plate fixation could be 
insufficient. Keeping in mind that a stabilisation of a pathologic fracture should 
be “once in a lifetime” and that the aim of the surgery is to maintain quality of 
life (i.e. full weight-bearing), a more durable option as primary stabilisation 
would have been preferable. Generally, such en-bloc resections and 
reconstructions are performed in tertiary orthopaedic-oncology centres, so 
patients should be referred if a more straightforward stabilisation is expected 
to be insufficient. Once again, the importance of adequate survival estimation 





estimation and these should be used before resection and reconstruction with 
endoprostheses.4,24-26 One of the most important aspects to take into account 
when estimating survival is the primary tumour, for the prognosis can differ 
widely depending on tumour biology and available systemic options.4 The 
primary tumour type and its sensitivity to radiotherapy also influences the local 
treatment options for impending and actual pathologic fractures. To provide an 
overview of the current treatment concepts a detailed treatment flowchart was 
developed (figure 8.3). As shown in this flowchart, the amount of bone stock (i.e. 
the size of a lesion and amount of cortical destruction) and whether the condyls 
are affected, are important aspects to take into account, in addition to the 
fracture type and expected survival. 
Despite not answering our research question, the included studies show that 
the overall revision rate for the distal femur is high compared to other femoral 
locations. Mavrogenis et al. report a 14% revision rate in the distal femur and 
only 1% in the proximal femur (1 dislocation in 78 treated proximal femora).12 
Wedin et al. report 25% revision rate in the distal femur and 9% in the proximal 
femur (10 of 108 treated proximal femora).  
The overall failure rate of EPRs in this systematic review (31%) is comparable to 
the overall failure rate in a study evaluating modular knee prostheses for 
primary tumours (29%).27 It is however higher than the 18% complication rate of 
prosthetic reconstructions of proximal femur metastases as reported by Harvey 
et al. Moreover, in the latter study infections accounted for only half of the 
complications, while dislocations caused the other half. For the distal femur, as 
evident in the current study, infections are the most common cause of 
complications. This is a well-known problem with endoprostheses,28 but should 
be regarded with even more caution in the metastatic population because these 
patients often are elderly and have further decreased immunity due to the 
extensive disease. Pre-operative radiotherapy has been reported as risk factor 
for infection in this patient population, but further analyses are required to 
determine whether this should affect the choice of a prosthetic reconstruction.29 
Pathologic fractures of the distal femur are one of the most difficult pathologic 
fractures to stabilise, but current literature is insufficient to provide evidence 
based recommendations on when to use an EPR. It is easy to conclude that 
randomised controlled trials and subsequent meta-analyses based on such 
randomised studies are required to find answers. However, the heterogeneity 
of patients with bone metastases and the relatively low incidence of pathologic 
fractures, especially of the distal femur, challenge performing a valuable 
randomised study. A second best option would be a prospective, multicentre 
cohort to record all treatments and complications. Such a cohort will still face 
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indication bias, but with a sufficient number of patients, some robustness will 
be granted. A current study (Clinicaltrials.gov NCT02705157) will hopefully 
provide much needed data.  
To conclude, based on this systematic review no evidence based 
recommendation can be given for the use of EPR in the treatment of distal femur 
pathologic fractures. The paucity of results in this literature search and poor 
quality of the few included studies illustrate the issues that surgeons treating 
pathologic fractures are constantly confronted with: there is insufficient 
adequate research on the treatment of pathologic fractures to answer relevant 
questions. International, prospective collaborations are needed to fill this void. 
Based on literature and expert opinion, indications for EPR in distal femur 
fractures are solitary metastases in patients with a long survival, a major 
affected joint surface, and insufficient bone stock for internal fixation. 
 
 
Figure 8.3 Overview of treatment options for pathologic fractures of the distal femur taking 
estimated survival into account.  
±If the lesion concerns a distal metastasis of kidney of thyroid carcinoma an en-bloc resection and 
reconstruction with EPR should be considered to improve survival. *Taking expected benefit on 
quality of life into account. If no improvement of quality of life is to be expected, comfort care should 
be the preferred treatment. LPO: lateral plate osteosynthesis. PMMA: polymethylmetacrylate. EPR: 
endoprosthetic reconstruction.   























































Figure 8.2 Distal femur fracture in a 45-year-old woman caused by a solitary metastasis of renal cell 
carcinoma (figure a). Stabilisation of the distal femur fracture was performed with a plate 
osteosynthesis without cement (figure b) and post-operative radiotherapy (5 x 4Gy) was 
administered. A maximum load of 25 kg was set for the left leg, so the patient could only mobilise 
with crutches. Over the next months the knee remained painful despite optimal pain medication. 
Further imaging of the knee (figure c) showed that there was no consolidation of the transverse 
fracture, that there were also vertical fractures, and that the plate was not completely adjacent to 
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the bone. To improve the quality of life of the patient (i.e. pain reduction and possibility for better 
mobilisation) the insufficient plate osteosynthesis was revised and a distal femur resection was 
performed and a modular tumour knee prosthesis was implanted (figure d).  
This case is an example in which a primary en-bloc resection and prosthetic reconstruction should 
have been considered. The location of the fracture and the expected long-term survival of the 
patient were signs that a plate fixation could be insufficient. Keeping in mind that a stabilisation of 
a pathologic fracture should be “once in a lifetime” and that the aim of the surgery is to maintain 
quality of life (i.e. full weight-bearing), a more durable option as primary stabilisation would have 
been preferable. Generally, such en-bloc resections and reconstructions are performed in tertiary 
orthopaedic-oncology centres, so patients should be referred if a more straightforward stabilisation 
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• Bone metastases of the long bones often lead to pain and pathological 
fractures. Local treatment consists of radiotherapy or surgery. Treatment 
strategies are strongly based on the risk of the fracture and expected 
survival. 
• Diagnostic work-up consists of CT and biopsy for diagnosis of the primary 
tumour, bone-scan or PET-CT for dissemination status, patient history and 
blood test for evaluation of general health, and biplanar radiograph or CT 
for evaluation of the involved bone. 
• A bone lesion with an axial cortical involvement of >30 mm has a high risk 
of fracturing and should be stabilised surgically. 
• Expected survival should be based on primary tumour type, performance 
score, and presence of visceral and cerebral metastases. 
• Radiotherapy is the primary treatment for symptomatic lesions without risk 
of fracturing. The role of post-operative radiotherapy remains unclear. 
• Main surgical treatment options consist of plate fixation, intramedullary 
nails and (endo) prosthesis. The choice of modality depends on the 
localisation, extent of involved bone, and expected survival. Adjuvant 
cement should be considered in large lesions for better stabilisation. 
  




Bone metastases arise most commonly in patients suffering from breast, 
prostate, kidney or lung cancer.1 Two-thirds of all patients dying of cancer 
reportedly develop bone metastases,2 however a modern, image-based study 
would probably present an even higher number. Due to constantly improving 
treatments the duration of the palliative phase is prolonged. Longer survival 
unfortunately gives each patient more time to develop metastases. 
Bone metastases of the long bones may lead to pain, pathological fractures, 
immobility, decreased functioning, and hypercalcaemia. Over half of the 
patients experience clinical symptoms for which treatment is required,3 of 
whom only a minority is surgically treated.4 In the long bones, pain is the most 
common symptom, followed by impending or actual pathologic fractures in 10-
25% of the patients.5 Pathologic fractures of the femur, 75% of which presenting 
in the proximal part, are roughly 3.5 times as common as fractures of the 
humerus.6   
This review discusses the local management of (impending) pathological 
fractures of the long bones, with focus on surgical treatment strategies. 
Diagnosis and evaluation 
For successful management the following adage should be followed: stop; think 
and stage; act. The most important information is gathered with the following 
four questions and flow-chart (figure 9.1).  
What is the origin of the lesion?  
A bone lesion with unknown aetiology is a primary bone tumour until proven 
otherwise. Denying this possibility might deprive patients of correct and curative 
treatments. If the patient has no history of malignancy a (PET-)CT scan of the 
chest and abdomen should be performed. In case no primary tumour is visible, 
a core needle biopsy of the bone lesion should be performed for histologic 
identification before treatment is engaged. When the patient has already known 
malignancy, but has no previous metastases and the lesion is solitary, a biopsy 
should be considered. In case of multiple lesions and a malignancy at high-risk 
for developing metastases (e.g. lung cancer), generally no additional histological 
confirmation is necessary. 
What is the dissemination status?  
The presence of other disease localisations influences the treatment strategy. 





oligometastases (between two and four bone metastases), or diffuse. Solitary 
lesions can in some cases (i.e. primary kidney cancer or bone sarcoma) be 
treated with curative, albeit generally palliative, intent.7 Defining a difference 
between oligometastases and diffuse metastases throughout the skeleton is a 
relatively new concept. Especially for kidney and breast cancer patients it is 
hypothesised that a more aggressive local treatment in the case of 
oligometastases might improve survival.8 In the past, the principal examination 
to assess the bone dissemination status was a total-body bone scintigraphy 
(technetium-99m or fluoride-18 scan). Currently the use of PET-CT is 
accelerating due to its increased accessibility and superior sensitivity and 
specificity to bone scintigraphy.9 Additionally, PET-CT provides information on 
other (visceral) disease localisations. If PET-CT is unavailable, then an additional 
CT of the thorax/abdomen should be considered to analyse visceral 
dissemination. 
 
Figure 9.1 Flowchart of diagnostic tests. 
*Survival prediction according to primary tumour type, patient performance score, visceral or 
cerebral metastases.19 **Fracture risk according to axial cortical involvement or circumferential 
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What is the general health of the patient?  
The general health status can be deduced from the patient history (nutritional 
status, weight loss and cognitive status, for example). Dehydration, thirst or 
drowsiness can suggest hypercalcaemia and blood tests (serum calcium and 
albumin) should be performed. If surgery is planned, laboratory studies should 
include a complete differential blood-cell count, erythrocyte sedimentation rate, 
C-reactive protein, electrolyte count (sodium, potassium), and serum alkaline 
phosphate.  
What is the local status of the involved bone?  
In daily practise, bi-planar conventional radiographs of the whole affected long 
bone are mandatory to evaluate the extent of the cortical destruction of the 
involved bone lesion and whether other adjacent bone lesions are present. The 
cortical destruction is a measure for estimating the fracture risk. A CT scan is a 
more precise alternative for obtaining this information; however, routine use of 
CT scans is less practical and more expensive than radiographs and thus not 
advised as a primary imaging modality. 
The information gathered with the standard work-up provides the basis for 
staging of the patient and determining the treatment strategy. The first step is 
the decision in a multi-disciplinary meeting on whether surgery is required. 
Radiotherapy is the treatment of choice for small lesions, while surgery is 
indicated for actual fractures. The difficulty lies in the group of patients with 
larger lesions and an uncertain risk of fracturing.  All treatments aim to maintain 
optimal, pain-free function of the extremities and should ensure direct weight 
bearing and mobility. Two important principles should be adhered. 
Prophylactic stabilisation of bone should be performed if there is a substantial 
risk of fracturing. If the risk of fracturing is low, the appropriate treatment is 
radiotherapy. While there is general consensus about the advantages of 
operating impending fractures over actual fractures, a clear, international 
definition of ‘a substantial risk’ has not been defined.10 To prevent over- and 
under-treatment, a careful balance between the advantages of a prophylactic 
treatment versus the risks of surgery and disadvantages of over-treatment for 
the patient has to be made. Multiple different factors for an impending fracture 
have been described, such as pain, size, site, and lesion aspect.11,12 However, 
because these factors are based on retrospective research, their predictive 
value is low.10 Based on prospective research, we advise the use of the axial 
cortical involvement of > 30mm and a circumferential cortical involvement of 





fracture risk analysis is CT-based,14 the axial cortical involvement is the most 
practical tool to use if only conventional radiographs are available.   
The selected rigid fixation should be durable for the remaining lifetime of the 
patient, while the recovery and rehabilitation time should not exceed the life 
expectancy. Survival can range from days to many years depending primarily on 
the primary tumour type. Median survival for patients with bone metastases 
from lung cancer is three months, while this extends to ten months for prostate 
and 17 months for breast cancer.15 Multiple factors are considered prognostic 
for survival besides primary tumour type and various prognostic models based 
on these factors have been designed, as shown in table 9.1.4,15-20 We advise the 
prediction of survival according to a simple and straightforward model, 
including primary tumour type, performance score, and the presence of visceral 
or cerebral metastases (figure 9.3).19 
If survival is less than six weeks, the possible benefits of a surgical intervention 
need to be strongly considered and generally care with conservative measures 
should be sought (such as care at a hospice). If surgical intervention is absolutely 
required, it should be as minimally invasive as possible with a short recovery 
time. For patients with an expected short-term survival (between six weeks and 
six months), more invasive procedures are warranted. However, the use of 
extensive reconstructions or large, complication-prone prostheses should not 
be pursued. Long-term survival (expected survival > six months) justifies and 





Figure 9.2 Measurement of metastatic 
lesions in the femur (in mm): largest axial 
measurement of lesion (L-lesion), largest 
transverse extension of the lesion (W-
lesion), largest axial cortical involvement 
(L-cort). (Reprinted with permission from: 
van der Linden YM, Kroon HM, Dijkstra 
SPDS, Lok JJ, Noordijk EM, Leer JWH, et al. 
Simple radiographic parameter predicts 
fracturing in metastatic femoral bone 
lesions: results from a randomised trial. 
Radiotherapy and Oncology. 2003; 
69(1):21-31) 
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Table 9.1 Prognostic factors for survival in patients with bone metastases 
 BAU FOR RAT BOL KAT WES JAN 
Site of bone 
metastases 
Skeletal Skeletal Skeletal Spinal Skeletal Skeletal LB 
Number of patients 241 189 1195 1043 350 1157 927 
Primary treatment Sur Sur Sur Con/Sur Con/Sur Con Sur 
Primary tumour X X X X X X*+† X 
Performance status   X X X X*+†  
Visceral metastasis X X X X X X† X 
Cerebral metastases X   X X   
Lymph node 
metastases 
 X      
Number of metastases X  X  X  X 
Chemotherapy     X   
Age       X 
Comorbidity       X 
BMI <18.5 kg/m2       X 
Laboratory results  X   X  X 
Gender  X    X†  
Pathologic fracture X X      
Surgeons’ estimate 
survival 
 X      
Patient reported pain      X†  
BAU: Bauer 199516; FOR: Forsberg 201117; RAT: Ratasvuori 201318; BOL: Bollen 201419; KAT: Katagiri 
revised 201420; WES: Westhoff 201415 *simplified model, †complex model; JAN: Janssen 2015. Skeletal: all 
sites. Spinal: axial skeleton. LB: long bones. Con: chemo/radiotherapy, Sur: surgery. 
Radiotherapy 
Palliative radiotherapy for painful bone metastases is well established and 
provides an effective symptomatic treatment. Overall response rate is 60%, 
depending on the primary tumour and the expected survival time.21 A single 
fraction of 8Gy is presently considered standard treatment for painful lesions 
with a low risk of fracture. If pain is recurrent after a single fraction, a second or 
third fraction of 8 Gy can be given without many treatment side-effects. For large 
lesions with extensive osseous destruction, it is believed that a higher total dose 
given in a fractionated scheme will lead to a higher tumour response with 
remineralisation to strengthen the bone and postpone the occurrence of a 
fracture.22    
Post-operative radiotherapy is commonly advised as prophylaxis for tumour 
progression and implant failure.23 However, this is not evidence based and 
further prospective research should be performed before statements can be 






Figure 9.3 Prediction model for survival. Category (A-D) indicates expected survival in months. 
(Reprinted with permission from: Bollen L, van der Linden YM, Pondaag W, Fiocco M, Pattynama 
BPM, Marijnen CAM, et al. Prognostic factors associated with survival in patients with symptomatic 
spinal bone metastases: a retrospective cohort study of 1 043 patients. Neuro-Oncology. 2014 Jul; 
16(7):991-8) 
Surgery 
Differing skeletal locations, life expectancies, patient characteristics (for 
example obesity) and types of fractures lead to variation in treatments. The 
planned procedure generally entails an intralesional approach. A more 
extensive procedure is unnecessary for oncologic control. An en-bloc resection 
is only indicated when there is vast destruction of bone or in the rare occasion 
of a curative intent of the procedure. In patients with actual fractures due to 
metastases of kidney and thyroid cancer, pre-operative embolisation of the 
metastasis is advised to prevent excessive peri-operative blood loss.24 Surgery 
should be performed within 72 hours following embolisation. 
For all pathologic fractures of the long bones, three principal surgical treatment 
options exist: intramedullary nail, plate, or (endo) prosthesis.  
Intramedullary nails offer several advantages: they protect a long segment of 
bone, the necessary dissection is relatively small, blood supply to the 
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periosteum is preserved, and rigid fixation can be achieved by locking with 
proximal and distal interlocking screws, and/or by using bone cement 
surrounding the nail.25 All intramedullary nails need distal locking to provide 
rotation stabilisation and prevent failure of fixation.26 Proximal fixation can be 
achieved with standard screws or with an interlocking lag screw or helical blade, 
for both the femur and the humerus. The large lag screw or helical blade allows 
for a stronger construct due to the increased surface area contact. An 
intramedullary nail allows for immediate and unrestricted stability. With time, 
however, intramedullary nails without cement augmentation are at risk of 
failure, because they are load-sharing devices instead of load-bearing devices. 
Other disadvantages are the need for adequate bone stock at the site of the 
locking screw(s) and its inapplicability for lesions close to the joint.  
Plate fixation offers several advantages: damage to the muscle cuff can be 
avoided, very distal fractures can also be adequately fixated, and a rigid fixation 
is possible with locking screws. In addition, the open approach provides good 
access and visualisation for curettage, fracture reduction and reposition, and 
application of adjuvant cement. The downsides of using a plate are the large 
incision needed, a longer surgical procedure and the lack of prophylactic fixation 
of the entire bone.  
Prosthetic reconstructions (endoprosthesis, segmental prostheses, hemi- and 
total joint arthroplasty) provide immediate stability, independent of the degree 
of fracture healing, and the risk of local progression or implant failure is 
minimized.27 The principal drawback of this method is the high risk of 
complications.28 The surgery is extensive, muscles need detaching and 
reattaching, and it is associated with increased blood loss.29 In addition, if post-
operative radiotherapy is believed to be an important adjuvant treatment, 
endoprostheses should not be used due to radiotherapy-induced osteoporosis 
and impaired bone healing, leading to inadequate screw fixation.30 The high 
costs of endoprostheses used to be a significant factor to take into account. 
However, manufacturers are developing cheaper endoprostheses indicated 
especially for metastatic disease so this has become a less decisive aspect. 
Each region has its own options and treatment strategies, as shown in tables 9.2 
and 9.3 for the femur and humerus, respectively. If the tibia, ulna, or radius is 
involved, treatment strategies for the humerus should be followed. Despite the 
extensive period of time during which bone metastases have been treated, no 
randomised controlled trials have been performed to evaluate the best surgical 
procedures for each setting.31 Therefore, the recommended procedures are 






Pathologic fractures of the proximal femur are most common in the femoral 
neck, followed by the sub and intertrochanteric regions, the diaphysis, and distal 
femur.32 The different treatment approaches are given in table 9.2. 
In general, the treatment strategy of the femur depends on the involvement of 
the acetabulum. If the acetabulum is grossly affected, a (modular) total hip 
arthroplasty (THA) with cup augmentation is indicated. When placing a THA for 
metastatic disease a relatively high risk of dislocation should be acknowledged. 
The muscular cuff is very likely weak or insufficient due to previous systemic 
treatment, radiotherapy, or immobilisation. To minimize the risk of hip 
dislocation we recommend a dual-mobility cup. In cases with extensive 
involvement of the proximal femur and acetabulum and where long-term 
survival is expected, a hemi-pelvic endoprosthesis is more suitable. If the 
acetabulum is unaffected or marginally affected (less than one-third of the 
circumference), the strategy depends on the localisation. 
For pathologic fractures of the femoral head and neck a (cemented) hemi-
arthroplasty is recommended. The secondary degenerative changes associated 
with hemiarthroplasties will rarely present.33 A long stem provides prophylactic 
stabilisation of the entire femur shaft, but is accompanied with higher risks of 
complications such as thrombo-embolic events.34 It is unclear in literature 
whether a long stem should be routinely placed.35  
The optimal treatment of pathologic fractures of the trochanteric region is a 
frequently discussed issue. The options consist of intramedullary reconstruction 
nails and prosthetic reconstruction, but there is poor evidence as to which 
serves patients better.36 The decision is primarily based on the quality of bone 
stock. If the bone stock is sufficient to create a stable situation (i.e. a small or 
solitary lesion), an intramedullary reconstruction nail including femoral neck 
and head fixation is advised for both actual and impending fractures as for both 
patients with a short and long expected survival.37 Cement can be considered to 
prevent mechanical failure, especially if the expected survival is long. If there is 
insufficient bone stock and doubt exists concerning the durability of the screw 
fixation in the femoral head, the choice of treatment needs more careful 
consideration. For patients with short-term survival, an intramedullary 
reconstruction nail with cement will provide sufficient stability, despite poor 
bone stock and irrelevant to the type of fracture. Patients with long-term 
expected survival and an actual fracture should be treated with a proximal 
femur modular tumour-prosthesis (PF-MTP) to provide an adequately durable 
situation (figure 9.4).38 A PF-MTP can also be considered if patients with a long-
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term survival present with an impending fracture; however, it might not be 
necessary, and intramedullary nailing with cement can provide sufficient 
stabilisation.  
Pathologic fractures of the diaphysis are commonly treated with intramedullary 
nails or plate osteosynthesis. If multiple lesions exist throughout the diaphysis, 
an intramedullary nail is recommended. Large lesions (>6cm) can be curetted 
prior to stabilisation and adjuvant cement will further stabilise the nail (figure 
9.5). An intramedullary nail is also recommended for an impending fracture 
through a small or solitary lesion. However, if an actual fracture presents 
through a small lesion, open reduction and plate fixation with adjuvant cement 
is an adequate option, irrespective of the expected survival. In cases with a long 
survival and solitary metastases (for example, renal cell) or very large and 
destructive diaphyseal lesions, a segmental prosthesis of the diaphysis is an 
option. 
The treatment of pathologic fractures of the distal femur generally consists of 
plating with adjuvant cement. However, if the condyles or metaphyses are 
largely affected the fixation of a plate is often impossible. In that case a distal 
femur modular tumour-prosthesis (DF-MTP) is recommended (figure 9.6). A DF-
MTP should also be considered for patients with long-term survival and 
fractures due to distal or metaphyseal lesions. If there is no actual fracture yet 
and survival is short-term, cement injection only, or in combination with radio-
frequency ablation, can be sufficient. However, if long-term survival is expected 
this might not provide sufficient prophylactic stabilization for an impending 
fracture, and an intramedullary nail with cement in the lesion or a DF—MTP 
should be considered. 
Humerus 
After the femur, the humerus is the second most commonly affected long bone 
by metastases.39 The mainstay treatment is rigid surgical stabilisation because 
of a high incidence of nonunion and inadequate relief of pain with conservative 
treatment.40 Although the upper extremities are not primarily weight-bearing, 
the proximal humerus is subject to rotational and bending forces due to the 
action of the rotator cuff, deltoid, pectoralis major and latissimus dorsi muscles. 
This demands great torsional strength of any kind of implant.41 An overview of 
treatment options is given in table 9.3. 
For the humeral head, options consist of plate fixation or a cemented hemi-
arthroplasty. The latter should be considered for actual fractures in patients 





bone stock. However, if the expected survival is short, there is adequate bone 
stock, or there is only an impending fracture one should refrain from being too 
invasive. Lesions in the proximal humerus generally require curettage and 
augmentation to prevent rapid local progression and loosening of the 
osteosynthesis.42 Therefore plate fixation is often the fixation method of choice. 
This gives immediate rigidity and allows for unrestricted function quickly post-
operative.43 Fixation with an ante-grade intramedullary nail and helical blade (or 
screws) strengthened with adjuvant cement is also possible; however, this is 
more appropriate in cases with extended involvement of the shaft than in cases 
with only proximal involvement. Total shoulder prostheses are not advised for 
bone metastases due to the high rate of complications, mainly recurring 
dislocations. If the glenoid is affected together with the proximal humerus, this 
can be filled up with cement.  
Fractures affecting the humeral shaft can be treated with plate fixation or 
intramedullary fixation (figure 9.7a and b, respectively). In the region between 
2-3 cm distal to the greater tuberosity and 5 cm proximal to the olecranon fossa, 
intramedullary nails achieve adequate stabilisation.44 Depending on the lesion 
size, adjuvant cement might be required to provide adequate fixation. If an open 
approach is chosen for augmentation, a plate fixation can then also be chosen. 
Impending fractures of the shaft can always be treated with intramedullary 
nails. In patients with short expected survival or high surgical risks (ASA 4), 
percutaneous, photodynamic intramedullary stabilization systems can also be 
an option to examine.45 The humeral diaphysis can also be treated with 
segmental prostheses according to the indications in the femur diaphysis.46 
Bone metastases arising in the distal humerus are rare and present unique 
treatment challenges.47 For actual fractures, intramedullary stabilisation will 
generally not provide sufficient stabilisation due to the anatomical localisation, 
thus plating with cement is advised. An impending fracture of the distal 
humerus can in most cases be treated with an intramedullary nail. Prosthetic 
reconstruction of the distal humerus rarely gives an adequate outcome and is 
associated with significant risks for complications and infections, and should not 
be pursued in a palliative setting. 
Conclusion 
The treatment of patients with impending or actual pathological fractures of the 
long bones requires multi-disciplinary teamwork. Treatment highly depends on 
the fracture risk in relation to expected survival.  Further individual tailoring is 
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required to define the most optimal palliative strategy for each affected patient 
to maintain his or her quality of life. 
Figure 9.4 Patient with osseous and pulmonary metastases from breast cancer. 
Progression of the proximal femur lesion in one month with subtrochanteric pathologic 






Figure 9.5 Patient with osseous and cerebral metastases from melanoma. 
Pathologic diaphyseal femur fracture after turning in bed. Expected survival 
< 6 months. Fracture stabilisation with intramedullary nail with curettage 
and augmentation of the lesion. 
Figure 9.6 Patient with solitary bone metastasis from non small cell lung carcinoma 
(diagnosed and treated 4,5 years ago). Metastasis of distal femur with extensive destruction 
1,5 year after radiotherapy for this lesion. Expected survival: > 6 months. Resection and 
reconstruction with DF-MTP. 
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Figure 9.7a Patient with osseous metastases from lung carcinoma. Pathologic fracture of 
proximal humerus diaphysis. Expected survival < 6 months. Plate fixation with cement. 
Figure 9.7b Patient with osseous metastases from renal cell carcinoma. Pathologic fracture of 
proximal humerus diaphysis. Expected survival < 6 months. Pre-operative embolisation and 
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Bone metastases of the long bones can cause pain and pathologic fractures. 
Local treatment consists of radiotherapy or surgical stabilisation. The most 
appropriate treatment depends on many factors, including the symptoms, the 
location and extent of the lesion, the wishes and expectations of the patient, 
and the expected remaining survival. This thesis aimed to develop a prognostic 
model for estimating survival in patients with cancer and symptomatic 
metastases of the long bones, evaluate current (surgical) treatment modalities 
and trends, and provide rationale for future prospective randomized trials. The 
first chapters of this thesis describe the developed model and how it is 
sustainable for future developments. The following chapters focussed on the 
evidence behind and outcomes of specific treatment modalities.  
Survival estimation of patients with symptomatic long bone metastases is 
crucial to prevent over- and undertreatment. Chapter 2 presented a simple, 
easy-to-use prognostic model for overall survival in patients with symptomatic 
long bone metastases. Based on a multicentre retrospective study of patients 
treated for symptomatic long bone metastases between 2000 and 2013 at 
several radiotherapy and/or orthopaedic departments (n=1520), the study 
shows that clinical profile (moderate: HR 1.8; 95%CI 1.5-2.1; unfavourable: HR 
3.3; 95%CI 2.8-3.8), a Karnofsky Performance Score ≤70 (HR 2.0; 95%CI 1.8-2.3), 
and the presence of VBM (HR 1.4; 95%CI 1.2-1.5) were significantly associated 
with a higher risk of death. These factors were combined to create twelve 
categories with their own median overall survival. Subsequently a flowchart was 
designed to aid the stratification of patients (figure 10.1). The model leads to 
four clinically relevant categories (A-D): A (29%), B (19%), C (31%), D (21%) that 
represent the following median survival: 21.9 (95%CI 18.7-25.1), 10.5 (95%CI 7.9-
13.1), 4.6 (95%CI 3.9-5.3) and 2.2 (95%CI 1.8-2.6) months, respectively. The 
discriminative ability was 0.70 with 12 categories and 0.69 with the final four 
categories. The model was validated with an external dataset of 250 patients. 
The application of the model to the external cohort shows similar results 
between observed and expected survival, suggesting that the model stratifies 
sufficiently in other datasets. The simplicity of the model should facilitate its use 
and result in an overall movement towards incorporating expected survival in 
the choice of the appropriate treatment. 
One of the assets of the previously described model is its versatility. This is 
ensured by the dynamic aspect of the clinical profiles, which allows for 
adjustment of the classification of a primary tumour. The profiles encompass 
not only tumour growth speed, but also contributing factors such as the 
effectiveness of (future) evolving systemic treatments. The increase of targeted 
therapies will create sub-types of various primary tumours in the future and 
 General summary 
 
 187 
thus flexibility in the categorization is of essence. The need for such flexibility is 
proven by the study described in chapter 3. The study assesses whether 
mutations in the epidermal growth factor receptor (EGFR) and Kirsten rat 
sarcoma (kRAS) genes are associated with overall survival in patients who 
present with symptomatic bone metastases from non-small cell lung cancer 
(NSCLC), and whether mutation status should be incorporated into prognostic 
models. 139 patients with NSCLC treated between 2007 and 2014 for 
symptomatic bone metastases and whose mutation status was known were 
studied. Median overall survival was 3.9 months (95% confidence interval (CI) 
2.1 to 5.7), but patients with EGFR (15%) mutations showed a median OS of 17.3 
months (95% CI 12.7 to 22.0) while those with kRAS mutations (34%) showed a 
median OS of 1.8 months (95% CI 1.0 to 2.7). Compared with EGFR-positive 
patients, EGFR- negative patients had a 2.5 times higher risk of death (95% CI 1.5 
to 4.2). The study subsequently re-evaluated the classification of primary 
tumours as presented in chapter 2. When NSCLC with an EGFR mutation was 
classified as ‘moderate’ instead of ‘unfavourable’, the discriminatory power of 
the model improved from 0.60 to 0.63, an increase of 5%. 
Figure 10.1 Stratification model for survival prognosis. 
Postoperative radiotherapy is commonly advised as adjuvant treatment after 
internal fixation of an actual or impending pathologic fracture. The systematic 
review in chapter 4 showed that substantial evidence for postoperative 





report a positive effect of postoperative radiotherapy regarding function, re-
interventions, and survival, these results should be interpreted with caution 
because the studies are retrospective and thus subject to indication bias, based 
on small cohorts, did not use standard, validated outcome measures, and used 
insufficient statistical analyses. To determine whether postoperative 
radiotherapy has a beneficial effect or whether it is a redundant treatment, a 
large, multicentre, randomized study is required. 
To evaluate the clinical practice, a questionnaire was sent to Dutch general 
orthopaedic surgeons and European oncological orthopaedic surgeons. The 
questionnaire aimed to assess the current trends in survival estimation and 
treatment preferences among national and international general and 
oncological orthopaedic surgeons, and to explore whether differences between 
the groups can identify areas of improvement in the care of patients with 
pathologic fractures. The results are described in chapter 5. Ninety-six of the 948 
approached members of the DOS (10.1%; groups 1 and 2) and 33 of the 182 
approached members of the EMSOS (18.1%; group 3) replied. Overall, survival 
estimation was accurate by more than 50% of all three groups if expected 
survival was short (<3 months) or long (>12 months). Treatment preferences 
showed that general orthopaedic surgeons prefer an intramedullary nail for 
actual fractures of the humerus and femur, irrespective of the expected survival, 
tumour type and location. Oncological orthopaedic surgeons recommend 
prosthetic reconstruction in patients with an expected long survival. Based on 
these results, we can conclude that better identification of patients who require 
centralised care as opposed to those who can be adequately treated in a 
regional centre can improve the care of patients with pathologic fractures. This 
differentiation should be based on expected survival, fracture location, tumour 
type and extent. 
Chapter 6 described the retrospective analysis of 228 intramedullary nails for 
actual (51%, n=117) or impending (49%, n=111) pathologic fractures of the 
femur. The results show that the cumulative incidence of local complications 
(8%), implant breakage (4%), and revisions (2.2%) is low, mostly as a result of the 
short survival of patients (median OS: 6 months). Independent factors 
associated with increased risk of implant breakage were an actual (as opposed 
to impending) fracture (cause-specific hazard ratio [HR_cs], 3.61; 95% CI, 1.23-
10.53, p = 0.019) and previous radiotherapy (HR_cs, 2.97; 95% CI, 1.13-7.82, p = 
0.027). The presence of an actual fracture was also independently associated 
with a higher risk of revision (HR_cs, 4.17; 95% CI, 0.08-0.82, p = 0.022), and use 
of cement was independently associated with a lower risk of revision (HR_cs, 
0.25; 95% CI, 1.20-14.53, p = 0.025). Based on these results, surgeons should 
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consider use of cement in patients with intramedullary nails with actual 
fractures and closer follow-up of patients after actual fractures and 
preoperative radiotherapy. Future, prospective studies should further analyse 
the effects of adjuvant therapies and surgery-related factors on the risk of 
implant breakage and revisions. 
To evaluate whether the complications encountered in intramedullary nails of 
the femur are also found in the humerus, a similar study was performed with 
182 intramedullary nails for actual (79%, n=143) and impending (21%, n=39) 
fractures of the humerus. The study aimed to to evaluate the cumulative 
incidence of and risk factors for failure. The results, as presented in chapter 7, 
show the failure percentage is 12.6%. Thirteen failures had a predominant 
mechanical component (including (peri-)implant fracture, non-union, migration 
of nail or screw) whereas nine failures had a predominantly oncological cause 
(ranging from painful moderate tumour progression to massive recurrence). No 
risk factors for failure could be identified from this cohort. The prognostic 
factors for failure in the femur cohort (fracture and use of cement) were not 
significant in this humeral cohort, so no recommendations can be made about 
the use of adjuvant cement. Median overall survival (OS) was 5.7 months (95% 
CI 4.8 – 6.7). The median OS of patients treated for an impending fracture (8.6 
[95% CI 5.5 – 11.7]) did not significantly differ from patients treated for actual 
fractures (5.3 [95% CI 4.2 – 6.4]) (p=0.112). While OS was expected to be shorter 
than in the femur cohort, the difference was less than expected (median OS 6.0 
months [95% 4.4 – 7.3] for the femur IMN cohort as reported in chapter 6). 
Based on this study, we can conclude only that the numbers of failure of 
humeral IMNs is relatively high. Underestimation of the reported number of 
failures should be taken into account, due to lack of standardized follow-up and 
short overall survival. The choice for an intramedullary nail should be carefully 
weighed and discussed with the patient. 
Chapter 8 was a systematic review on the treatment of pathologic fractures of 
the distal femur. Pathologic fractures of the distal femur are less common than 
those of the proximal femur, but also one of the most difficult pathologic 
fractures to stabilize. Only two studies qualified for the systematic review, but 
their quality was poor and no factors indicating the need for endoprosthetic 
reconstruction could be identified. Based on literature and expert opinion, 
indications for EPR in distal femur fractures are solitary metastases in patients 
with a long survival, a major affected joint surface, and insufficient bone stock 
for internal fixation. The paucity of results in this literature search and poor 
quality of the few included studies illustrate the issues that surgeons treating 





adequate research on the treatment of pathologic fractures to answer relevant 
questions. International, prospective collaborations are needed to fill this void. 
Until results of such studies are published, all surgical treatments, for all 
locations, are predominantly based on retrospective studies, experience, and 
expert opinion.  
Chapter 9 gave an overview of the surgical treatment of pathologic fractures. 
The treatment of patients with impending or actual pathological fractures of the 
long bones requires multi-disciplinary teamwork. Primary steps in the treatment 
are correct diagnosis of a metastasis. If a patient is not known with metastatic 
bone disease, a biopsy should be performed to prove the diagnosis of a 
metastatic lesion. In the back of ones’ mind should always be the possibility of 
a primary bone tumour. After confirming a metastasis, further diagnostics 
should be undertaken to evaluate the dissemination status (CT thorax-abdomen 
for visceral metastases; PET-CT or radiographs of both humeri and femurs for 
bone metastases; CT-brain if any clinical indication for brain metastases), the 
general health of the patient (patient history [nutritional status, weight loss], 
blood tests [serum calcium and albumin]), and the local status of the affected 
bone including the extent of the lesion (bi-planar radiographs of the entire bone 
or CT scan of the lesion if radiograph is insufficient). The collected data is 
necessary to determine the most appropriate intervention, which depends on 
the expected survival, the location of the lesion and whether it concerns an 
actual fracture or there is a risk of fracture. A bone lesion with an axial cortical 
involvement of >30 mm has a high risk of fracturing and should be stabilised 
surgically. Radiotherapy is the primary treatment for symptomatic lesions 
without risk of fracturing. Main surgical treatment options consist of plate 
fixation, intramedullary nails and (endo) prosthesis. Adjuvant cement should be 
considered in large lesions for better stabilisation. Further individual tailoring is 
required to define the most optimal palliative strategy for each affected patient 
to maintain his or her quality of life. 
The next chapter (chapter 11) discusses the conclusions and clinical implications 
of this thesis, as well as future perspectives for the treatment of pathologic 
fractures of the long bones. Finally, after the English summary in this chapter 
(chapter 10), the Dutch summary follows in the chapter 12. In the appendices 
information is provided on the OPTIModel App and the prospective OPTIMAL 
study. In addition, the translation and validation of the Toronto Extremity 
Salvage Score (TESS) to Dutch is reported. 
  








The care for patients with cancer and symptomatic bone metastases of the long 
bones is a broad topic made up of many different elements, including a range 
of symptoms and anatomical locations, survival and fracture prediction, and 
various treatment strategies. This thesis focused on some of these elements to 
provide reliable and solid data so that genuine steps forward can be taken 
regarding the care of this patient population. The current chapter places the 
results in a clinical perspective and evaluates whether some of the Unknowns as 
described in the introduction have become Knowns. These Unknowns referred to 
(1) estimating survival, (2) estimating fracture risk, and (3) faults and merits of 
specific treatment modalities. Not until we can label these aspects as Knowns, 
will we be able to determine the optimal treatment for each individual patient. 
As mentioned in the introduction, the second Unknown, regarding fracture risk 
estimation, is beyond the scope of this thesis. 
Survival estimation 
One of the primary aims of this thesis was to develop and validate a prognostic 
model for survival from the moment a patient presents with a symptomatic long 
bone metastasis (e.g. a painful lesion, an impending fracture or an actual 
pathologic fracture). The importance of estimating survival at the moment of a 
symptomatic long bone metastasis has been stressed many times throughout 
this thesis, because without adequate survival estimation the risk of 
overtreatment (e.g. resection and reconstruction in a patient with an expected 
survival of 3 months) or undertreatment (e.g. lack of surgical stabilisation of a 
pathologic fracture in a patient with an expected survival of 6 months) is 
significant. Such a risk does not comply with the palliative intent of the care for 
patients with symptomatic bone metastases. This ‘palliative intent’ means that 
the aim of local treatment is optimal symptom management, i.e. care as 
opposed to cure, in the light of the remaining survival. All treatments aim to 
keep a patient ambulant for as long as possible with the desired quality of life, 
preventing unnecessary treatments and hospital visits. Especially for impending 
and actual fractures, (surgical) treatment should be “once and for all”, 
preventing failures and associated revisions on one hand, and too extensive 
interventions, recovery and rehabilitation times on the other hand. Survival 
estimation however, is difficult, as previously described by Chow et al. and White 
et al.,1,2 and physicians tend to overestimate remaining survival. The results 
from chapter 5 show that general orthopaedic surgeons mostly ask the referring 
medical specialist (e.g. medical oncologist, lung or urology specialist) to give an 
estimation. Despite the experience of medical specialists with predictions of 
survival in the adjuvant setting, e.g. when deciding on starting systemic 
therapies in breast cancer patients, we believe that patients with symptomatic 
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bone metastases form a different group than the mainstay of a referring 
medical specialists’ patient population. This means that the prediction models 
that medical specialists use, in which the starting time point is the moment of 
diagnosis or treatment of the primary tumour,3-5 are generally not applicable. 
For example, the referring lung oncologist might have a prediction model for 
overall survival for a patient with newly diagnosed advanced non-small cell lung 
cancer at time of diagnosis; say the patient has an expected survival of twelve 
months. If this patient sustains a symptomatic bone metastasis, e.g. an 
impending pathologic fracture seven months later, the initial prognosis of the 
referring lung oncologist is not applicable any more. Once a metastatic lesion 
becomes symptomatic (i.e. painful, fracture present or impending), a sudden, 
steeper decline in the survival curve of the patient can be expected than in the 
initially predicted curve because symptomatic bone metastases lead to 
impaired mobility, reduced quality of life, and increased mortality.6,7 
Undeniably, other factors than a bone metastasis becoming symptomatic also 
affect survival (e.g. pulmonary metastases), but that does not diminish the need 
for a new survival estimation with a specific model once a long bone metastasis 
becomes symptomatic.  
Since the 1990’s several specific prognostic models have been developed, but 
as the results in chapter 5 show, only 10% of the orthopaedic surgeons 
participating in the questionnaire use such a model. The most recent and 
comprehensive are the updated model of Katagiri et al.8 and model by Forsberg 
et al..9 Katagiri et al. developed the first version of their model in 200510 and 
recently published an update to incorporate the development of effective 
targeted chemotherapeutic regimens.8 In the updated model, not only the 
primary tumour, presence of visceral metastases, performance score, previous 
chemotherapy, and number of metastases are taken into account, but also 
several laboratory values: C-reactive protein, lactate dehydrogenase, serum 
albumin, serum calcium (corrected), platelet count, and total bilirubin. These are 
either classified as abnormal (CRP ≥ 0.4 mg/dl, LDH ≥ 250 IU/L, or serum albumin 
<3.7 g/dl) or as critical (platelet <100,000/µL, serum calcium ≥ 10.3 mg/dl, or total 
bilirubin ≥1.4). A strong aspect of this model is the differentiation within primary 
tumour types, depending on hormone-dependence (for breast and prostate 
cancer) or targeted treatment (for lung cancer), and thus the recognition that 
primary tumour types should not be regarded as single entities. Unfortunately, 
Katagiri et al. did not report a C-statistic or area under the curve, so no 
conclusions can be made about the discriminative ability of their model. A 
weakness of the model by Katagiri et al. however, is the large number of 
variables and especially the addition of laboratory values, because this makes it 





are invasive procedures for the patient and are rarely done before irradiation. 
Therefore, this model is less applicable for a large part of its target population. 
Moreover, the large number of variables and their weight in the total score, as 
well as the meaning of the total score, are difficult to remember. While this 
seems a futile argument, it is of relevance for the applicability of the model in 
daily practise. Amid the pressure of a busy out-patient clinic or hectic emergency 
department, a physician wants to fall back on an easy-to-use model that 
requires readily available and straight-forward input. In our opinion, the model 
by Forsberg et al. has slightly the same limitations. In their model, based on a 
machine-learned Bayesian belief network model (i.e. a probabilistic graphical 
model that explores the conditional, probabilistic relationships between a set of 
variables to estimate the likelihood of an outcome), predictive variables are 
categorised as first-degree (surgeon estimate, haemoglobin concentration, 
absolute lymphocyte count, completed pathologic fracture, and performance 
score) or second degree if related to one of the first-degree variables.9 The first-
degree factors for three-month survival were different to those for twelve-
month survival. The predictive ability of this model is strong (mean area under 
the curve for 3-month survival: 0.85 [95% CI 0.80 – 0.93]; for 12-month survival: 
0.83 [95% CI 0.77 – 0.90]) and the model has been validated in several (small) 
external cohorts. The limitations, however, again concern the elaborate number 
of variables required and the use of non-readily available variables (i.e. 
laboratory values). Forsberg et al. have made the model available for all through 
their website (www.pathfx.com). The fact that the statistics behind the model 
are so complicated that the model cannot be used without a website, is a 
downside. Not per se in daily practise, because use of digital aids is wide-spread, 
but more so because the user does not understand how the estimated survival 
is established. Thus while the design of the model is on one hand its strongest 
aspect, it is at the same time its weakest. We are convinced that physicians are 
most likely to use a clinical aid if (1) they recognise the aid is better than their 
own knowledge and (2) if the aid is easy and intuitive to use and understand. 
Creating awareness is the most important to convince physicians to use a 
prognostic model as opposed to their own, or the referring medical specialists’, 
estimation. The second aspect, an easy-to-use model, lies predominantly in the 
design of the model and limited amount of prognostic factors. The latter was 
the essence of the OPTIModel, as described in chapter 2. With only three 
variables and a clear flowchart, the model is straightforward to use. The two 
cases on the next pages show the necessity of such a model, as well as the easy 
applicability of the OPTIModel. These two examples are extremes in the 
spectrum of patients with symptomatic bone metastases, but throughout the 
entire spectrum it is relevant to estimate the remaining survival before 
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discussing treatment options with patients and their family. As part of shared 
decision-making, which might play an even greater role in the palliative setting 
than in other medical practises, it is important to explain and discuss the role of 
the expected survival on treatment choices. 
Case A is a 64-year old woman who was treated for breast cancer (hormone 
receptor positive) 15 years earlier. She now presents at the outpatient clinic 
with pain in her left hip since several days. The pain is continuously present 
and non-opioid pain medication is insufficient. She was an active lady, but it 
now been home-bound due to the pain when mobilising. An x-ray shows a 
per-trochanteric fracture (figure 11.1). Given the history of cancer and lack 
of adequate trauma, the cause of the fracture is most likely pathologic and 
a biopsy confirms the diagnosis of a bone metastasis of the breast cancer. A 
CT scan shows no lung or liver metastases, but there are other bone 
metastases in the spine and one rib. The fracture is treated with a 
reconstruction type intramedullary nail and adjuvant radiotherapy (24 Gy in 
6 fractions) five weeks postoperative. A year-and-a-half later, the same 
patient presents at the outpatient clinic, again with pain of the left hip. X-ray 
shows breakage of the nail at the junction with the collum screw, causing 
dislocation of the femur fragments. The broken nail is removed and replaced 
with a new nail with adjuvant cement around the collum screw. Six months 
later, the pain is still present in the left hip. A CT scan shows a pseudo-
arthrosis of the fracture, lysis around the collum screw and collapse of the 
cranial part of the femur head. To prevent further collapse and lysis, cement 
is injected around the collum screw. Nonetheless, two months later, further 
lysis and migration of the collum screw is seen, causing perforation of the 
collum screw through the femur head. More than two years after primary 
presentation, the failed intramedullary nail is removed and a modular 
proximal femur reconstruction is placed. This gives good function and 
mobility until the patient’s death (due to progressive disease) two years later.  
This case is a clear case of undertreatment caused by the lack of survival 
estimation at the first presentation. Application of the OPTIModel at 
presentation would have shown that the expected survival of the patient was 
more than 12 months: favourable clinical profile (breast cancer), Karnofsky 
performance score 90 (“an active woman”), and no visceral and/or brain 
metastases. According to the model the patient falls in category A, with a 95% 
confidence interval of survival between 27 and 34 months. Given the long 
expected survival, the failure of the intramedullary nail could have been 
anticipated, because an intramedullary nail is a load-sharing device, while it 





therefore not very long. The treatment for this patient would have thus been 
more optimal, without all re-operations, if she had received a prosthetic 
reconstruction in the first place. Postoperative radiotherapy would then also 
have been redundant.  
Figure 11.1 Per-trochanteric fracture.   Figure 11.2. Sub-trochanteric fracture. 
Case B is a 50-year-old man with deteriorating clinical condition who was 
diagnosed with disseminated non-small cell lung cancer shortly before 
presentation at the emergency department with acute onset of pain in the 
upper right leg after getting up out of bed. The patient is unable to bear 
weight on the leg. An x-ray shows a sub-trochanteric fracture (figure 11.2); 
its location corresponding to a hotspot on the PET-CT of a week earlier. The 
PET-CT had also shown multiple metastatic bone metastases and large 
nodules in both lungs. Although the general health of the patient was already 
poor and he required help for daily activities, he expressed the wish for 
surgery, because he would like to be able to walk around the house. Surgical 
stabilisation is required to enable mobilisation and a modular proximal 
femur reconstruction prosthesis is placed. Intensive physiotherapy is 
required during the postoperative phase to adequately mobilise. Three 
months postoperatively the patient passes away due to advanced disease. 
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This case is in great contrast with case A, but again shows the importance of 
survival estimation when a patient presents with a pathologic fracture. Here, the 
patient would have fallen into category D (unfavourable clinical profile, 
Karnofsky performance score 50, visceral metastases present), with an expected 
survival of less than three months (95% confidence interval: 2-3 months). It is 
thus questionable whether such an extensive operation matched the short 
expected survival. Possibly, if survival had been estimated before surgery, a less 
invasive option would have been chosen, enabling earlier discharge, less risk of 
complications, and quicker return of function. The last phase of life of this 
patient would then have been spent more at home, surrounded by his family 
instead of focussing on rehabilitation. 
The fact that we use as few variables as possible in the model could have an 
inverse effect on the discriminative ability (C-statistic 0.70). A model with a lot of 
detailed variables, might also be able to give more detailed results. However, 
survival estimation is used to make adequate treatment choices. There is no 
difference between the treatment choice of an estimated survival of 5.5 months 
or 6 months; therefore, it is not required to measure and estimate this 
difference in survival. In this setting, the predictive accuracy only has to be as 
much as the clinically relevant differences. One could also argue whether the 
included variables are truly as simple as we report.11 To know whether visceral 
metastases are present, imaging diagnostics (PET-CT or CT scan of thorax and 
abdomen) are required. This is indeed true, but we have made the assumption 
that in countries with modern and well-developed healthcare systems 
dissemination examination is part of standard work-up of patients with 
metastatic disease. The need for considerable additional radiological imaging 
does make it questionable whether the model is applicable around the globe, 
especially in countries with less accessible and organised healthcare. We have 
chosen to use the Karnofsky Perfomance Score (KPS)12 as measure for general 
health. Instructions for the application of this score are straightforward and it is 
therefore easy to use. During the development of our model, collecting the KPS 
retrospectively caused the greatest challenge, because it was not standard 
practise to report the score in the medical records. Lack of the performance 
score was therefore the largest cause of exclusion from the multivariate 
analysis. Also, in many cases the performance score was reported as Eastern 
Cooperative Oncology Group/World Health Organisation Score. Fortunately, the 
WHO score can be easily converted to a KPS score.13 For daily use of the model, 
the incorporation of the performance score as KPS cannot be regarded as 
difficult; it merely requires an interpretation of the impression of general health 
a physician always makes of the patient.  Patient reported outcome (PRO) and 





evaluate the quality of care. Although some might argue that these measures 
should be incorporated in survival models because they are patient driven, we 
do not think that incorporation of such measures would improve the model, as 
also shown by Westhoff et al..14 Not only would it hinder the quick use of the 
model, but more importantly, PROMs and PREMs are not developed as 
reflection of the functioning or quality of life on its own; they are always 
associated with the health care or treatment a patient has received.  
The OPTIModel is developed for all symptomatic long bone metastases 
requiring local treatment and is thus based on both irradiated and surgically 
treated patients. This enables multidisciplinary use of the model, as opposed to 
the previously mentioned models of Katagiri and Forsberg, which can be used 
only for patients with an indication for surgery as that is their reference 
population. Taking into regard that it is not uncommon for patients to receive 
radiotherapy and surgery for either the same or various different lesions, it is 
an asset that the treating radiation oncologists and surgeons can discuss the 
optimal treatment using the same model. One could argue that an important 
element of the treatment of bone metastases is left aside here: the medical 
oncologist and all systemic treatments that might affect survival. This is indeed 
true and deliberate; although it is not our intention to dismiss the important role 
of systemic treatments, the focus of the research was on local treatment. 
Whether the OPTIModel can be applied to patients receiving systemic treatment 
for symptomatic (long) bone metastases, remains to be investigated in future 
research. 
The model presented in this thesis was validated with an external data set from 
Austria including surgically treated patients only. As the majority of patients with 
symptomatic bone metastases are treated with radiotherapy, further validation 
should be performed with a larger cohort, consisting of prospectively collected 
data and including both operated and irradiated patients. To ensure worldwide 
validation, cohorts from differing cultures and varying patient populations 
should be used.  
As Katagiri et al. already recognised, primary tumours should in many cases not 
be regarded as a single entity.8 This is also the message of chapter 3, which 
shows that EGFR positive non-small cell lung cancer should be categorised more 
favourably than non-small cell lung cancer without the mutation. Bollen et al. 
showed an alike subcategorization of breast cancer in spinal metastases15 and 
Ratasvuori et al. showed the preferential survival of solitary kidney 
metastases.16 The clinical profile grouping in the OPTIModel has currently 
already taken these latter two aspects into account, even though the results of 
the referred two studies do not focus specifically on long bone metastases. 
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Analysis for these tumour types in long bone metastases is currently being 
performed in our centre with new data. Of course, there a many more primary 
tumour types that could be subdivided in this model, such as melanoma or 
thyroid cancer patients, since within these primaries, genetic alterations (e.g. 
BRAF mutations) lead to distinct survival patterns, based on the applicability of 
successful systemic treatments.17,18 Unfortunately, we did not have sufficient 
number of patients to make subgroups for all these tumour types. Hopefully, 
international collaborations and future data collection will be able to provide 
more data, so more primary tumour types can be allocated with more precision 
to the correct clinical profile. 
To ease the use of the OPTIModel as prognostic tool, we developed a web-based 
version of the flowchart (www.optimal-study.nl/tool), as well as an application 
for smartphones (as described in the appendix). Both are meant to be a 
supportive tool in making an estimation of survival. The app goes one step 
further and also provides treatment options, given the survival estimation, 
location and type of fracture, and details of the lesion. Both model and app are 
not a replacement of the experience and good clinical judgement of a multi-
disciplinary team. As Jonathan Forsberg mentions in his thesis, “decision 
support models are designed to provide objective data on which an 
independent practitioner may base a decision”.19 In other words, the models do 
not provide the decision itself; it is up to the physician to interpret the outcome 
of the model and make a decision. We agree with Forsbergs’ opinion that 
physicians should always maintain a healthy scepticism towards all supportive 
tools, including (- especially? -) those that are easily accessible throughout the 
web. Moreover, the fact that the app is easily accessible through app stores for 
all physicians, also makes it easily accessible for patients. We should look further 
into whether patients actually find and use the app, as it is not publicised 
beyond the medical environment, and whether this affects the conversation 
between physician and patient. 
Beside guiding the physician through survival estimation and aspects relevant 
for treatment choices, the app we developed can be used as method to stratify 
patients between those patients that can be treated by a general orthopaedic 
surgeon in a regional hospital and patients who need referral to a specialised 
centre to receive less standard care. Chapter 5 shows that general orthopaedic 
surgeons tend to treat all pathologic fractures with an intramedullary nail, while 
oncological orthopaedic surgeons consider a prosthetic reconstruction in 
patients with a long expected survival. Although the results are based on only a 
small fraction of all orthopaedic surgeons as the response percentages were 





patient receives is partly determined by the surgeon to whom he or she is 
referred. For a large part of all actual and impending pathologic fractures this is 
fine, because their optimal treatment would be an intramedullary nail. Specific 
patients however, who would benefit from other, possibly oncological, 
reconstructions, would not receive their most optimal treatment if not referred 
to a specialised centre. Complete centralisation of the treatment of pathologic 
fractures to centres specialised in oncological orthopaedics is not feasible due 
to the absolute number of pathologic fractures. In addition to accurate 
identification of patients who require referral, we would recommend all 
hospitals, or perhaps partnering hospitals, to assign “ownership” of pathological 
fracture treatment to one or several physicians. This will enable those specific 
physicians to become more familiar with the unique aspects of pathological 
fracture fixation, which will subsequently lead to improvement of care. Whether 
these designated physicians should treat all pathological fractures personally 
remains a logistical aspect, but they should at least be consulted before 
treatment decisions are made. We believe that centralisation of care on a local 
basis will lead to more individualised treatment and therefore better quality of 
life for patients. Additionally, creating such a local centre point for pathologic 
fractures will facilitate research.  
Treatment 
Insufficient knowledge on the faults and merits of specific treatment modalities 
was the final Unknown. Or more particularly, a collection of many Unknowns. 
These Unknowns concern the surgical treatment of pathological fractures. 
Regarding radiotherapy of bone metastases, more research, with higher levels 
of evidence, has been performed. A recent systematic review shows that 29 
randomised trials have been performed aiming to define the optimal 
radiotherapy schedule comparing 8 Gy single dose fraction to multi-fraction 
schemes ranging from 20 Gy in 5 fraction, 24 Gy in 6 fractions, to 30-39 Gy in 10-
13 fractions.20 Response rates showed no significant differences between the 
single or multi-fraction regimens. The elaborate number of well-executed and 
large prospective studies regarding radiotherapy is in contrast with the limited 
number and quality of studies on the surgical treatment of long bone 
metastases. In part this is due to the fact that the number of patients receiving 
radiotherapy for bone metastases is larger than those receiving surgery, making 
research easier. Also, standardised data collection for research purposes might 
be more established among radiation oncologists than orthopaedic surgeons. 
Finally, the difference in amount of evidence is also caused by the fact that we 
cannot speak of “the surgical treatment of long bone metastases” as a single 
subject. Taking only the two large long bones into account (i.e. femur and 
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humerus) and generalised treatment modalities (i.e. prosthesis, plate, nail), we 
are already looking at six categories, whilst ignoring other important factors 
such as location (i.e. proximal, shaft or distal) and type of fracture (i.e. actual or 
impending). For each of these categories it would be desirable to set indications 
based on evidence. Taking the number of subcategories into account, and within 
such subgroups endless more varieties (use of cement, estimated survival, 
primary tumour type, or level of activity, for example), striving to determine 
indications for all subcategories is ambitious to say the least. In this thesis we 
aimed to focus on three general subcategories: intramedullary nails for the 
femur, intramedullary nails for the humerus, and actual fractures of the distal 
femur. The latter was subject of a systematic review, while retrospective cohorts 
were studied for the prior two. We were unable to further specify characteristics 
of the study populations, because that would limit the number of eligible 
patients or studies.  
The study in chapter 6 reported of 245 intramedullary nails for actual or 
impending fractures in the femur over a fifteen-year period in five centres. Not 
all centres were able to submit data of patients over the entire study period, but 
nonetheless, this number gives insight into the relatively small numbers of 
patients we are dealing with when researching surgical treatments of long bone 
metastases. A fracture occurred in 8% of the nails and an actual fracture (as 
opposed to an impending fracture) and previous radiotherapy on the affected 
bone showed to be independent risk factors for such an implant fracture, both 
increasing the risk of breakage threefold. These risk factors show the 
importance of accurate fracture prediction. If a lesion erroneously gets classified 
as low risk for fracture, it is possible that the patient will get referred for 
radiotherapy, subsequently develops a pathologic fracture, and then has to 
undergo surgery burdened with both risk factors for complications. Accurate 
survival estimation also plays a role here, because of the aspect of time in both 
fracture prediction and the risk of developing a complication after 
intramedullary nailing. 
The results in chapter 7 showed that the treatment of actual and impending 
pathologic fractures of the humerus with intramedullary nails is not so simple 
as it seems. In the retrospective cohort containing 182 intramedullary nails, 
12.6% failed. This percentage is probably an underestimation due to the lack of 
standardised follow-up and the short survival of the patients (median 5.7 
months [95% CI 4.8 – 6.7]). Unfortunately, despite the large cohort, no risk 
factors for failure could be identified. Other studies on the surgical treatment of 





intramedullary nails.21,22 Future research is thus required to identify treatment-
related aspects that should be encouraged or avoided by surgeons. 
Future directions 
Throughout this thesis it has become clear that there are still pressing questions 
concerning the treatment of pathologic fractures; hence the previously 
mentioned ‘Unknowns’. The primary conclusion from both systematic reviews 
(chapter 4 and 8) is that there is insufficient published literature to present any 
evidence based recommendations. The results in chapter 6 and 7 provide 
interesting views on the use of intramedullary nails, but, like all retrospective 
cohort studies which have been published on this subject, the results are biased 
by indication. It is questionable whether we have been able to revolve the 
Unknowns of intramedullary nails for the femur and humerus into Knowns. 
While several national guidelines have been developed to improve the 
treatment of metastatic bone disease,23,24 these are hardly based on reliable, 
unbiased, scientific data, because the latter is not available, as is also mentioned 
in the instructional review in chapter 9. As briefly mentioned in the introduction, 
we believe there are several causes for the imbalance between the incidence of 
pathologic fractures and the amount of prospective studies. The heterogeneity 
of the patient population and therefore struggle to form a sufficiently large, 
comparable cohort is one of the causes. Additionally, we suspect that the 
palliative intent of the treatment generates less encouragement to start or 
participate in a study, from a physician and patient point of view, respectively. 
In line with the previous two factors, randomisation between two (standard) 
treatments could be regarded as unethical in certain cases, because all patients 
in this phase of life should receive the most tailored treatment, instead of being 
assigned to a study treatment protocol. Nonetheless, the care of patients with 
pathologic fractures should be converted from primarily experience based to 
predominantly evidence based. In order to achieve such a transformation, the 
prospective part of the OPTIMAL Study was designed. The aim of this study is to 
define optimal local treatment strategies (including radiotherapy and surgery) 
in relation to location, type of fracture and expected survival. This will enable a 
more personalised treatment that will lead to improvement of quality of life.  
The prospective OPTIMAL Study (ClinicalTrials.gov identifier: NCT02705157) 
consists of a prospective, multicentre, multi-disciplinary cohort that provides 
subgroups for multiple embedded (randomised controlled) trials. This relatively 
new design, known as ‘cohort multiple randomised controlled trial’ (cmRCT), is 
an attempt to facilitate a more pragmatic approach to performing prospective 
studies as well as time- and resource efficiency.25 In a cmRCT study, a 
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prospective cohort is the backbone of the study. From this cohort, subgroups 
can be selected that are eligible for a certain ‘sub-study’ (e.g., a RCT). The step-
wised manner of informed consent is a unique asset of this study design. At 
inclusion in the prospective cohort patients are asked for informed consent for 
(i) the prospective cohort, and (ii) for randomisation if the patient is eligible for 
a certain sub-study that requires randomisation. If the patient agrees to (i) and 
(ii) and he is indeed eligible for a RCT in a subgroup, the patient is randomised. 
Only if randomised for the intervention group, will the patient be informed 
about the outcome of the randomisation. A third step of informed consent then 
follows, regarding consent for the subgroup RCT itself. If the patient is 
randomised for the control group, no further notice will follow and the patient 
will continue participation in the cohort without further notice. Details of the 
cmRCT design are published in appendix B in the summary of the treatment 
protocol. Primary outcome measures are patient-reported outcome measures 
(PROMs) regarding quality of life and pain after treatment. Using PROMs is a 
primary asset of the OPTIMAL Study. Previous studies on treatment of bone 
metastases have primarily focussed on radiological or physician-measured 
outcomes (e.g. implant failure, revision), while the palliative character of the 
treatment especially requires knowledge of whether treatments actually affect 
quality of life and lead to a pain-free and functional extremity. In the prospective 
OPTIMAL study, patients receive a number of questionnaires before treatment 
and at set moments after treatment, among others the Dutch version of the 
Toronto Extremity Salvage Score (TESS) of which our translation and validation 
study is reported in the appendix.26 The prospective OPTIMAL cohort is currently 
active in seven centres in the Netherlands and including patients from both 
orthopaedic and radiotherapy departments.  
The first embedded RCT has also launched: The PostOperative RadioTherapy 
(PORT) Study (ClinicalTrials.gov identifier: NCT02705183). Patients who 
participate in this RCT are thus also included in the OPTIMAL cohort. The PORT 
Study aims to answer the question that has remained after performing the 
systematic review in chapter 4: “is postoperative radiotherapy required?” Based 
on the results of the review, we can conclude there is no evidence for or against 
postoperative radiotherapy. Sceptics of this prospective study question whether 
evidence is required for things that ‘obviously’ work. However, what is ‘obviously 
working’ in this setting? The effects of radiotherapy on oncologic control, and 
pain in case of bone metastases without signs of impending or actual 
pathological fractures, are indeed proven. Postoperatively though, its role is less 
clear. The role of postoperative radiotherapy needs clarification, not only to 
determine if it should be given, but also to establish the regimen type if it is 





control) a single fraction or multi fraction regimen is effective. Pain is generally 
dealt with by the surgical stabilisation, so that should not be the reason for 
irradiation. What remains is the need for oncologic control (i.e. preventing 
tumour progression) and remineralisation, because it is thought this reduces 
the risk of implant failure. It is however questionable whether this aspect plays 
a role in a palliative treatment, when the mean overall survival is short (<6 
months). We hypothesise that most patients do not develop implant failures 
because they die before these can occur, not because they receive 
postoperative radiotherapy. Moreover, in practise we see that many patients 
receive a single fraction postoperatively, which is effective for pain control, but 
it is questionable whether a single fraction is sufficient for oncologic control. If 
we could accurately select patients that do need postoperative radiotherapy (a 
long expected survival, for example), and appoint them a specific single or multi 
fraction regimen, many patients could avoid unnecessary time in hospital, and 
economic resources might be saved. All patients receiving surgery (nail, plate, 
or prosthesis) for a long bone metastasis are eligible to participate in the PORT 
Study. The study is a non-inferiority study between postoperative radiotherapy 
(‘standard care’) and no postoperative radiotherapy (‘intervention’). 
Unfortunately, up to date the inclusion rate is very low. This is most probably 
due to the fact that surgeons are accustomed to referring a patient 
postoperatively to the radiation oncologist. Once the patient is at the 
radiotherapy outpatient clinic, he or she is not easily convinced anymore to 
participate in a study that possibly will not give them radiotherapy. Surgeons 
thus need to be more aware of the lack of evidence for postoperative 
radiotherapy and discuss with their patients that radiotherapy is possibly not 
needed. But, as seen more often, old habits die hard. Once the role of 
postoperative radiotherapy is defined, we should look further at the timing of 
this radiotherapy. Currently, patients receive their irradiation 3 to 6 weeks 
postoperatively to give the wounds time to heal. With minimal invasive 
treatments long wound healing is not required and postoperative radiotherapy, 
if required, could possibly already be given directly in the same hospital 
admission, or, maybe even preoperative.27 Whether this is desirable and 
feasible requires further research. 
Future studies planned within the cmRCT context of the OPTIMAL Study will 
focus on the treatment in more specific subgroups with regard to expected 
survival, fracture location and type. The IlluminOss study will aim to identify 
whether fixation of actual or impending pathologic fractures of the humerus in 
patients who qualify for an intramedullary fixation (i.e. short to mid-term 
expected survival, fractures of proximal humerus if sufficient bone stock in the 
head or of the humerus shaft) with an IlluminOss intramedullary fixation will 
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lead to the same levels of quality of life and pain reduction as a standard 
intramedullary nail. If this is the case, such an intramedullary fixation method, 
with a combination of balloons, light activated monomers, and flexible 
catheters, could be considered as substitution for conventional intramedullary 
nails, because they are reported to be less-invasive and quicker to insert.  
The CarboFix study will focus on the subgroup of patients who qualify for 
intramedullary fixation of the femur (i.e. actual or impending fractures, short to 
mid-term expected survival, lesions located in the femur shaft, or if sufficient 
bone stock in the head in the proximal femur). These patients will be 
randomised between a standard intramedullary nail and a CarboFix 
intramedullary nail, the latter of which is made of material that is stronger than 
conventional nails. Aim of the study is to detect whether the quality of life and 
pain as reported by the patient is not worse than of the conventional nails, while 
leading to less implant failures due to the properties of the material.  
What remains difficult in these intended studies, is that the choice for a specific 
implant is left to the surgeon. Although a framework is provided of which 
patients would be eligible for such an implant, no hard indications are set. This 
is a consequence of the pragmatic approach to research we are required to do 
in this patient population. Although numbers of patients are rising, pathologic 
fractures are still less common than traumatic fractures, and to be able to 
include sufficient number of patients in a study, a pragmatic approach is 
essential. In the planned studies, we are focussing on specific types of implants. 
Future studies however, also need to focus on the indications for certain 
implants. Again, that is where the ethical aspect plays a role, since in this 
palliative setting, it might be difficult to randomise a patient between two 
treatment modalities, when the surgeon has the feeling that one of either would 
be better for a patient due to the size of the lesion, the bone stock, the 
preference of the patient, or for any other reason. No study will be able to 
deduct such specific in- and exclusion criteria that all relevant factors are 
covered, and still be able to include sufficient number of patients. Some 
indication bias will thus always remain present in studies on treatments for 
patients with symptomatic bone metastases. A promising study has been 
initiated by colleagues in the Memorial Sloan Kettering Cancer Center in which 
patients with actual or impending fractures of the intertrochanteric, 
pertrochanteric or subtrochanteric region of the proximal femur are being 
randomised between long-stem cemented hemi-arthroplasties and 
intramedullary nails (ClinicalTrials.gov identifier: NCT02164019). Despite 
participation of multiple centres in the USA, recruitment of sufficient patients is 





study completion within an acceptable period. We are planning to collaborate 
with our American colleagues in their study to hopefully answer this important 
question. Additionally, we plan to further develop our existing collaborations 
with centres in Europe to further optimise the treatment of patients with 
symptomatic long bone metastases. 
The subject of this thesis has been the treatment of long bone metastases, but 
bone metastases occur throughout the entire skeleton. Our focus was 
predominantly on actual and impending fractures, which bring their own 
distinct problems and solutions. They cannot be compared with the 
consequences of spinal cord compression; both require their own approach. 
One group of metastatic bone lesions has up to now remained beyond the focus 
of researchers and studies: lesions in the pelvis. Future studies should not only 
focus on further perfecting and personalising treatment of long bone and spinal 
metastases, but also shine light on the lesions in the pelvis. Due to the unique 
anatomy of the pelvis, other treatment modalities than radiotherapy and 
surgery, such as cementplasty or radiofrequent ablation, could prove effective. 
Additionally, specific attention should be directed at identifying the best 
treatment in case of pelvic and long bone metastases combined.   
To conclude, the current treatment of symptomatic metastases of the long 
bones is predominantly based on experience and low level evidence studies, 
while the treatment of patients with long bone metastases requires 
personalisation to provide adequate palliative care. To achieve adequate 
palliative care, answers to several Unknowns are required. This thesis has made 
a start to making the Unknowns known by developing a prognostic model that 
can provide adequate survival estimation. This thesis has also attempted to 
provide more detailed evidence on the faults and merits of certain treatment 
modalities. However, the prospective OPTIMAL study should provide further, 
less biased, answers regarding the outcome of treatment modalities. Accurate 
survival and fracture prediction, and specific pairing of treatment to patient, will 
enable individualised palliative care for patients with symptomatic metastases 
of the long bones, which will lead to optimisation of their quality of life. 
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Botmetastasen van de lange pijpbeenderen kunnen pijn en pathologische 
fracturen veroorzaken. Lokale behandeling bestaat uit radiotherapie en/of 
chirurgische fixatie. De meest geschikte behandeling hangt af van verschillende 
factoren, waaronder de symptomen, de locatie en uitgebreidheid van de laesie, 
de wensen en verwachtingen van de patiënt, en de verwachte overleving. Doel 
van dit proefschrift was om een prognostisch model te ontwikkelen voor de 
inschatting van de overleving van patiënten met kanker en symptomatische 
botmetastasen van de lange pijpbeenderen, de huidige (chirurgische) 
behandelingen en ontwikkelingen te evalueren, en onderbouwing voor 
toekomstige gerandomiseerde studies te ontwikkelen. De eerste hoofdstukken 
van dit proefschrift beschrijven het ontwikkelde model en hoe dit model 
toekomst-bestendig is. De daaropvolgende hoofdstukken gaan over de 
onderbouwing en uitkomsten van verschillende behandelmodaliteiten.  
Het inschatten van de overleving van patiënten met symptomatische 
botmetastasen van de lange pijpbeenderen is cruciaal om over- en 
onderbehandeling te voorkomen. In hoofdstuk 2 wordt een eenvoudig 
prognostisch model voor overleving in patiënten met symptomatische 
botmetastasen van de lange pijpbeenderen gepresenteerd. De studie, 
gebaseerd op een multicenter, retrospectief cohort van patiënten behandeld 
voor  symptomatische botmetastasen van de lange pijpbeenderen tussen 2000 
en 2013 bij verschillende radiotherapie dan wel orthopaedische afdelingen 
(n=1520), toont dat het klinisch profiel (“moderate”/matig: hazard ratio [HR] 1.8 
[95% CI 1.5-2.1]; “unfavourable”/ongunstig: HR 3.3 [95% CI 2.8 - 3.8]), een 
Karnofsky Performance Score van 70 of lager (HR 2.0 [95% CI 1.8 - 2.3]), en de 
aanwezigheid van viscerale en/of hersenmetastasen (HR 1.4 [95% CI 1.2 - 1.5]) 
significant gerelateerd zijn met een hoger risico op overlijden. Deze factoren 
werden gecombineerd tot twaalf categorieën, met elk hun eigen mediane 
overleving. Vervolgens werd een stroomschema ontwikkeld om het gebruik van 
het model te vergemakkelijken (figuur 12.1). Het model leidt tot vier klinisch 
relevante overlevings-categorieën (A-D): A (29%), B (19%), C (31%), D (21%) die 
overeenkomen met de volgende mediane overleving: 21.9 (95% CI 18.7 - 25.1), 
10.5 (95% CI 7.9 - 13.1), 4.6 (95% CI 3.9 - 5.3) en 2.2 (95% CI 1.8 - 2.6) maanden, 
respectievelijk. Het onderscheidende vermogen van het model was 0.70 met 
twaalf categorieën en 0.69 met de uiteindelijke vier categorieën. Het model 
werd gevalideerd met een externe dataset van 250 chirurgische patiënten. 
Toepassing van het model in het externe cohort toonde overeenkomstige 
resultaten tussen de geobserveerde en verwachte overleving op basis van het 
model. Dit toont dat het model ook voldoende patiënten kan stratificeren in 
andere datasets. De eenvoud van het model maakt het gemakkelijker in gebruik. 
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Dit zou ervoor moeten zorgen dat het meenemen van de verwachte overleving 
bij het maken van een behandelkeuze een algemene trend wordt.  
Een van de unieke kenmerken van het hiervoor genoemde model, is het 
vermogen om aan te passen aan ontwikkelingen binnen de geneeskunde. Het 
dynamische aspect van de klinische profielen maakt het mogelijk dat de 
classificatie van een primaire tumor verandert. De indeling in de klinische 
profielen is niet alleen op basis van groeisnelheid van een tumor, maak ook 
afhankelijk van factoren zoals de effectiviteit van (toekomstige) ontwikkelende 
systemische behandelingen. De toename van doelgerichte therapieën zal er in 
de toekomst voor zorgen dat vele primaire tumoren onderverdeeld worden in 
subtypes. Flexibiliteit in de indeling van de klinische profielen is dus van groot 
belang, zoals getoond in hoofdstuk 3. De studie beschreven in hoofdstuk 3 
analyseert of mutaties in het ‘epidermal growth factor receptor’ (EGFR) gen en 
het ‘Kirsten rat sarcoma’ (kRAS) gen gerelateerd zijn met overlevingsduur in 
patiënten die zich presenteren met symptomatische botmetastasen op basis 
van een niet-kleincellig longcarcinoom (NKCLC) en of deze gen mutaties 
geïncorporeerd zouden moeten worden in prognostische modellen voor 
overleving. Honderdnegenendertig patiënten met NKCLC die tussen 2007 en 
2014 behandeld waren voor een symptomatische bot metastase en van wie de 
mutatie status bekend was, werden bestudeerd. De mediane overleving was 3.9 
maanden (95% betrouwbaarheidsinterval (CI) 2.1 - 5.7), maar patiënten met een 
EGFR-mutatie hadden een mediane overleving van 17.3 maanden (95% CI 12.7 
- 22.0), terwijl patiënten met een kRAS-mutatie een mediane overleving van 1.8 
maanden (95% CI 1.0 - 2.7) hadden. Vergeleken met EGFR-positieve patiënten 
hadden EGFR-negatieve patiënten een 2.5 hogere kans op overlijden (95% CI 1.5 
- 4.2). De beschreven studie heeft vervolgens de classificatie van primaire 
tumoren, zoals beschreven in hoofdstuk 2, geëvalueerd. Als niet-kleincellig 
longcarcinoom met een EGFR-mutatie geclassificeerd wordt als “matig” 
(moderate) in plaats van “ongunstig” (unfavourable), verbetert het 
onderscheidend vermogen van 0.60 naar 0.63, een toename van 5%. 
Postoperatieve radiotherapie wordt vaak voorgeschreven als adjuvante 
behandeling na chirurgische fixatie van een actuele of dreigende pathologische 
fractuur. De systematische review in hoofdstuk 4 toont dat hier geen goed 
onderbouwd wetenschappelijk bewijs voor is. Slechts twee studies werden in de 
review geïncludeerd. Beide studies spreken van een voordelig effect van 
postoperatieve radiotherapie ten aanzien van functie, re-interventies en 
overleving, maar deze resultaten moeten worden geïnterpreteerd met enige 
terughoudendheid omdat de studies retrospectief zijn en er dus sprake is van 





gestandaardiseerde en gevalideerde uitkomstmaten, en inadequate statistische 
analyses gebruiken. Om te bepalen of postoperatieve radiotherapie een 
gunstige uitkomst heeft of dat het een overbodige behandeling is, moet worden 
onderzocht in een grote, multicenter, gerandomiseerde studie.  
Figuur 12.1 Stroomschema voor verwachte overleving.  
Om een overzicht te krijgen van de behandelingen van pathologische fracturen 
in de praktijk werd een enquête verstuurd naar alle leden van de Nederlandse 
Orthopedie Verenging (NOV) en Europese oncologische orthopaeden. Het doel 
van de enquête was om de huidige trends ten aanzien van de inschatting van 
overleving en behandelvoorkeuren onder nationale en internationale algemene 
en oncologische orthopaeden te inventariseren en te onderzoeken of er 
verschillen zijn tussen de groepen die tot verbetering van de zorg van patiënten 
met pathologische fracturen zou kunnen leiden. De resultaten van de enquête 
zijn beschreven in hoofdstuk 5. Zesennegentig van de 948 benaderde leden van 
de NOV (10.1%, groepen 1 en 2) en 33 van de 182 benaderde leden van de 
Europese oncologisch orthopaeden (18.1%, groep 3) reageerden op de enquête. 
De inschatting van de overleving was accuraat in meer dan 50% van de 
respondenten in alle drie groepen als de verwachte overleving kort (<3 
maanden) of lang (>12 maanden) was. Als de verwachte overleving tussen 3 en 
12 maanden was, was er meer verdeeldheid onder de respondenten in alle 
groepen. De behandelvoorkeuren lieten zien dat algemeen orthopaedisch 
chirurgen de voorkeur hebben voor een intramedullaire pen ter behandeling 
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van een pathologische fractuur van femur en humerus, onafhankelijk van de 
verwachte overleving, tumor type en locatie. Oncologisch orthopaeden raden 
een reconstructie met prosthese aan in patiënten met een lange verwachte 
overleving. Op basis van deze resultaten zouden we kunnen concluderen dat 
een betere identificatie van patiënten die behandeling in een gespecialiseerd 
(gecentraliseerd) centrum nodig hebben ten opzichte van patiënten die 
adequate behandeling in een regionaal centrum kunnen krijgen, de gehele zorg 
van patiënten met een pathologische fractuur zou kunnen verbeteren. Deze 
differentiatie tussen patiënten zou gebaseerd moeten zijn op verwachte 
overleving, de locatie en uitgebreidheid van de laesie en het tumor type van de 
primaire tumor.  
Hoofdstuk 6 beschrijft de retrospectieve analyse van 228 intramedullaire 
pennen voor actuele (51%, n=117) en dreigende (49%, n = 111) pathologische 
fracturen van het femur. De resultaten tonen dat de cumulatieve incidentie van 
lokale complicaties (8%), falen van het implantaat (4%), en revisie (2.2%) laag is. 
Dit komt vooral door de korte overleving van patiënten (mediane overleving 6 
maanden). Een actuele (ten opzichte van een dreigende) fractuur (cause-specific 
hazard ratio [HR_cs], 3.61; 95% CI 1.23-10.53; p = 0.019) en eerdere 
radiotherapie (HR_cs, 2.97; 95% CI, 1.13-7.82, p = 0.027) waren onafhankelijke 
factoren gerelateerd aan een verhoogd risico op falen van het implantaat. De 
aanwezigheid van een actuele fractuur was ook onafhankelijk gerelateerd aan 
een hoger risico op revisie (HR_cs, 4.17; 95% CI, 0.08-0.82, p = 0.022), terwijl het 
gebruik van cement gerelateerd was met een lager risico op revisie (HR_cs, 0.25; 
95% CI, 1.20-14.53, p = 0.025). Op basis van deze resultaten zouden chirurgen 
kunnen overwegen om cement te gebruiken bij een intramedullaire pen in 
patiënten met een actuele fractuur en betere follow-up van patiënten die 
behandeld worden voor een actuele fractuur na eerdere radiotherapie. In de 
toekomst moeten prospectieve studies verder uitwijzen wat de toegevoegde 
waarde van adjuvante behandelingen en implantaat-gerelateerde factoren is op 
het voorkomen van implantaat falen en revisie.  
Een gelijksoortige studie werd uitgevoerd ten aanzien van intramedullaire 
pennen in de humerus, om te evalueren of de complicaties die gezien worden 
in het femur ook gezien worden in de humerus. Deze studie, zoals beschreven 
in hoofdstuk 7, analyseerde 182 intramedullaire pennen voor actuele (79%, 
n=143) en dreigende (21%, n=39) pathologische fracturen van de humerus. Het 
doel van de studie was om de cumulatieve incidentie van en risico factoren voor 
falen te analyseren. De resultaten tonen een faalpercentage van 12.6%. In 
dertien gevallen was het falen veroorzaakt door een hoofdzakelijk mechanische 





of pen) terwijl in de oorzaak in negen gevallen hoofdzakelijk oncologisch was. 
Op basis van dit cohort konden geen risico factoren voor falen geïdentificeerd 
worden. De factoren gerelateerd aan falen in het femur cohort (actuele fractuur 
en geen gebruik van cement) waren niet significant in dit cohort van humeri, dus 
er kunnen geen aanbevelingen worden gedaan ten aanzien van het gebruik van 
adjuvant cement in de humerus. De mediane overleving was 5.7 maanden (95% 
CI 4.8 – 6.7). Tussen patiënten met een actuele fractuur en een dreigende 
fractuur zat geen verschil in mediane overleving: 5.3 maanden (95% CI 4.2 – 6.4) 
versus 8.6 (95% CI 5.5 – 11.7) (p=0.112). Vooraf was verwacht dat de mediane 
overleving van het cohort van humerus pennen korter zou zijn dan van de femur 
pennen, dit verschil was echter minder dan verwacht (mediane overleving 6.0 
maanden [95% 4.4 – 7.3] voor de femur pennen, zoals beschreven in hoofdstuk 
6). Op basis van deze studie kunnen we slechts concluderen dat het aantal 
gefaalde pennen na fixatie in de humerus voor actuele of dreigende 
pathologische fracturen relatief hoog is. Daarbij moet rekening gehouden 
worden met het feit dat dit aantal gefaalde pennen zeer waarschijnlijk een 
onderrapportage is, gezien er geen gestandaardiseerde follow-up was en door 
de korte overleving van patiënten. De keuze voor een intramedullaire pen in de 
humerus moet derhalve goed worden overwogen en besproken met de patiënt. 
Hoofdstuk 8 was een systematische review over de behandeling van 
pathologische fracturen van het distale deel van het femur. Pathologische 
fracturen van de distale femur komen minder vaak voor dan die van het 
proximale femur en zijn ook een van de meest ingewikkelde pathologische 
fracturen om te stabiliseren. Slechts twee studies voldeden aan de 
inclusiecriteria van de review, maar de kwaliteit van de studies was slecht en er 
konden geen factoren geïdentificeerd worden die als indicatie voor een 
endoprothese zouden gelden. Op basis van de literatuur en 
ervaringsdeskundigen zijn indicaties voor een endoprothese voor het distale 
femur: een solitaire metastase bij patiënten met een lang verwachte overleving, 
een uitgebreid aangetast gewrichtsoppervlak, en onvoldoende bot kwaliteit 
voor interne fixatie van schroeven in het distale femur. De schaarste aan 
resultaten in de literatuur en de slechte kwaliteit van de paar geïncludeerde 
studies illustreren de kwesties waar chirurgen die pathologische fracturen 
behandelen constant tegenaan lopen: er is onvoldoende adequaat onderzoek 
over de behandeling van pathologische fracturen om relevante vragen te 
beantwoorden. Internationale, prospectieve samenwerking is nodig om deze 
lacune te vullen. Tot de resultaten van zulke studies gepubliceerd zijn, zullen alle 
chirurgische behandelingen, voor alle locaties, vooral gebaseerd zijn op 
retrospectieve studies en klinische ervaring.  
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Hoofdstuk 9 gaf tenslotte een overzicht van de chirurgische behandeling van 
pathologische fracturen. De behandeling van patiënten met actuele of 
dreigende pathologische fracturen van de lange pijpbeenderen vergt 
multidisciplinaire samenwerking. De eerste stappen in de behandeling zijn een 
correcte diagnose van een metastase. Als een patiënt niet bekend is met 
gemetastaseerde ziekte, moet een biopt altijd afgenomen worden uit de laesie 
om de diagnose van een metastase te bevestigen. In de differentiaaldiagnose 
moet immers altijd een primaire bottumor staan. Na de bevestiging van een 
metastase, is verdere diagnostiek nodig ten aanzien van de disseminatie status 
van de patiënt (CT thorax-abdomen voor viscerale metastasen; PET-CT of 
röntgenfoto’s van beide humeri en femora voor botmetastasen; CT-hersenen 
als er klinische verdenking op hersenmetastasen bestaat), de algemene 
gezondheid van de patiënt (voorgeschiedenis [voedingsstatus, gewichtsverlies], 
bloedonderzoek [serum calcium en albumine]), en de lokale status van het 
aangedane bot, inclusief de uitgebreidheid van de laesie (röntgenfoto’s van het 
gehele bot in twee richtingen of een CT-scan van de laesie indien de 
röntgenfoto’s onvoldoende zijn). De verzamelde data is nodig om de meest 
geschikte behandeling te bepalen, welke afhangt van de verwachte overleving, 
de locatie van de laesie, en of het een actuele of dreigende fractuur betreft. Een 
laesie met een axiale corticale aantasting van >30 mm heeft een hoog risico op 
fractuur en moet profylactisch gestabiliseerd worden. Radiotherapie is de 
primaire behandelmodaliteit bij symptomatische (pijnlijke) laesies zonder hoog 
risico op fractuur. Primaire chirurgische opties zijn onder andere plaat fixatie, 
intramedullaire pen fixatie en endoprothese. Adjuvant cement moet worden 
overwogen bij grote laesies voor een betere stabilisatie. Verder personalisatie 
van iedere behandeling is nodig om de optimale palliatieve strategie te bepalen 
en voor elke patiënt de kwaliteit van leven zo goed mogelijk te behouden. 
Uit alle hoofdstukken en de discussie kan geconcludeerd worden dat de huidige 
behandeling van symptomatische metastasen van de lange pijpbeenderen 
vooral gebaseerd is op ervaring en studies van lage kwaliteit, terwijl de 
behandeling van deze patiënten gepersonaliseerd moet worden om adequate 
palliatieve zorg te kunnen bieden. De resultaten uit dit proefschrift hebben 
daarvoor de basis gelegd, echter verdere, onafhankelijke resultaten uit de 
prospectieve OPTIMAL-studie zijn nodig om beter onderbouwde conclusies te 
kunnen trekken. Precieze inschatting van zowel de overleving als het 
fractuurrisico en specifieke koppeling van behandeling aan patiënt, zullen het 
mogelijk maken om gepersonaliseerde zorg te kunnen leveren. Daarmee zal de 
kwaliteit van leven van patiënten met symptomatisch metastasen van de lange 












A digital and online application 
 
The OPTIModel application is designed to aid clinicians in the decision-making 
of any patient presenting with long bone metastases. The content of the 
application is based on the prognostic model as described in chapter 2 and 
treatment recommendations as described in chapter 9.  
First, users are guided through a flowchart to estimate the remaining survival as 
shown in the screenshots in figure A.1. 
Subsequently, users are guided through a second flowchart to receive a 
recommendation for local treatment, based on the initial survival estimation 
and the location, extent, and presentation of the metastasis as shown in the 
screenshots in figure A.2. 
This application does not serve as treatment protocol and no rights may be 
derived from this information by physicians or patients. 
The application can also be used on the following website: www.optimal-
study.nl/tool (figure A.3). 
The application can be downloaded (free of charge) in the Apple App Store and 
Google Play Store. 
 






Figure A.1 Screenshots of the steps of the first part of the OPTIModel to estimate the remaining 
survival. As shown in the example in the last screenshot, the outcome is presented as estimated 
median survival (with 95% confidence interval) and the corresponding survival category according 
to the Optimal prognostic model (OPTIModel) as reported in chapter 2. 
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Figure A.2 Screenshots of the some of the steps of the second part of the OPTIModel that result in 
an advice for treatment (both radiotherapy or surgery) for symptomatic bone metastases of the 





Figure A.3 Screenshot of the webpage www.optimal-study.nl/tool to use the OPTIModel online. The 
model can also be used on the site if the app is not downloaded (right part of the screen).  




Study protocol for  
The OPTIMAL Study –  
a cmRCT 
 
The following description of the prospective OPTIMAL Study is a shortened 
version of the study protocol as reviewed and approved by the medical ethical 
committee of the Leiden University Medical Center. The full protocol can be 
found online at https://clinicaltrials.gov (NCT02705157). The version below 
focusses on the cohort multiple randomised controlled trial (cmRCT) and why 
we chose to use this study design for the prospective OPTIMAL Study. Details on 
data collection, analysis, registration of (serious) adverse events, and data 
storage can be found in the full protocol.  
Cohort multiple randomised controlled trial (cmRCT) 
The following paragraphs will portray the difficulties with randomised controlled 
trials, describe the cmRCT design, discuss our reasons for choosing this design, 
and explain how we plan to adopt and adjust this design to be applicable in the 
study population we wish to study and to be feasible as a multicentre study.  
Difficulties with RCTs in the palliative setting 
Although Randomised Controlled Trials (RCT) are considered to provide high-
grade evidence, the classical RCT poses several challenges, especially in 
pragmatic cancer research. Recruiting sufficient numbers of patients is known 
to be extremely difficult, not in the least due to cumbersome and time 
consuming procedures of informed consent, randomization, and inclusion.1 
Furthermore, the mandatory elaborate informed consent for all eligible 
patients, which is regarded as ethical requirement, is often a barrier for patients 
to join trials. The abundance of complicated information given combined with 
the uncertainty of randomization often leads to rejection of participation.2 
Moreover, the recruited (trial) population is often unrepresentative of the 
reference population, thus leading to poor external validity. It is also possible 
that patients withdraw from a trial when they do not get the experimental 




field of oncology, there are often multiple treatments for the same disease, 
leading to multiple trials for the same population. These all have heterogeneous 
outcomes and are thus difficult to compare. Finally, modern technology has 
often surpassed the investigated intervention before the trial has ended.3 
In the field of palliative medicine, the previously described difficulties become 
yet more evident. This is not only our personal experience from earlier trials we 
have performed in the Netherlands, but has also been described in the ZonMw 
report entitled “Successful inclusion in the palliative setting” (in Dutch: 
“Succesvol includeren in de palliatieve zorg”).4 This research was performed in 
response to the observed inclusion problems of studies in the palliative setting. 
Physical and emotional frailty are two major factors limiting inclusion. Due to 
physical frailty patients might deny participation; a lack of energy to fill out 
questionnaires or physically demanding visits at outpatient clinics can be 
reasons to refuse participation. Emotional frailty is possibly a more important 
reason for denial of participation, or earlier drop out. The partaking in a 
research forces a patient to think about his illness in some way or another. This 
can be extremely confronting, especially if patients have problems coping with 
their situation. Furthermore, it is plausible that this emotionally unstable 
situation influences patients in their decision-making. Many patients remain in 
a state of doubt and have difficulty drawing up the balance, thus being given the 
choice of participating in randomised research can be very demanding.  
Mirroring this emotion is the reserve treating physicians feel to ask their 
patients to join a study. The physician often does not want to burden the patient 
any further than the illness already does. The often long and intensive relation 
between physician and patient further increases this protective attitude.  
A more logistical problem with research of patients in the palliative setting is 
that they are often out of reach of the researchers. The majority of the patients 
in this phase receives care from their general practitioner or the local hospital, 
and does generally not visit an academic hospital unless necessary. 
The ZonMw report looked into 13 research projects (total budget 2.8 million 
euro) aimed at improving quality of life and pain of patients in the palliative 
phase.4 Four of these studies have been completed, 1 has been discontinued 
due to inclusion problems, and 1 did not start because the needed sample size 
was not considered feasible. One of the four completed studies did so on time, 
2 were delayed, and 1 changed the aims because the number of patients 
included could not answer the primary question. All research projects reported 
problems with inclusion, mainly because too many eligible patients are missed 
at inclusion. Half of the studies had problems with the inclusion itself, for 
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example due to certain extra measurements (laboratory analysis) needed for 
the study or because patients were too ill to think about participation in a trial.  
It is thus clear that inclusion in the palliative phase is difficult and although the 
majority of these limiting factors cannot be changed, they are aspects that need 
to be taken into account when setting up a new study. The ‘cohort multiple 
randomised controlled trial’ design has characteristics that will lessen the 
burden for the patient and ease the inclusion for the study. Only by employing 
such a design, will it be possible to answer several pending questions 
concerning the treatment of patients with bone metastases of the long bones. 
Figure B.1 Cohort multiple randomised controlled trial design. 
Cohort multiple randomised controlled trial 
In 2010 a new research design, the ‘cohort multiple Randmised Controlled Trial’ 
(cmRCT) was developed by Relton et al. in which several solutions are offered 
for the problems associated with classical RCTs.5 The backbone of this design is 
an observational prospective cohort in which patients with the condition of 
interest (i.e. bone metastases of the long bones) are included (dark blue arrow 
in figure B.1). These patients are treated according to usual care and baseline 
data are registered. Secondly, all patients in the cohort are asked to periodically 




asked for consent to be informed about possible trials in the future. This 
consent entails permission for random selection if the patient is eligible for a 
certain trial. For each trial, a random sample is selected from the group of 
consenting and eligible patients (light blue box in figure B.1), who will be offered 
the intervention treatment (light blue half of arrow in figure B.1). Only this group 
will be notified about the trial. After notification follows a second informed 
consent for participation in the specific trial. If patients do not wish to 
participate, they will cross over into the ‘control group’, compromising all 
patients not randomly selected, and receive standard usual care. The patients 
who were consenting and eligible but not randomly selected receive standard 
care as usual without being informed about the trial (dark blue half of the arrow 
in figure B.1). 
Reasons for using this design 
With the cmRCT design, patients are not randomized between treatments, but 
between whether or not they are invited for the intervention arm of a trial. This 
enables ‘patient centred’ informed consent: only those patients selected for the 
intervention arm are offered information about the trial. Thus only these patients are 
confronted with the possibly difficult choice of participating in a specific trial. 
Their choice however is a lot clearer than it would normally be, because this 
group knows that if they consent, they will surely receive the intervention. 
Likewise, those patients that have not been selected receive straightforward 
information regarding the standard care only, without any possibly confusing 
information about a trial. 
This aims to replicate ‘real world’ routine health care, in which patients are only 
informed about treatments for which they are eligible. This is the keystone 
aspect of the study design and is of great importance for our potential trial 
participants who are under substantial emotional stress associated with the 
end-of-life stage. 
It is important to realise that this design is not the same as a Zelen design. The 
Zelen design randomises patients before a single form of consent has been 
given. The Zelen design has for that reason been subject to ethical criticisms and 
is not often applied. In the design we propose, patients are informed on 
beforehand of the possibility of random selection (when they are eligible for a 
certain trial), and this will only be performed if the patient consents to that. 
Patients are clearly informed about the If the patient does not consent, he will 
receive standard care, i.e. the same care he would have received had there not 
been a trial.  
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For the research questions posed in our OPTIMAL study and in the setting we 
propose to perform our study, there is little room for setting up a traditional 
RCT. An alternative approach seems to be more appropriate and the outline of 
the cmRCT design is most suitable. Keystones are the ‘patient centred’ informed 
consent and the possibility for multiple prospective trials at the same time. Also, 
trials will be better comparable and a shorter period of time will be needed for 
including sufficient amount of patients, thus lowering the costs. Especially in a 
fragile patient population, such as patients with symptomatic bone metastases, 
the cmRCT design is uttermost suitable. 
Although the clinical experience with cmRTC model is limited, it is currently 
being used in several studies in the UK, Canada, and The Netherlands 6-8 after 
ethical approval of respective ethical review committees. In The Netherlands, 
the University Medical Centre Utrecht (UMCU) is active in the field of further 
developing the cmRCT design. At their radiotherapy department they currently 
have 3 cohorts, with each one or more active trials. Their numbers of inclusion 
into the cohorts, informed consent for notification about trials, and inclusion 
into trials are promising. Recently, Young-Afat et al. wrote a brief report about 
their experiences with this new design.9 They stated that the cmRCT design 
avoids prerandomization and actively engages participants in the research 
process during cohort participation. All preparations to employ the cmRCT 
design in the OPTIMAL Study have been in close collaboration with our 
colleagues at the UMCU. 
Adjustment to the design 
There are multiple research questions we wish to investigate and the study 
design for each trial will differ according to the research question. Therefore, in 
addition to only performing randomized controlled trials within the cmRCT 
design, we plan to use different designs, best suitable for each new study. 
Reasoning for the specific design will be extensively addressed in each separate 
study protocol.  
This small adjustment is necessary, especially, in trials where two or more 
surgical techniques are going to be compared. Whereas very few eligible 
patients will be treated in a single year, even the cmRCT design and the 
multicentre setting can’t address this sufficiently.  
Thus, some trials will be comparative cohort trials, others pragmatic cluster 
randomized trials, and some with a cmRCT design. For this reason, we renamed 




In conclusion, current knowledge concerning adequate, personalized treatment 
of metastatic lesions of the long bones is insufficient. Several factors of great 
importance are generally acknowledged: the aim of treatment should be 
maintaining or improving the quality of life; expected survival is an important 
factor to bear in mind; and current literature on local treatment modalities is 
inconclusive. For this reason, it is of upmost importance to explore whether 
other (innovative) treatments can be an alternative or addition to the current 
standard treatment options. The OPTIMAL Study, a cohort multiple 
(Randomised Controlled) Trial accounts for differing life expectancies and 
focusses on quality of life outcomes. The study will provide high-grade evidence 
as to which treatment is superior to others.  
Objectives 
The OPTIMAL Study in its entirety aims to provide a more personalized 
treatment for metastases in the long bones based on expected survival and 
impending fracture risk in order to improve functioning and the quality of life 
for the remaining lifetime in patients with disseminated cancer. The OPTIMAL 
Study will provide the infrastructure for a prospective cohort (OPTIMAL cohort) 
and multiple independent trials according to the cm(RC)T design. The specific 
aims of the cohort are discussed in this protocol.  
The primary aim of the cohort is to describe the quality of life and pain 
perception of patients after local treatment (radiotherapy and/or surgery) of 
metastases of the long bones, for both the entire cohort as well as for specific 
treatments separately.  
Secondary aims are to describe the complication rate and survival of patients 
after local treatment (radiotherapy and/or surgery) of metastases of the long 
bones.  
The specific aims of further future individual trials within the cm(RC)T design will 
be described in separate protocols and submitted to the medical research ethics 
committee (METC) independently. In general, however, all trials will be 
pragmatic research trials in search of answers to which treatment (radiotherapy 
or surgery) fits specific patients (categorised by metastasis location, expected 
survival and fracture risk) best.  
Study design 
The OPTIMAL Study encompasses the OPTIMAL cohort and multiple 
independent trials. The cohort is primarily aimed at collecting patient reported 
outcomes, but will also provide the facility to select eligible patients for specific 
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trials according to the cm(RC)T design. This offers the possibility to perform 
multiple trials at the same time in the same patient population, as shown in 
figure B.1. Currently one trial is ongoing (the PORT study), the details of which 
are discussed in a separate protocol. Future trials will also be described in 
separate protocols, which will be submitted to the medical research ethics 
committee (METC) independently. 
The OPTIMAL cohort 
The OPTIMAL cohort is the backbone of the OPTIMAL Study. The cohort will be 
prospectively collected and multicentre, including all consecutive patients with 
BMLB who have signed informed consent. These patients will be followed 
prospectively, and data concerning patient and treatment characteristics as well 
as patient reported outcomes on quality of life will be collected. Baseline data 
will be collected by the physician and entered into the OPTIMAL database. These 
baseline data match the information that is obtained for standard care. For the 
assessment of patient reported outcomes a set of internationally and nationally 
validated questionnaires will be used. Further details are discussed in chapter 
5. The OPTIMAL cohort will additionally serve as facility for efficient, systematic 
and simultaneous evaluation of new and existing interventions for bone 
metastases.  
Informed consent 
Informed consent will consist of the following three steps.  
(1) Participation in the cohort (use and registration of routinely collected 
clinical data and (possibly) contacting the general practitioner or 
other physicians involved). 
(2) Prospective registration of patient reported outcome measures 
(quality of life, pain). 
(3) Approval to be approached for participating in future (intervention) 
studies. 
Informed consent is signed after full oral and written information has been 
provided. Consent for step 1 (use and registration of routinely collected clinical 
data) is mandatory for participation in the OPTIMAL Study. Step 2 is a straight-
forward consent for receiving and completing questionnaires about patient-
reported outcomes. Step 3 is the crux for the ‘patient-centred’ informed 
consent. Patients who sign step 3 can be invited to participate in one or more of 
the studies within the OPTIMAL Study if they meet the inclusion criteria of a 
certain study and in case of a randomized trial, at random selection, as 




Figure B.2 Flowchart of informed consent.  
For a new study, all consenting and eligible (i.e. according to study specific 
inclusion and exclusion criteria) patients are identified. From this sub-group, in 
case of a randomized trial, a random selection is made of patients who are 
invited to participate in the intervention arm. All patients (randomly) selected 
for the innovative treatment, will receive detailed information about the 
intervention and the study. Subsequently they may accept or refuse 
participation (figure B.3).  
Those eligible patients who are not randomly selected will receive standard care 
as usual, without being informed about the randomized trial; this is the essence 
of ‘patient-centred’ informed consent.  
Consenting to step 3 thus implies permission for being randomly selected to 
receive information about and be invited for a randomized trial on one hand, 
and for the use of clinical and self-reported data if patients are eligible but not 
selected for the intervention arm of a trial on the other hand. Patients are clearly 
informed that, if they are selected for and invited to the intervention arm of a 
trial, they are free to refuse it, in which case they will receive standard care. 
Patients are also informed that if they are not selected, they will be part of the 
control-arm, and that they therefore may be (temporarily) ineligible for some 
Patient with BMLB
Informed consent for cohort (step 1)?
Informed consent for patient reported outcome measures 
(step 2)?





Cohort & questionnaires only
Cohort & questionnaires & 
check eligibility for next trial
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future trials. In no case however, will patients be withheld from evidence based 
standard treatments.  
Also, patients participating in in the OPTIMAL Study are permitted to participate 
in other research (e.g., a ‘classic’ RCT) outside the OPTIMAL Study. 
Figure B.3 Schematic overview of process from cohort to trial. 
Study population 
Population (base) 
All patients visiting the radiation oncologist or the orthopaedic surgeon of 
participating centres, for possible local treatment of a symptomatic BMLB or 
impending fracture, will be registered in the OPTIMAL registry. This includes 
patients with newly diagnosed metastatic bone disease as well as patients 
undergoing re-treatment of the same lesion or patients who have received 
previous treatment for other lesions. 
Inclusion criteria 
To participate in the cohort, the patient must meet all of the following criteria: 
• Aged 18 or older 
• Symptomatic bone metastasis deriving from the bones of the 
extremities (humerus/femur and further distal) requiring pain 
medication or intervention with radiotherapy or surgery, or, non-
symptomatic bone metastasis with an expected high risk of fracturing 
requiring treatment 
• Radiographic or histologic proof of metastatic bone disease, originating 
from a solid tumour or primary bone tumour 
• Histologic diagnosis of the primary tumour or – if the primary tumour is 
unknown - at least adequate diagnostic investigations into the origin of 





A potential patient will be excluded from participation in the cohort if any of the 
following criteria are met: 
• Communication with patient is hampered (e.g. language barrier, severe 
cognitive impairment, dementia) 
• The symptomatic lesion originates from multiple myeloma, solitary 
plasmacytoma or lymphoma of bone 
Note: Previous treatment for metastatic bone disease at the present location is 
not an exclusion criterion. 
Methods 
Study parameters 
At moment of inclusion baseline patient data will be collected for the OPTIMAL 
cohort, which will also be used for all other studies nested within the OPTIMAL 
Study. Data will comprehend information concerning demographics (date of 
birth, gender), medical history (primary tumour, dissemination status), clinical 
status (systemic treatment) and functioning (Karnofsky performance score, pain 
score, pain medication). Details concerning the treatment(s) will be reported 
when relevant.  
Patient reported outcome measures 
Patients will be invited to fill out questionnaires about pain, quality of life (QoL), 
and functioning at baseline (pre-treatment; if possible), and 4, 8, 12, and 24 
weeks after initial treatment, then every six months for minimal two years or 
until death. All subsequently or concomitantly symptomatic metastases will be 
registered (including treatment and follow-up), but a new course of 
questionnaires will generally not be initiated. These outcome measures will be 
applied in the entire OPTIMAL cohort. The outcome measures and time-points 
are the same for all trials within the OPTIMAL Study. 
(1) Pain has been chosen as primary endpoint because it can act as a proxy 
for mechanical complications (i.e. loosening). Mechanical complications 
are only relevant for these patients if they give clinical complaints 
needing treatment.  
To measure the primary endpoint patients will be asked to score the 
worst pain in the past 24 hours on a NRS from 0-10. In addition, patients 
will be asked to list their usual pain medication and the escape 
medication they used the previous 24 hours. These questions are 
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derived from the Brief Pain Intervention (BPI) score, which is advised by 
the International Consensus Statement for Bone Metastasis Research10. 
The BPI is a pain assessment tool for use with cancer patients developed 
by the Pain Research Group of the WHO Collaborating Centre for 
Symptom Evaluation in Cancer Care and is also available in Dutch. 
However, multiple questions are similar to questions in the EORTC 
QLQ15-PAL and EORTC QLQBM-22 (described below). Thus to spare 
patients answering the same questions twice, we have selected only 2 
questions from the BPI.  
 
(2) Quality of life; For longitudinal assessment of quality of life after 
treatment, we will use nationally and internationally used, validated and 
recommended questionnaires: European Organization for Research 
and Treatment of Cancer (EORTC) QLQ-C15-PAL11 and EORTC QLQ-
BM22.12,13 In addition, the EQ-5D questionnaire will be conducted. The 
EORTC is currently developing a utility scoring instrument for the EORTC 
QLQ-C30 (from which the QLQ-C15-PAL originates). We expect this 
scoring instrument will also be applicable for the QLQ-C15-PAL. After 
validation of this scoring instrument has taken place, we plan to apply 
it to our data. This would make the addition of the EQ-5D questionnaire 
redundant and it will then be withdrawn. 
 
(3) Function; For assessing improvements in functional outcomes after 
treatment, the Toronto Extremity Salvage Score (TESS) for upper and 
lower extremities will be used.14  
Observational clinical data 
Observational clinical data will be collected at baseline (pre-treatment; if 
possible) and at first, and possibly second, post-operative follow-up (generally, 
patients are subsequently only seen if there are complications or new 
complaints): 
(1) Complications; For complication rate, the Henderson classification of 
complications will be applied.15 This classification identifies five primary 
modes of endoprosthetic failure: soft tissue failure (type 1), aseptic 
loosening (type 2), structural failure (type 3), infection (type 4), and 
tumour progression (type 5). Wound complications with clinical 
consequences will be registered separately. Re-operations due to 






(2) Radiological status; Progression of BMLB will be monitored with 
conventional radiography and on indication with CT scan. This is 
according to usual care, generally at six weeks and 3 months. No 
additional outpatient visits or imaging will be requested for study 
purposes only. The radiological images will be used to place the 
subjective reports of pain (as reported by the NRS) into perspective. 
 
(3) Survival; Dates of death will be derived from the Hospital Electronic 
Patient Registry (in Dutch: Ziekenhuis Informatie Systeem, ZIS), which is 
linked to the Municipal Personal Records Database (in Dutch: 
Gemeentelijke Basisadministratie, GBA). If this is not possible or not up to 
date, data will be derived from the general practitioner. The utmost will 
be tried to prevent sending questionnaires to deceased patients. 
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The aim of this study was to translate and culturally adapt the Toronto Extremity 
Salvage Score (TESS) to Dutch and to validate the translated version. 
Methods  
The TESS lower and upper extremity versions (LE and UE) were translated to 
Dutch according to international guidelines. The translated version was 
validated in 98 patients with surgically treated bone or soft tissue tumors of the 
LE or UE. To assess test-retest reliability, participants were asked to fill in a 
second questionnaire after one week. Construct validity was determined by 
computing Spearman rank correlations with the Short Form- (SF-) 36.  
Results  
The internal consistency (0.957 and 0.938 for LE and UE, respectively) and test-
retest reliability (intraclass correlation coefficients 0.963 and 0.969 for LE and 
UE, respectively) were good for both questionnaires. The Dutch LE and UE TESS 
versions correlated most strongly with the SF-36 physical function dimension (r 
= 0.737 for LE, 0.726 for UE) and the physical component summary score (r = 
0.811 and 0.797 for LE and UE). 
Interpretation  
The Dutch TESS questionnaire for lower and upper extremities is a consistent, 
reliable and valid instrument to measure patient-reported physical function in 
surgically treated patients with a soft tissue or bone tumor. 
  




The preferred treatment of bone and soft tissue tumors of the extremities is 
limb-sparing surgery. Measuring physical function after surgery is of the utmost 
importance to determine the success of treatment and to improve patient care. 
Patient-reported outcome measures enable the surgeon and the patient to 
objectively evaluate the patients’ pain and function in order to optimize clinical 
care.  
The Toronto Extremity Salvage Score (TESS)1 is a valid and reliable disease-
specific measure developed to evaluate physical disability in patients treated for 
extremity sarcoma. Different questionnaires are available for the upper and 
lower extremities. The TESS was originally developed in English and has 
currently been translated and validated in five other languages (Japanese,2,3 
Korean,4 Chinese,5 Danish,6 Portuguese7).  
While the TESS is commonly used in the Netherlands, it has not been translated 
or validated for use in the Dutch language using standardized and 
methodologically sound procedures. The current study aims to translate and 
culturally adapt the TESS (for upper and lower extremities) to Dutch and to 
validate the translated version among patients with surgically treated bone or 
soft tissue tumors of the extremities. 
Methods 
This research was reviewed and approved by the Medical Ethical Committee of 
the Leiden University Medical Center. A waiver for informed consent was 
provided based on the law for medical research on humans in the Netherlands 
(April 2016; P16.060).  
Translation and cross-cultural adaptation 
The methodology used for translation and adaption concerns a well-established 
process, based on published guidelines for the cross-cultural adaptation of self-
reported measures by Beaton et al.8 and Guillemin et al..9 During the course of 
translation, adaptation, and validation the TESS questionnaires for the lower 
extremity (LE) and upper extremity (UE) were handled separately. Forward 
translation from the English TESS into Dutch was performed by three bilingual 
translators, with Dutch as mother tongue (JJW, CWPGvdW, JB). One of these 
translators (JB) was unaware of the concepts addressed and without a medical 
background. This led to a first Dutch consensus version. Two independent, 
bilingual translators with English as mother tongue and without medical 




The expert committee, compromising a methodologist (TVV), the principal 
investigator (MAJvdS), and four translators (JJW, CWPGvdW, JB, TT) reviewed all 
versions and components of the original questionnaire and the translations to 
reach consensus on the final wording to be used in the Dutch version of the 
TESS.  
Patients 
Consecutive eligible patients who visited the outpatient clinic between July and 
September 2016 (regarding LE) or February 2017 (regarding UE) for follow-up of 
previous surgery for bone or soft tissue tumors of the extremities were invited 
to complete the translated and adapted TESS. Eligible patients were identified 
by checking the electronic medical records of patients scheduled for follow-up. 
Inclusion criteria were: (i) aged 18 or older, (ii) a minimum of 3 months since 
surgical treatment for an aggressive benign or malignant bone tumor or soft 
tissue sarcoma, and (iii) no sign of local or systemic recurrent disease. Patients 
with whom communication was impaired or who could not complete 
questionnaires unaided were not asked to complete the questionnaires. 
Baseline characteristics of the participating patients, including age, gender, 
primary tumor, location of primary tumor, and time since primary surgery were 
collected.  
Instruments 
The TESS is a self-administered questionnaire that includes 30 items regarding 
activity limitations in daily life, such as restrictions in body movement, mobility, 
self-care and performance of daily tasks and routine. The degree of physical 
disability is rated from 0 (not possible) to 5 (without any problem). The raw score 
is converted to a score ranging from 0 to 100 points, with higher scores 
indicating less functional limitations. Patients are able to answer questions 
concerning activities they do not perform in daily life with “not applicable”. These 
questions are deducted from the calculation of the total score. 
The SF-36 is a widely used questionnaire to survey health-related quality of life.10 
The SF-36 has been validated for the Dutch population11 and is administered as 
part of standard-care protocol in our hospital. The questionnaire measures 
eight dimensions of health and reports a score (from 0 (worst) to 100 (best)) for 
each category.10 The scores from the eight categories can also be grouped into 
two summary scores: the physical and mental component summary scores (PCS 
and MCS). These summary scores were standardized using normative data from 
the Dutch general population with a mean score of 50 and standard deviation 
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of 10.11 The scores give an indication of the functioning of the patient population 
in comparison with the general population. 
Assessments 
Eligible patients were invited to participate in the study by a research assistant 
when presenting at the outpatient clinic. The questionnaires were provided on 
paper. The first questionnaire was to be completed while waiting for the 
outpatient appointment. The second questionnaire (with a stamped return 
envelope) was handed out at the outpatient clinic together with the first 
questionnaire and patients were asked to complete the questionnaire one week 
later at home and send return by post. The questionnaires were paired by a 
code, to enable test-retest analysis. 
Once patients agreed to participate in the study, their name was recorded. 
Patient identifying information was however not coupled to the questionnaire 
number, thus ensuring anonymity of the questionnaire. 
Analyses 
Prior to analysis, patients who answered 80% or more of the questions of the 
first TESS questionnaire with “not applicable” were excluded. For calculation of 
mean scores and analyses of difficult or “not applicable” questions, the first 
completed questionnaire of each patient was used. 
Reliability 
Internal consistency measures the homogeneity of all parts of the instrument, 
and was evaluated by means of calculation of Cronbach’s alpha.12 Cronbach's 
alpha provides a measurement of the strength of the relationship among the 
items of the questionnaire, with a value of >0.80 generally being considered as 
acceptable for scaling of the measure.13 Test-retest variability concerns the 
ability of an instrument to create reproducible results when no real change has 
occurred for a subject. For this purpose, the intraclass correlation coefficient 
(ICC) was estimated between the responses to the first (test) and the second 
(retest) questionnaire for each item and for the total score. Bland-Altman plots 
were computed to visualize the absolute differences between the two 
assessments against the mean of the two tests to show the limits of 
agreement.14  
Validity 
Construct validity measures the extent to which the scores of an instrument 




construct validity of the TESS was determined by calculating the Spearman rank 
correlation-coefficient between the TESS and the SF-36 dimension and summary 
scale scores.  
All statistical analyses were performed with IBM SPSS version 23.0 (Armonk, NY, 
USA). The strength of agreement for the correlation coefficients and the ICC was 
defined as strong (≥0.70), moderate (>0.50 to <0.70), and weak (≤0.50).15 A p-
value of <0.05 was considered statistically significant.  
Results 
Translation process 
The translators and expert committee encountered no major linguistic or cross-
cultural challenges during the translation and cross-cultural adaptation phase 
of the TESS-LE and TESS-UE questionnaires. The translation and adaptation 
process finally resulted in a Dutch TESS-LE and TESS-UE questionnaire, which 
can be found online.  
(https://www.hindawi.com/journals/sarcoma/2017/6197525/sup/) 
Patients 
Ninety-eight patients (49% male) with a mean age of 48.7 years (range 18.1–83.8) 
were included (figure C.1). The characteristics of the patients and their TESS and 
SF-36 scores are presented in Table C.1 and C.2.  
Dutch TESS LE and UE questionnaire results  
Overall, the mean score of the TESS questionnaire was 77.5 (standard deviation 
(SD) 19.8) for the lower extremities and 90.2 (SD 14.9) for the upper extremities 
(table C.2). Getting up from kneeling was regarded the most difficult of all 
activities (mean score 3.21) in the LE questionnaire. Lifting a box to an overhead 
shelf was regarded the most difficult of all activities (mean score 3.94) in the UE 
questionnaire. Five patients (10.0%) scored a maximum score (100) on the TESS-
LE, versus 19 patients (39.6%) on the TESS-UE. On the TESS-LE patients answered 
a median of 1 question with “not applicable” (range 0–17 questions). The 
questions concerning getting in and out of bath (n=11, 22%), driving a car (n=9, 
18%) and sexual activities (n=9, 18%) were most frequently answered as “not 
applicable”. Regarding the TESS-UE, the median number of questions answered 
with “not applicable” was 0 (range 0–7 questions) The most common “not 
applicable” UE-activities were those about working the usual number of hours 
(n=5, 10%) and tying a tie or bow at the neck of a blouse (n=5, 10%). 
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Figure C.1 Flowchart of participating patients. 
Reliability 
The internal consistency was good with Cronbach’s alpha of R = 0.957 for the 
TESS-LE and R = 0.938 for the TESS-UE. The Spearman rank correlation 
coefficients between one item and the total score (excluding that item) ranged 
from 0.955–0.958 per item for the TESS-LE and from 0.933–0.939 per item for 
the TESS-UE. Twenty-five and eighteen of the LE (50%) and UE patients (38%) 
completed the “retest” questionnaire, respectively. The test-retest reliability was 
strong with ICCs of 0.963 (95% confidence interval (CI) 0.916–0.984) and 0.969 




Table C.1 Patient and tumor characteristics of patients with benign and malignant bone and soft 
tissue tumors who completed the TESS questionnaire  
 TESS LE  TESS UE 
N 50 48 
Age: mean (range) 48.9 (18.6 – 74.9) 48.5 (18.1 – 83.8) 
Gender: % male 47 52 
Time since surgery in years: mean 
(range) 
3.5 (0.03 – 18.8) 3.0 (0.03 – 17.8) 
   
Location n (%)   
Shoulder 0 1 (2) 
Humerus 0 21 (44) 
Upper arm (soft tissue) 0 6 (13) 
Radius 0 2 (4) 
Metacarpals 0 9 (19) 
Digits 0 7 (15) 
Femur 22 (44) 0 
Upper leg (soft tissue) 1 (2) 0 
Knee 2 (4) 0 
Tibia 12 (24) 0 
Fibula 1 (2) 0 
Lower leg (soft tissue) 3 (6) 0 
Foot 2 (4) 0 
Missing data* 7 (14) 2 (4) 
   
Primary tumor n (%)   
Atypical cartilaginous tumor 10 (20) 22 (46) 
Chondrosarcoma grade 2/3 5 (10) 4 (8) 
Osteosarcoma 6 (12) 3 (6) 
Soft tissue sarcoma 4 (8) 5 (10) 
(Tenosynovial) Giant cell tumor 6 (12) 2 (4) 
Osteochondroma 2 (4) 0 
Fibromatosis 1 (2) 1 (2) 
Cartilagenous tumour - benign 2 (2) 2 (4) 
Bone other - malignant 2 (4) 1 (2) 
Soft tissue other - benign 2 (4) 3 (6)  
Bone other - benign 3 (6) 3 (6) 
Missing data* 7 (14) 2 (4) 
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Table C.2 Mean and median scores of TESS and SF-36 for the lower and upper extremities 
 Lower extremity Upper extremity 
 Mean (SD) Median (range) Mean (SD) Median (range) 
TESS 77.5 (19.8) 80.2 (13.3 – 100) 90.2 (14.9) 96.3 (21.6 – 100) 
     
SF-36     
Physical functioning 60.5 (26.2) 65.0 (10.0 – 100.0) 80.4 (22.4) 85.0 (10.0 – 100.0) 
Role limitations: physical 47.5 (43.2) 25.0 (0.0 – 100.0) 62.0 (42.5) 75.0 (0.0 – 100.0) 
Social functioning 72.8 (25.3) 75.0 (0.0 – 100.0) 82.8 (22.6) 87.5 (12.5 – 100.0) 
Role limitations: emotional 82.7 (33.8) 100.0 (0.0 – 100.0) 80.6 (36.2) 100.0 (0.0 – 100.0) 
Mental health 72.9 (19.8) 80.0 (28.0 – 96.0) 78.2 (18.1) 80.0 (36.0 – 100.0) 
Vitality 61.5 (22.6) 65.0 (15.0 – 100.0) 62.5 (22.3) 70.0 (15.0 – 100.0) 
Bodily pain 62.1 (27.3) 57.1 (0.0 – 100.0) 72.9 (26.2) 73.5 (0.0 – 100.0) 
General health 
perceptions 
60.8 (25.5) 67.0 (10.0 – 100.0) 62.7 (19.9) 65.0 (15.0 – 100.0) 
Physical component score  40.5 (11.2) 39.0 (16.5 – 58.6) 46.7 (9.9) 48.4 (23.4 – 61.9) 
Mental component score  50.6 (10.9) 54.2 (14. 0 – 67.9) 50.2 (9.8) 53.7 (20.5 – 62.8) 
 
The Bland-Altman plots for both questionnaires showed there were no signs of 
systematic bias (figures C.2 and C.3). The mean difference between the first and 
second questionnaire was 1.65 (SD 8.55) for the TESS-LE and -1.01 (SD 3.51) for 
the TESS-UE. 
Validity 
The mean scores for the eight SF-36 dimensions of the patients in the study and 
the physical and mental component scores (PSC/MSC) are shown in table C.2. 
The correlation was strong between the TESS-LE and the SF-36 dimensions: 
physical functioning, role physical, social functioning, vitality, bodily pain, PSC 
(table C.3). There was a moderate correlation between the TESS-LE and the SF-
36 dimensions: role emotional, mental health, and general health perceptions. 
The correlation with the MSC was poor. For the TESS-UE the dimensions physical 
functioning, role physical, bodily pain, and PSC strongly correlated, while the 
correlation was moderate for the dimensions social functioning, role emotional, 






Table C.3 Construct validity. Spearman rank correlations of the TESS (upper and lower extremities) 
with the SF-36 dimensions  
Spearman Lower extremity Upper extremity 
Physical functioning 0.737 0.726 
Role limitations: physical 0.766 0.766 
Social functioning 0.810 0.585 
Role limitations: emotional 0.511 0.525 
Mental health 0.505 0.383 
Vitality 0.704 0.586 
Bodily pain 0.777 0.766 
General health perceptions 0.540 0.465 
Physical component score  0.811 0.797 
Mental component score  0.429 0.347 
Figure C.2 Bland-Altman plot of the test-retest reliability of the Dutch TESS-LE. The solid line shows 
the mean difference of the two tests (1.65) and the dashed lines show the 95% limits of agreement 
(-15.11; 18.41).  
Figure C.3 Bland-Altman plot of the test-retest reliability of the Dutch TESS-UE. The solid line shows 
the mean difference of the two tests (-1.01) and the dashed lines show the 95% limits of agreement 
(-7.89; 5.86). The dot with 0 difference between test and retest and a 100 mean score represents ten 
patients. 




The TESS questionnaires for both the lower and upper extremities (LE and UE) 
are commonly used patient-reported outcome measures for functioning after 
the treatment of bone or soft tissue tumors in the Netherlands. However, there 
is currently no validated Dutch version. This study translated and culturally 
adapted a Dutch variant of both versions (LE and UE) of the TESS questionnaire. 
The cultural adaption was limited to a minimum, which might be due to the 
similarities regarding the performance of daily activities between the Canadian 
and the Dutch societies.  
Six questionnaires were excluded from the analysis because too many (>80%) 
questions had been answered with “not applicable”. For both the LE and UE 
versions, there was one questionnaire that was completely answered with “not 
applicable”, of which no score could be computed. In the other four 
questionnaires, the number of “not applicable” answers ranged from 24-29. 
Although the summary score excludes the “not applicable” answers, a score 
based on only one or several items did not appear trustworthy to the authors. 
In the original TESS publication, no advice is given as to dealing with such 
outcomes. Neither do previous articles validating the TESS questionnaire report 
of questionnaires with this amount of “not applicable” answers. Reasons for the 
high incidence of “incomplete” questionnaires are unclear; however, the TESS 
was the second questionnaire to fill in, after the SF-36, and it is possible that 
patients ran out of patience after the first 36 questions.  
The internal consistencies and test-retest reliabilities of the Dutch TESS-LE and 
TESS-UE were comparable with the original version of the TESS1 and with other 
translated and validated versions.3-6 As in all other versions, the test-retest 
reliability was slightly higher of the UE version than the LE version.  
In the TESS-UE 19 patients (39.6%) scored the maximum score. This ceiling effect 
reduces the possibility of measuring improvement and makes discrimination in 
patients who are doing well difficult. In the validation of the Japanese translation 
of the LE-TESS a ceiling effect for 17% of the participants was registered. None 
of the other translation and validation studies report the presence of absence 
of a ceiling effect. Therefore, it is difficult to place the current result in context; 
was the testing group too good or is the TESS-UE really not sensitive enough to 
discriminate patients with good function of the upper extremity? It is however 
important to take this result into account when interpreting questionnaire 




While the original1 and most other language versions3-5 test the validity with the 
MusculoSkeletal Tumor Society (MSTS) score16, this study tested the validity with 
the SF-36. The SF-36 was used as comparison with the TESS because it is 
standard procedure for patients to fill out the questionnaire at the outpatient 
clinic. Moreover, as opposed to the MSTS questionnaire which is designed as a 
physician-reported outcome measure, the SF-36 is designed as patient-reported 
outcome. From that point of view, the SF-36 is suitable to compare with the TESS, 
which is also patient reported. An additional comparison with the MSTS 
questionnaire would have brought further information, because that is a 
disease-specific questionnaire, but this was not possible because the MSTS 
questionnaire is not regularly completed by the physicians in the outpatient 
clinic. The correlation between the Dutch TESS (both LE and UE) and SF-36 was 
strong in the expected dimensions: physical component summary, physical 
functioning, role physical, and bodily pain. In both questionnaires the 
correlation with the mental component summary was poor, as was to be 
expected because the TESS is developed to measure physical functioning only.  
This study is limited by several factors. Although the total population is 
sufficiently large, the subpopulations for the lower and upper extremities are 
small. The number of patients included in the current study was based on 
previous studies validating the TESS. The TESS was validated in other languages 
in cohorts ranging from 22 to 126 patients, thus a total of 98 patients in the 
current study seems reasonable. The TESS-LE was previously tested in cohorts 
ranging from 16 to 102 (mean 60, median 48)3-6, so the LE cohort in this study 
was of average size. The TESS-UE has been validated in four other languages 
with small cohorts (6, 23, 43, 56 patients). The current validation in 48 patients 
is thus one of the larger cohorts. 
The proportion of patients returning the second questionnaire ranged between 
38% and 50% which left a small group for the test-retest validity. There are no 
clear reasons why the return-rate was low. However, as the second 
questionnaire had to be filled in from home and sent by post, it is conceivable 
that people simply forgot. It would have been interesting to analyze whether 
there was a selection in the patients returning the second questionnaire. 
However, due to the anonymity of the questionnaires, this could not be 
retrieved. 
The comprehension of the questions was not tested in separate questions. 
However, patients received verbal instructions to report any unclear questions 
or issues concerning the interpretation of questions to the researcher handing 
out the questionnaires at the outpatient clinic. Although some patients 
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commented on the amount of questions, no issues were raised concerning the 
content or meaning of the questions.  
The study did not test the Dutch responsiveness to the questionnaire. For use 
in clinical practice, especially for follow-up in the direct post-operative phase, it 
would have been useful to know the ability of the questionnaire to accurately 
detect change when this occurs. However, to test the reliability in the current 
validation study the population of interest was the group that was longer post-
operative and with a stable situation.  
To conclude, the Dutch TESS questionnaire for UE and LE is a reliable and valid 
instrument to measure patient-reported physical function for patients 
undergoing limb salvage surgery for benign and malignant bone and soft tissue 
tumors. The Dutch version of the TESS can be used for future cross-cultural 
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